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SHM  Somatic hypermutation 
SSC  Side scatter 
STAT  Signal transducer and activator of transcription 
TACE  TNF-α converting enzyme 
T-ALL  T cell acute lymphocytic leukemia 
TCR  T cell receptor 
TFH  T follicular helper 
Tg  Transgenic 
TGF-β Transforming growth factor - Beta  
Th1  T helper cell type 1   
Th2  T helper cell type 2 
TIMP  Tissue inhibitor of metalloprotease 
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TLR  Toll-like receptor 
TNF  Tumor necrosis factor 
TNP  Trinitrophenol 
VCU  Villus/Crypt Unit 
VEGF  Vascular endothelial growth factor 
WPG  Whole β-glucan particle  
WT  Wild type 
YFP  Yellow fluorescent protein 
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ADAM10 is a zinc-dependent metalloprotease.  ADAM10 has emerged as a key 
regulator of cellular processes by cleaving and shedding extracellular domains of 
multiple transmembrane receptors and ligands.  In this study, we examined the role of 
ADAM10 in the immune system.  Here, we show that knocking out ADAM10 on the 
mature B2 cell causes a defect in the development of secondary lymphoid architecture 
that becomes more severe post-immunization.  We also show that overexpression of 
ADAM10 leads to a defect in hematopoiesis, which eliminates B2 lymphocyte 
development.  This defect additionally induces accumulation of myeloid derived 
suppressor cells, MDSCs.  ADAM10Tg MDSCs function synonymous to tumor MDSCs.  
Of the two subpopulations of MDSCs, granulocytic MDSCs increase parasitic clearance 
in a model of N. brasiliensis.  Monocytic MDSCs are more immunosuppressive in 
regards to tumor.  Both subpopulations are dependent on the presence of mast cells for 
activity.  It is thought that this relationship is mediated through histamine and IL-13.  
During N. brasiliensis infection, ADAM10Tg mice, lacking B2 B cells but having intact 
B1 B cells, makes increased IgE over WT mice.  This production of IgE is thought to be 
produced by the B1 cells.  Of the two types of B1 cells, B1a cells make the majority of 
the IgE.  This IgE production is enhanced by MDSC accumulation and can be induced 
by MDSC adoptive transfer in a parasite-free mouse.  Lastly, ADAM10 is the key 
sheddase for CD23 on B2 cells.  When IgE is bound to its antigen to form an immune 
complex, IC, it binds CD23 and is internalized.  After CD23 bound to IgE ICs is 
internalized, it is sorted into bexosomes.  These bexosomes are transferred to dendritic 
cells which are responsible for presenting to T cells and inducing an increased antigen-
   
 
 
specific immune response.  Overall, ADAM10 is important for many aspects of the 
immune response
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Section 1 
Chapter 1:  ADAM10 and the Maintenance of Secondary Lymphoid Architecture 
1.1.1 Introduction to ADAM10 
 ADAM10 is a member of a family of a disintegrin and metalloproteases (ADAMs).  
ADAMs belong to the metzincin superfamily, along with matrix metalloproteases (MMP) 
and ADAM-thrombospondins (ADAM-TS).  While all functionally active metzincin 
proteases contain a zinc binding motif, ADAMs are unique in that they also contain a 
transmembrane domain and are active while membrane bound.  ADAMs are 
membrane-anchored and are therefore responsible for the processing of receptors and 
ligands expressed on the membrane surface, known as ectodomain shedding. ADAMs 
can mediate ectodomain shedding and regulated intramembrane proteolysis (RIP) of 
transmembrane proteins.  ADAMs cleave mainly type I and type II transmembrane 
proteins and shedding of these extracellular domains releases soluble fragments into 
the extracellular space1.  This ectodomain shedding can lead to down-regulation of 
events that depend on transmembrane receptor-ligand expression or can activate 
paracrine and/or autocrine signaling by the production of a soluble mediator.  Typical 
substrates of ADAMs are growth factors, cytokines, chemokines and their receptors, as 
well as cell adhesion molecules and differentiation factors1,2. While ectodomain 
shedding is thought to occur constitutively, RIP requires receptor-ligand interaction3.  
ADAMs are widely expressed and are key in many developmental processes.  ADAMs 
regulate cell-cell and cell-matrix interactions, they modulate differentiation, migration, 
receptor-ligand signaling or repulsion1,4.  The prototypical ADAM is composed of a 
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prodomain, metalloprotease domain, a disintegrin domain that confers substrate 
specificity, a cysteine-rich region, a transmembrane domain, and a cytoplasmic tail5,6.  
 ADAMs were initially discovered as type I transmembrane proteins with shared 
homology to snake venom integrin ligands7.  ADAMs and ADAM-related proteins have 
been described in many different species.  These include everything from the yeast, 
Schizosaccharomyces pombe to the nematode worm, Caenorhabditis elegans, and the 
fruit fly, Drosophila melanogaster 8–10.  Forty different ADAM family members have been 
currently identified in the mammalian genome, with 37 expressed in the mouse and 22 
in humans11,12.  ADAMs shown to possess zinc-dependent protease activity are termed 
active ‘sheddases’13,14.  These are ADAMs 8,9,10,12,15,17,19,20,21,28,30 and 33.  All 
of these ADAMs share a typical consensus sequence (HEXGHXXGXXHD)15.   
 ADAM10 was characterized through study of its homolog, Kuzbanian (kuz), in 
Drosophila.  In 1996, kuz was initially identified and studies of embryos deficient in kuz 
elucidated essential roles in lateral inhibition required for development of peripheral and 
central nervous systems16.  Cloning and sequencing of kuz demonstrated the presence 
of disintegrin and metalloproteinase domains highly homologous to bovine 
metalloprotease (BMP)16.  BMP was later named ADAM10 and was found to have α-
secretase activity and cleave myelin basic protein.  It was then well characterized in the 
cleavage of amyloid plaque proteins and Alzheimer’s disease17.  Through subsequent 
studies involving dominate negative mutants of kuz, it was demonstrated that kuz 
initiated RIP of Notch and the nervous system defects seen in initial studies were due to 
defective Notch signaling18.  Murine studies of ADAM10-deficient embryos reveal early 
mortality at embryonic day 9.5, resulting from multiple defects in the cardiovascular and 
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central nervous systems19,20.  In the beginning, it was highly controversial that ADAM10 
was responsible for Notch cleavage21,22.  ADAM17, or TNFα converting enzyme 
(TACE), was thought to be responsible for S2 cleavage of the Notch1 receptor and was 
reported by several groups23–27.  It is now thought that ADAM10 and ADAM17 may be 
functionally redundant and when one is absent, a compensatory mechanism will 
increase the other one and visa-versa28,29.  Increased evidence emerged that ADAM10 
was exclusively involved in Notch signaling by examination of murine embryos deficient 
in ADAM10.  These embryos mimicked features of Notch1-deficient murine 
embryos22,30.  This was further supported by ADAM17-deficient embryos, as they lacked 
similarity to the Notch1-deficient embryo31.  Following these observations, two groups 
utilizing ADAM10-deficient mouse embryonic fibroblasts (MEFs) reported that while 
multiple proteases can perform ligand-independent proteolysis of Notch1, ADAM10 is 
required for ligand-dependent cleavage27,32. Thus, ADAM10 may play a more critical 
role in Notch signaling than earlier in vitro studies predicted. 
 Some of ADAM10’s most well characterized substrates are Notch receptors, 
such as Delta-like 1-4 and Jagged 1-2.  Notch receptors regulate cellular differentiation.  
Notch signaling is initiated by ADAM10 mediated proteolysis of the extracellular domain 
of the Notch receptor.  The extracellular domain is released and endocytosed by 
adjacent ligand-expressing cells.  This cleavage event, termed S2 cleavage, produces a 
substrate that can be cleaved by the γ-secretase complex (S3 cleavage).  This releases 
the Notch intracellular domain (NICD), that translocates to the nucleus where it 
complexes with transcription factor RBP-Jκ and induces transcription of Notch target 
genes, such as CD21, Hes 1, Hes 5 and Deltex-1 as diagramed in Figure 133.   
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 Other substrates for ADAM10 include CD23, TNFα, and many others3,5.  It is well 
accepted that ADAM10 mediates cleavage of membrane-bound substrates, but recent 
evidence shows that ADAM10 is not restricted to the plasma-membrane and can cleave 
substrates on the exosomal membrane34,35.  Additionally, ADAM10 is highly expressed 
in the endoplasmic reticulum (ER), providing a potential new location of activity36.  
ADAM10 normally cleaves in cis, but recent studies of the substrate, ephrin, have 
shown that trans-cleavage is possible37.  Little is known about the regulation of 
ADAM10.  ADAM10 is expressed as a zymogen and activation occurs after the pro-
domain is cleaved by a furin protease38,39. Following activation, in vitro ADAM10 activity 
can be inhibited by tissue inhibitors of metalloproteases (TIMP)-1 and TIMP-317,40. 
Additionally, enhancement of proteolytic activity can be achieved by calcium influx, 
retinoic acid receptor signaling, PKC signaling, cholesterol depletion, kainite receptor 
signaling and N-glycosylation41–46.   
1.1.2 ADAM10 in lymphocyte development 
Notch1 signaling is essential for the commitment to T cell lineage, thus ADAM10 
is important given its role in Notch signaling47,48. Enforced Notch1 signaling in bone 
marrow (BM) progenitors, expressing the constitutively active NICD, promote T cell 
development48. In fact, human mutations surrounding the S2 cleavage site of Notch1 
results in ligand-independent proteolysis and excessive Notch1 activation. This 
ultimately leads to T cell acute lymphocytic leukemia (T-ALL). This mutation accounts 
for approximately 50 percent of all T-ALL cases21.  
  B2 lymphocytes comprise the majority of circulating B cells. They develop from 
common lymphoid progenitors (CLPs) and differentiate into pro-, pre-, and ultimately 
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immature B cells prior to exiting the BM. Given that the Notch1 cleavage site recognized 
by ADAMs is not present in murine Notch2, and that B cells express Notch2 rather than 
Notch1, ADAM10 was initially not thought to be involved in B2 cell development24,25,49–
52. Just as Notch signaling promotes CLP commitment to the T cell lineage, it prevents 
B lineage fate. Thus, multiple studies have demonstrated that enforced expression of 
active NICD in BM progenitors completely abrogates B2 cell development48,52. Following 
exit from the BM, B2 cells enter a transitional stage and undergo further maturation in 
the spleen, where the majority differentiates into follicular (FO) B cells.  A small subset 
of these cells, develop into the marginal zone (MZ) B cell lineage, including pre-MZ B 
cells and MZ B cells. By generating B cell-specific Notch2 knockout mice, it was 
demonstrated that Notch2 signaling is required for the balance in development of the 
MZ B cell lineage versus the FO B cell lineage. MZ B cells initiate immune responses to 
blood-borne infections and assist in transporting antigen into the splenic follicles25,53. B 
cell specific deletion of the downstream transcription factor RBP-Jκ, which binds the 
NICD fragment released after S3 cleavage, also resulted in a severe loss of MZ B cell 
development with a concomitant increase in FO B cell development54.  It is thought that 
Notch signaling induces a high turnover of E proteins, HEB, E2A, and E2-2, which are 
implicated in the regulation of peripheral B cell maturation54.  In mouse models where B 
cell-E proteins are deleted, an increase in MZ B cell lineages occurs to the detriment of 
the FO B cell lineage54,55.  Moreover, by deleting ADAM10 in a mature B cell-specific 
manner using the CD19-cre (ADAM10B-/-), Gibb et al. demonstrated an absolute 
requirement for ADAM10 in MZ B development56. Analysis of Notch target gene 
expression in these mice revealed a dramatic defect in Notch2 signaling. Furthermore, 
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in contrast to WT B cells, ADAM10-null cells were completely unresponsive to DLL-1-
induced Notch stimulation. These findings not only revealed the importance of ADAM10 
in B cell development, but also demonstrated that ADAM10 is responsible for activating 
RIP-mediated signaling through Notch2. No compensatory cleavage of Notch2 by other 
proteases occurs, thus ADAM10 may be the only protease that can recognize the 
Notch2 cleavage site, which is distinct from the Notch1 site24.  Notch signaling has also 
been implicated in other B cell functions.  Notch signaling alongside B cell receptor 
(BCR) and CD40 signaling enhances B cell activation as well as, B cell differentiation 
into antibody secreting cells (ASC) in vitro. Notch signaling has also been implicated in 
germinal center (GC) formation50,57,58. This is thought to be due to defects in 
development of follicular helper T cells (TFH), which are essential to the GC response 
and T cell specific Notch1 and Notch2 defects lead to reduced GC B cell numbers and 
decreased high affinity antibody59. 
1.1.3 Introduction to secondary lymphoid tissues 
Secondary lymphoid tissues are the primary sites of adaptive immune responses.  
Most lymphocytes within these tissues are mobile and transitory, yet secondary 
lymphoid structure is highly organized and tightly maintained.  The development of 
these tissues occurs when hematopoietic lymphoid tissue inducer cells (LTi) expressing 
lymphotoxin αβ (LT) and mesenchymal cells expressing LTβ receptor interact60–62.  LT-
deficient mice completely lack LNs, peyer’s patches (PP) and have disrupted splenic 
architecture60–64.  LT signaling induces mesenchymal cells to differentiate into stromal 
organizer cells and to induce chemokine expression, leading to the recruitment of naïve 
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lymphocytes62.  Disruptions in the TNFα level, a cytokine in the same family as LT, 
results in abnormal LN and splenic architecture as well29,65,66. 
Secondary Lymphoid organs consist of lymph nodes (LN), spleen, bronchiolar-
associated lymphoid tissues (BALT), gut-associated lymphoid tissues (GALT), tonsils, 
PP and other organized lymphoid tissues associated with mucosal surfaces.  These 
organs are located at strategic sites where they can trap foreign antigens entering the 
body61,67–69.  The segregation of cells within these organs is thought to enhance the 
efficiency of immune responses by arranging B and T cells into zones that provide them 
interaction with certain antigen presenting cells (APC) and regulatory cells61.  It is also 
thought that the organization provides a framework for circulating naïve lymphocytes to 
encounter concentrated foreign antigen61. 
Lymphatic vasculature delivers antigen-presenting cells from the periphery, as 
well as foreign antigen into the LN.  This lymph enters the LN through the afferent 
lymphatics into the marginal sinuses, directly underneath the LN capsule.  Under the 
marginal sinuses lies the outer cortex, or B cell zone consisting of B cell follicles. 
Directly beneath this is the paracortex or T cell zone.  Underneath this lies the medullary 
chords containing macrophages and plasma cells, and in the center of the LN medullary 
sinuses are where the efferent lymphatics remove lymph fluid from the LN61,62. 
Circulation enters the LN through high endothelial venules (HEV) in the 
paracortex, bringing naïve lymphocytes in contact with antigen on APCs70.  A dendritic 
cell (DC) or other APC carrying an antigen migrates to the paracortex71.  This is 
dependent on the chemokine CCR7 binding to its ligands CCL19 and CCL2172,73.  This 
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DC up-regulates CD80/CD86 co-stimulatory molecules as well as processes and 
presents the antigen on major histocompatibility class (MHC) II.  MHC II binds to the 
specific T cell receptor (TCR) providing the initial signal needed for an immune 
response. Co-stimulation of CD28 by CD80/CD86 provides the second signal that is 
essential for the activation of the T cell.   An additional specific cytokine milieu induces 
differentiation of the T helper (Th) cell60,74,75.   
Three lineages of CD4+ Th cells diverge at this point with respect to the antigen 
type and signals from APC.  The Th1 lineage responds to intracellular pathogens and 
when inappropriate responses occur, can result in autoimmunity76,77. Differentiation to 
Th1 cell is initiated by signal transducer and activator of transcription 1 (STAT1) 
activation through interferon γ (IFN-γ) and or (interleukin) IL-27.  This induces the 
transcription factor T-bet up-regulation.  In conjunction with H2.0-like homeobox (HLX) 
and other transcription factors activated post TCR signal, ifnγ transcription is increased 
and the transcription factor GATA-binding protein 3 (GATA3) is antagonized.  This leads 
to the downstream up-regulation of IL-12 receptor that binds to IL-12 produced by the 
APC.  This IL-12 signaling induces the transcription factor STAT4 and paired with runt-
related transcription factor-3 (RUNX3), drives Th1 differentiation78–83.  The Th2 lineage 
responds to helminthes, but when responding to innocuous particles can lead to allergic 
disease77.  Th2 cell differentiation involves STAT5 and STAT3 and/or Notch mediated 
immunoglobulin-κ J region (RBPJ) induction of GATA3 through STAT6 and IL-4.  A 
positive feedback loop drives Th2 differentiation and IL-4, IL-5, IL-13 production84–86.  A 
third Th cell lineage, the Th17 cell responds to extracellular bacteria and fungi.  This 
differentiation is started with activation of STAT3, inducing IL-21.  IL-21 signaling in 
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conjunction with transforming growth factor β (TGFβ) by the APC induces the 
expression of transcription factor retinoic-acid-receptor-related orphan receptor-γt 
(RORγt), IL-17, and IL-23R.  IL-21 and IL-17 drive Th17 cell differentiation87–91. 
Th cells then up-regulate CXCR5 and traffic to the B-T border of the B cell 
follicle, where Th cells activate B cells92–94.  The initial signal is delivered via antigen 
specific BCR binding native epitopes on the antigen and the second signal is co-
stimulation with Th cell CD40 ligand binding CD40 on the B cell95.  This is also 
influenced by particular Th lineage cell-secreted cytokine milieu.  These B cells can then 
choose three particular fates:  a short-lived extra FO plasma cell that secretes low 
affinity antibody, an early memory B cells, or give rise to the GC reaction60,74,75,96.   
GC reaction occurs in the B cell follicles of the LN.  Within the GC, B cells 
undergo extensive differentiation and proliferation during the process called affinity 
maturation96.  The GC is divided into two zones morphologically, the light zone and dark 
zone60,97.  B cells were traditionally thought to move through the GC from dark zone to 
light zone, but can move from light to dark or intra-zonally98.  Within the dark zone, the B 
cell undergoes extensive proliferation, somatic hypermutation (SHM) and class switch 
recombination (CSR)60.  Initially, the B cell moves to the center of the follicle, where they 
rapidly divide as centroblasts99.  This is where B cells begin SHM, the result of point 
mutations in the variable regions of heavy and light chain in an attempt to create higher 
affinity antibody19,99. CSR allows replacement of the µ gene with either γ, α, or ε60.  
Different cytokines drive CSR to different antibody classes100.   This occurs though a 
process of excising loops of DNA involving activation induced cytidine deaminase (AID) 
and results in the same antibody specificity with new antibody classes, thus new 
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antibody function60,100.  CSR is rare outside the GC reaction, but can occur60.  Follicular 
dendritic cells (FDCs) are essential for the GC reaction60n92-n94).  FDCs and TFH are 
found mainly in the light zone and are essential for positive selection and affinity 
maturation60,74,101.  After SHM and CSR, centroblasts exit the cell cycle and move the 
light zone of the GC as centrocytes96. Centrocytes sample antigens bound to immune 
complexes on FDCs or antigen on TFH cells.  This drives the positive signal through the 
BCR for high affinity, antigen-binding B cells to survive74,102,103.  Low affinity or self-
reactive B cells are deleted from the GC by apoptosis104–106.  These B cells move on to 
become long-lived plasma cells, memory B cells or reenter the dark zone for further 
rounds of SHM and CSR107,108. 
The spleen, as a secondary lymphoid organ, undergoes many of the same 
processes as the LN.  It is organized differently as it contains two types of tissue.  The 
red pulp is mainly a filter for damaged and aging erythrocytes, and the white pulp 
contains the peri-arteriolar lymphoid sheaths (PALS)61.  Directly surrounding the central 
arteriole is a T cell rich compartment.  This compartment is encircled by B cell follicles 
containing pockets of FDCs61,68.  The red pulp is separated from the white pulp by a MZ 
made up of MZ B cells and MZ macrophages61.  MZ B cell development requires CD19, 
Notch2 and ADAM10 protein expression and signaling as reviewed earlier25,56,109. 
Regardless of the organ, B cells and T cells segregate into specific zones based 
upon chemokine secretion by stromal cells and chemokine receptor expression.  When 
these chemokine gradients are disrupted, B and T cell positioning changes, which 
cripples the adaptive immune response.   
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Here we aim, in this section, to address the role of ADAM10 in secondary 
lymphoid architecture and GC formation.  We utilize ADAM10 deletion in mature B cells 
utilizing the CD19-cre (ADAM10B-/-) to show dramatic defects in GC formation and 
antibody responses, accompanied with changes in splenic and LN architecture110. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
12 
 
Chapter 2: Materials and Methods 
1.2.1 Mice 
ADAM10B-/- mice were previously described56. To generate ADAM10B-/- N2ICD-TgB+. 
ADAM10B-/- were mated to N2ICD-Tgflox/flox mice111. CD19-cre mice were wild type (WT) 
littermates of ADAM10B-/- and ADAM10B-/-N2ICD-TgB+mice.  CD23Tg mice have been 
previously described112.  BALB/CJ mice were used as littermate controls of CD23Tg 
mice. 
1.2.2 PCR and Quantitative PCR 
PCR 
For genotyping, DNA was isolated using Direct Tail PCR Solution as directed by the 
manufacturer (Viagen).  Mangomix (Bioline) was used for amplification of CD19 cre-
lines, ADAM-10 floxed alleles, YFP-Rosa and N2ICD transgenes.  Cycling conditions 
were as follows, 95°C for 3 minutes then 35 cycles of 94°C for 1 minute, 55°C for 1 
minute, 72°C for 2 minutes, and a final extension at 72°C for 10 minutes.  Sequences of 
all primers described above are listed in Table 1. 
Quantitative PCR 
Total RNA was extracted and purified from draining and non-draining mouse LNs using 
TRIzol reagent (Invitrogen).  Samples were treated with DNase (Takara Bio), mixed with 
phenol/chloroform/isoamyl alcohol solution (25:24:1 USB), and precipitated with etyl 
alcohol.  The purity of RNA was quantified by a spectrophotometer (ND-100; 
NanoDrop).  One microgram of RNA was reverse transcribed using High Capacity 
cDNA RT kit (Applied Biosystems).  Real-time quantitative PCR was performed with a 
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real-time PCR machine (iQ5; Bio-Rad Laboratories).  Primers and probes for running a 
TaqMan quantitative PCR assay were purchased from Applied Biosystems.  Taqman 
gene expression assays used included:  CCL19: Mm00839967_g1, IL-21:  
Mm00517640_m1.  Primers for CCL21 were synthesized by IDT as previously 
described113.  PCR products, labeled with 6-FAM-conjugated probes, were amplified 
with 18S as an internal control.  Reaction parameters were as follows: hold at 48°C for 
30 minutes and hold at 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 
seconds and 60°C for 60 seconds. Results were analyzed with iQ5 real-time PCR 
software (version 2.0).  Sequences of all primers and probes, except those included in 
purchased Taqman gene expression assays described above, are listed in Table 1. 
1.2.3 Immunization 
For all immunization protocols, mice were of 6-12 weeks of age, unless otherwise 
stated.  When experiments were terminated, mice were euthanized via isofluorane 
inhalation and cervical dislocation.  All mouse protocols were approved by Virginia 
Commonwealth University’s Institutional Animal Care and Use Committee. 
Mice were immunized with a single 10µg 4-Hydroxy-3-nitrophenylacetyl injection 
coupled to keyhole limpet hemocyanin at a ratio of 27:1 (NP27KLH – from this point 
called NP-KLH) (Biosearch Technologies).  For intra-peritoneal injections, mice were 
given 200µL of immunization mixture, made as follows:  10µg of NP-KLH in 100µL of 
PBS and 100µL of alum (4mg).  For footpad injections, mice were given 25µL of 
immunization mixture, made as follows: 10µg of NP-KLH in 10µL of PBS and 15µL of 
alum (0.6mg).  Mice were bled weekly via tail vein nick and cardiac punctured when the 
experiment was terminated. 
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1.2.4 Cell Isolation 
Tissue preparation 
Single cell suspensions of peripheral LN cells and splenocytes were generated by 
disrupting tissue between frosted glass slides. Red blood cells (RBCs) were then lysed 
using ACK lysis buffer (Quality Biological).  Cells were plated or stained depending on 
experimental design. 
Magnetic Bead Isolation 
Cellular isolations were carried out using magnetic bead selection (Miltenyi Biotec).  
Briefly, single cell suspension was generated as described above.  Cells were 
resuspended in MACS buffer (PBS pH 7.2, 0.5% BSA, and 2mM EDTA) and incubated 
with the corresponding magnetic beads for 15 minutes at 4°C.  Cells were then washed 
and passed through a magnetic column via manufacturer’s protocol (Miltenyi Biotec).  
When cells were isolated via negative selection, LD columns were used and flow-
through was harvested.  On the other hand, when cells were isolated via positive 
selection, LS columns were used.  In this case, after cells were passed through the 
column, columns were washed and flushed with MACS buffer and the eluted cells were 
utilized for experiments.  For B cell isolation, cells were isolated via positive selection 
(B220+ cells) for all cells or via negative selection (CD43-) for isolation of naïve or 
untouched B cells. 
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1.2.5 Enzyme Linked Immunosorbant Assay (ELISA) 
Total antibody levels 
For total Ig ELISAs, ELISA plates were coated with 5µg/mL of goat-anti Ig (Southern 
Biotech) in BBS (0.15M sodium choloride, 0.01 M borate buffer, pH=8.5).  Plates were 
then incubated at 37°C for an hour or at 4°C overnight.  Plates were then washed three 
times with ELISA wash (PBS with 0.02% Tween20).  Blocking solution (PBS with 0.02% 
Tween20 and 2% FBS) was added to plates.  Plates were then washed three times with 
ELISA wash and samples were added, diluted in block.  For standard curve, normal 
mouse Ig (Southern Biotech) was used.  Plates were then incubated at 37°C for an hour 
or at 4°C overnight.  Plates were washed three times with ELISA wash and goat-anti Ig-
AP was diluted in block (1:400 dilution) (Southern Biotech).  After 1 hour incubation at 
37°C, plates were washed and developed with phosphate tablets (Sigma-Aldrich) 
dissolved in substrate buffer (0.1g MgCl2.6H20, 0.2 NaN3, 50mL diethanolamine, pH to 
9.8 per 500mL).  Absorbance at 405nm was measured. 
NP-specific ELISA 
For NP-specific ELISAs, ELISA was carried out as previously described with minor 
modification.  Plates were coated with NP14BSA (Biosearch Technologies) (15µg/mL in 
PBS) for samples and with 5 µg/mL of goat-anti-Ig (Southern Biotech) in BBS for 
standards.  The remaining steps were carried out as previously described (see total 
antibody levels).  For measurement of high affinity antibodies, the protocol was carried 
out as described except that plates were coated with NP4-BSA (both low and high 
affinity antibodies bind NP14BSA).  The described NP-specific ELISA protocol allows for 
the relative quantification of high vs. low affinity antibodies114. 
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1.2.6 Flow cytometry, immunofluorescence and confocal microscopy 
Flow cytometry 
Cell isolation was conducted as previously described (1.2.4).  Cells were labeled 
following RBC lysis and filtered through 40µm cell strainers.  For surface staining, cells 
were washed in FACS buffer (2% FBS in PBS).  1-3x106 cells were resuspended in 50-
100µL.  Cells were then incubated on ice with 1-5µg of Fc block (2.4G2) for 10 minutes 
to prevent non-specific staining.  Subsequently, cells were incubated for 30 minutes on 
ice with different combinations of 0.25-0.5µg of anti-mouse antibodies.  Cells were then 
washed with FACS buffer and analyzed.  Flow cytometry analysis was performed using 
a Canto or Aria ll (BD Biosciences) using DIVA software at the Flow Cytometry Core at 
Virginia Commonwealth University.  Flow cytometry data analysis was conducted with 
Flowjo v8.8.7 (Tree Star). 
Immunofluorescence and confocal microscopy 
Spleen and LNs were flash frozen on dry ice in OCT compound (Tissue-Tek; Sakura).  
Serial 10µm sections were cut from frozen blocks using a cryostat (Frigocut 2800E; 
Jung), mounted on Superfrost Plus slides (VWR), fixed in absolute acetone for 15 
minutes, and air-dried.  Slides were blocked with 10% Normal Horse Serum with 3% 
BSA in PBS for 20 minutes to prevent background staining and then washed in ice cold 
PBS.  Antibody was incubated in block solution for 60 minutes in the dark with different 
anti-mouse antibodies (concentrations varied for each antibody, see Table 2).  Slides 
were washed in ice cold PBS 3 times for 5 minutes on oscillation in the dark.  Slides 
were mounted with #1 cover slips (CORNING) using Vectashield Hardset mounting 
medium (Vector Labs).  Slides were allowed to dry in the dark at room temp for 2 hours 
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before storage at 4°C until visualization.  Slides were examined with a confocal laser 
scanning microscope (TCS-SP2 AOBS; Leica) fitted with an oil Plan-Apochromat 40x 
objective. Two lasers were used:  argon (488nm) for FITC, and HeNe (543 nm) for PE 
and APC.  Parameters were adjusted to scan at a 512x512 pixel density and an 8-bit 
pixel depth.  Emissions were recorded in three separate channels.  Digital images were 
captured, overlayed, and processed with the Confocal and LCS Lite programs (Leica). 
Antibodies 
All antibodies used for flow cytometry are listed in Table 2. 
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Table 1.  Primer sequences 
S- sense, AS- anti-sense 
PCR 5’ > 3’ 
ADAM10:  Intron8 CAGTGTAAATGTGAACTCACCC 
ADAM10:  Intron9 CGTATCTCAAAACTACCCTCCC 
N2ICD:  N2AD1 CCTTATGATGTTCCCGATTATGC 
N2ICD:  N2AD2 AGTACACCCATCTGGGCCTCG 
YFP:  oMIR4982 AAGACCGCGAAGAGTTTGTC 
YFP:  oMIR8545 AAAGTCGCTCTGAGTTGTTAT 
YFP:  oMIR8546 GGAGCGGGAGAAATGGATATG 
CD19-cre:  oMIR1084 GCGGTCTGGCAGTAAAAACTATC 
CD19-cre:  oMIR1085 GTGAAACAGCATTGCTGTCACTT 
Quantitative PCR  
18S S AAAATTAGAGTGTTCAAAGCAGGC 
18S probe CGAGCAGCCGCCTGGATACCGC 
18S AS CCTCAGTTCCGAAAACCAACAA 
CCL21 S AGACTCAGGAGCCCAAAGCA 
CCL21 AS GTTGAAGCAGGGCAAGGGT 
CCL21 probe CCACCTCATGCTCCAATAAGT 
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1.2.7 In vitro activation 
For IgG1 and IgE production, B cells or splenocytes were cultured with CD40L-
transfected Chinese hamster ovary (CHO) cells as a B cell stimulant (6x104cells/well) or 
with 1µg/mL of stimulating anti-CD40 antibody (Invitrogen) and IL-4 (10,000U/mL; NIH) 
for seven days.  Supernatants were then harvested and analyzed for IgG1 and IgE 
production by ELISA.  Cells were also stimulated with 50µg/mL of LPS (Sigma-Aldrich).  
Four days later, supernatants were harvested and analyzed for IgM and IgG3 
production. 
1.2.8 Statistical analysis 
When dealing with two groups, p-values were calculated using unpaired two-tailed 
Student’s t-tests in GraphPad Prism, unless samples did not form a Gaussian 
distribution, indicated by a failed D-Agostino and Pearson omnibus normality test.  In 
the case of non-parametric populations, p-values were calculated using two-tailed Man-
Whitney test.  When more than two were compared, p-values were calculated using a 
one-way analysis of variance with a Tukey post-test.  Error bars represent the standard 
error of the mean (SEM) between samples. p<0.05 is considered significant. 
 
 
 
 
 
   
20 
 
Table 2. Flow cytometry and immunohistochemistry antibodies 
Specificity Clone Label Source Concentration 
Used 
Immunohistochemistry 
B220/CD45R RA3-6B2 FITC, PE Biolegend 3µg/mL 
CCL21 59106 Unlabeled R&D 7.5µg/mL 
CD19 6D5 PE Biolegend 3µg/mL 
CD21/CD35 7G6 FITC Biolegend 3µg/mL 
CD3ε 17A2 PE, FITC Biolegend 2µg/mL 
GL7 (B and T 
activation marker) 
GL7 FITC eBioscience 
BD Bioscience 
3µg/mL 
IgD 11-26c.2a PE Biolegend 3µg/mL 
Thy1.2 30-H12 FITC, PE Southern 
Biotech 
3µg/mL,5µg/mL
Rat IgG  Dylight 549 AbD Serotec 1:200 
ADAM-10 139712 FITC R&D 3µg/mL 
Flow cytometry 
ADAM-10 139712 FITC, PE R&D 
B220/CD45R RA3-6B2 FITC, PE, 
APC, 
PE/Cy7 
Biolegend 
CD16/CD32 2.4G2 Unlabeled In house 
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CD38 90 PE/Cy7 Biolegend 
CD21/CD35 7G6 PE Biolegend 
IgG1 A85-1 APC, PE BD Biosciences 
IgD 11-26c.2a PE, 
PerCP/Cy5.5
BD Biosciences 
IgM RMM-1 PE, APC, 
APC/Cy7, 
PerCP/Cy5.5
Biolegend 
All made against mouse unless otherwise noted 
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Chapter 3:  B cell ADAM10 deficient mice have altered responses to T-dependent 
antigens 
1.3.1 Generation of mature B cell specific ADAM10 deficient mice 
Our lab generated B cell-specific ADAM10 knockout mice (ADAM10B-/-).  These 
mice were generated by crossing homozygous floxed ADAM10 animals with CD19-cre 
animals115.  These ADAM10B-/- mice lacked MZ B cells, had drastically reduced 
numbers of pre-MZBs and a significant increase in FO B cells56.  In order to follow 
recombination in the CD19+ cells, ADAM10B-/- mice were crossed with the YFP reporter 
mouse.  This mouse only expresses YFP after cre-driven recombination, in cells where 
the recombination occurs56.  The generation of these mice is outlined in Figure 2. 
 The CD19-cre mediates efficient recombination of loxP-flanked gene sites in 
mature cells116.  CD19 is expressed starting at the pro-B cell stage, but CD19-cre 
recombination is limited in the immature B cell, the pre-B cell117.  Only ten percent of 
CD19+ B cells in CD19-cre+ YFP+ mice have undergone cre-mediated recombination in 
the BM118.   
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Figure 1.  ADAM10 and Notch signaling 
ADAM10 mediated RIP of Notch2 is required for MZ B cell development25.  The Notch2 
heterodimer on B cells binds ligands Jagged 1-2 and Delta-like-1 that are present on 
stromal cells or APCs.  Binding initiates sequential cleavage events by ADAM10 (S2 
cleavage) and γ-secretase complex (S3 cleavage).  Cleavage releases the Notch2 
intracellular domain (N2ICD).  Transport of the N2ICD to the nucleus followed by 
binding to the transcription factor RBP-Jκ allows the release of co-repressors (CoR) and 
attraction of co-activators (CoA) to the transcriptional complex.  The activated complex 
transcribes Notch target genes, including CD21/35, Deltex-1, Hes 1, and Hes 5, that 
promote development of MZ B cells.  Deletion of ADAM10, Notch2, and RBP-Jκ from B 
cells, or Delta-like 1 from stromal cells prevents MZ B cell development. 
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Figure 2. ADAM10 B cell-specific knockout 
CD19-cre mice express cre-recombinase under the CD19 promoter.  When CD19 
expression is turned on in cells that normally express CD19, such as mature B cells, cre 
is expressed.  Note, that this allele is kept heterozygous with the WT CD19 allele to 
avoid disruption in CD19 expression.  In our ADAM10 floxed mice, loxP sites flank the 
ADAM10 gene.  Upon expression of cre, recombination occurs at loxP sites, excising 
the gene and knocking out ADAM10.  Additionally, these mice utilize the YFP reporter 
gene.  With expression of cre, recombination occurs at loxP sites flanking a STOP 
sequence upstream of the YFP-Rosa gene.  With the excision of the STOP sequence, 
the YFP-Rosa gene is transcribed.  This yellow fluorescent molecule allows cre 
expression to be monitored as well as ADAM10-deletion. (A) Normal ADAM10 
expression occurs without cre-recombinase.  Thus, ADAM10 is not deleted and YFP 
expression is not induced.  (B) Cre-recombinase is expressed when CD19 is turned on, 
this ADAM10 is knocked out and YFP is expressed. 
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1.3.2 ADAM10 is essential for secondary lymphoid architecture 
ADAM10 is highly expressed in GC B cells 
 ADAM10 cleaves many substrates closely linked to humoral immune responses, 
not only Notch1 and 2, but TNFα and CD23 as well28,47,119.  We therefore sought to 
examine the role of B cell ADAM10 in humoral responses.  First, in collaboration with 
Joanna Cichy from Jagiellonian University, Krakow, Poland, we examined the 
expression of ADAM10 with in secondary lymphoid tissue undergoing GC response.  
PPs are located in the gut and have a high level of GC activity.  Flow cytometry of PPs 
demonstrated that while less than 2% of naïve B cells expressed ADAM10, over 80% of 
GC B cells were ADAM10+ (Figure 3A,B).   These results were confirmed by 
immunoflourescent staining of sectioned PPs for ADAM10, PNA, and IgD.  Consistent 
with the flow cytometry results, ADAM10 was highly expressed by cells within GCs 
(Figure 3C). 
Humoral immune responses in ADAM10B-/- mice 
Given the significant expression of ADAM10 in GC B cells, we investigated its 
role in humoral responses by using B cell-specific ADAM10-deficient mice 
(ADAM10B−/−). Basal levels of serum IgM, IgG1, IgG2a, and IgG2b were significantly 
reduced in ADAM10B−/− mice when compared with WT, suggesting a defect in antibody 
production (Figure 4A). To directly assess antigen-specific antibody production, we 
immunized ADAM10B−/− mice intra-peritoneally (i.p.) with NP-KLH and examined serum 
levels of NP-specific antibody. ADAM10B−/− mice showed reduced levels of NP-specific 
IgM 7 d post-immunization. However, levels reached control values by day 14 and 
through the remainder of the experiment (Figure 4B). In contrast, NP-specific IgG 
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levels, both total and high affinity, were reduced 4 weeks post-immunization (Figure 
4B). This reduction in IgG was not specific to a particular isotype, as antigen-specific 
IgG1, IgG2a, and IgG2b were dramatically reduced in ADAM10B−/− mice (Figure 5A). 
Furthermore, even when immunization with a high antigen dose, 1 mg NP-KLH, was 
performed, ADAM10B−/− mice failed to mount a normal antibody response, 
demonstrating that the defect in antibody production cannot be overcome by simply 
providing more antigen (Figure 5B). 
Germinal Center formation is impaired in ADAM10B-/- mice 
As demonstrated in Figure 5, antigen-specific ASCs were reduced in immunized 
ADAM10B-/- mice.  Being that long lived plasma cells (PC) and memory cells are 
generated within the GC120, GC formation in ADAM10B−/− mice was examined. GC B 
cells, defined as IgMloIgDloB220+IgG1+CD38lo, were enumerated by flow cytometry121 
(Figure 6A). Remarkably, the number and percentage of GC B cells within the spleen 
was dramatically decreased in ADAM10B−/− mice (Figure 6B,C). 
ADAM10B-/- mice have altered splenic and lymph node architecture 
To better understand the relationship between decreased GC B cells and the 
defects in antibody production depicted in Figure 4, we assessed GC formation in 
immunized mice by immunohistochemistry. As depicted in Figure 7A, although several 
GCs could be detected in littermate controls, as determined by GL7+ cells, draining LNs 
of ADAM10B−/− mice contained a paucity of GL7+ clusters. Interestingly, GL7+ cells were 
scattered throughout the LNs of ADAM10B−/− mice (Figure 7A). Given the unusual 
pattern of GL7 expression, we then analyzed B and T cell localization within the LNs. 
Surprisingly, the distribution of B and T cells was aberrant, suggesting that B cell-
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specific ADAM10 deletion leads to changes in LN structure (Figure 7B). In contrast, LN 
structure in non-draining nodes or unimmunized mice, were relatively normal with 
regard to B and T cell segregation, but B cell follicles appear thin, reminiscent of TNFα 
or LTβ-deficient mice (Figure 7D)65,122.  
Given that FDCs play a crucial role in GC formation and lymphoid tissue 
structure123–125, we stained draining LN sections for FDCs with CD21/CD35 (CR2).  
FDCs are known to up-regulate CD21/CD35 subsequent to activation126.  Consistent 
with the absence in GCs and disorganized lymphoid architecture, FDC networks were 
not detectable in LN and spleen from ADAM10B-/- mice (Figure 7C, 8D).  Unlike the 
draining LNs, GL7 staining was not detected in spleen of ADAM10B−/− mice (Figure 8A). 
However, although normal in unimmunized mice, splenic architecture was also clearly 
altered post-immunization (Figure 8B,C). 
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Figure 3.  ADAM10 expression on GC B cells 
A and B, Expression of ADAM10 on gated GC PNAhiIgDlo (blue) and naive PNAloIgDhi 
(red) B (CD19+) cells isolated from PPs. Flow cytometry gates used to define the GC 
and naive B cell populations are indicated on the left. To demonstrate specificity of 
staining, we used isotype-matched monoclonal antibody (mAb) (isotype). A, Gating 
protocol is shown. B, Percentage of ADAM10+ cells in naive and GC B cells. C, Frozen 
serial sections of PPs were stained to detect B cell follicles (B220+, blue), GCs (PNA+, 
green), and ADAM10 (red) (right panel). To demonstrate specificity of staining, we used 
isotype-matched mAb instead of mAb against ADAM10 (left panel). Original 
magnification ×20. The mucosal epithelium (E) also reacts with PNA and anti-ADAM10.  
Figure courtesy of Joanna Cichy, from Jagiellonian University, Krakow, Poland. 
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Figure 4. ADAM10B−/− mice have impaired humoral responses. 
A, Serum IgM, IgG1, IgG2a, and IgG2b were measured by capture ELISA from non-
manipulated 8- to 12-wk-old mice. B, ADAM10B−/− mice and WT littermate controls were 
immunized with 10μg NP-KLH emulsified in alum. At the indicated times, serum 
samples were collected and total NP-specific IgM, total IgG, and high-affinity IgG 
antibody titers were determined by ELISA, with NP-16–BSA as capture Ag for total and 
NP-4–BSA as capture Ag for high-affinity ELISA. C, Mice were immunized with NP-KLH 
emulsified in alum, rested for 42 d, and boosted with 10 μg NP-KLH for 5 d. Mice were 
bled weekly throughout the course of the experiment. Total and high-affinity Ag-specific 
IgG levels were measured by ELISA at each time point. The relative unit (RU) values for 
alum-injected mice were <0.001.  ADAM10B-/- (filled bars) and WT (open bars).  Bars 
represent the mean ± SE of five to nine mice per group (*p < 0.05, **p < 0.01, ***p < 
0.001). Data represent results obtained in at least two independent experiments. 
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Figure 5.  Decreased NP-specific IgG secretion is not IgG subset dependent and 
cannot be overcome by high antigen dose 
A. ADAM10B-/- mice and WT controls were immunized with NP-KLH emulsified in alum. 
Twenty-eight days after primary immunization, samples were collected and NP-specific 
IgG1, IgG2a and IgG2b antibody titers were determined by ELISA with NP14BSA as 
capture antigen. B. ADAM10B-/- and WT controls were immunized i.p. with 1mg of NP-
KLH emulsified in alum.  Samples were collected at the indicated time post 
immunization, and NP-specific antibodies were measured.  The relative unit (RU) values 
for alum-injected mice were less than 0.001.  Bars represent the mean ± SEM of 5 mice 
per group.  Data represents results obtained in two independent experiments. (*p<0.05, 
**p<0.01, ***p<0.001). 
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Figure 6. GC formation after T-dependent immunization 
ADAM10B−/− and WT mice were immunized with 10μg NP-KLH emulsified in alum. 
Fourteen and 21 days post-immunization, flow cytometry was carried out and the 
presence of GC B cells (IgMloIgDloB220+IgG1+CD38−) in the spleen of WT and 
ADAM10B−/− mice was assessed. Staining protocol is depicted (A). Both percentage (B) 
and total number (C) of GCs were enumerated. ADAM10B-/- (filled bars) and WT (open 
bars). Bars represent the mean ± SE of eight mice per group. *p < 0.05, **p < 0.01. 
Data are representative of three independent experiments. 
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Figure 7.  Immunohistochemistry analysis of GC formation and LN architecture 
after T-dependent immunization 
ADAM10B−/− and WT mice were immunized with 10μg NP-KLH emulsified in alum. 
Fourteen days after immunization, draining LN sections were stained for (A) GL7 
(green) and IgD (red); (B) Thy1.2 (green) and B220 (red); (C) CD21/35 (green) and 
B220 (red). D, Non-draining LNs were also stained with CD3 (green) and B220 (red). 
Photomicrographs are representative of three independent experiments. Original 
magnification ×20. 
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Figure 8.  Immunohistochemistry analysis of GC formation and splenic 
architecture after T-dependent immunization 
 ADAM10B−/− and WT mice were immunized with 10μg NP-KLH emulsified in alum. 
Fourteen days after NP-KLH immunization, spleens were isolated and sectioned. 
Sections were stained for (A) GL7 (green) and IgD (red). Photomicrographs are 
representative of three independent experiments. B, Spleens isolated from naive 
animals or (C) isolated 14 d post-immunization, were stained with CD3 (red) and B220 
(green). Photomicrographs are representative of three independent experiments. 
Original magnification ×20 (A, B); ×10 (C). 
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ADAM10B-/- mice have dysregulated chemokine expression following antigen challenge 
Chemokine gradients maintain tight control over the organization of secondary 
lymphoid tissue.  To determine if altered chemokine expression was contributing to the 
structural changes observed in the ADAM10B-/- mouse, we assessed draining and non-
draining LN chemokine expression by quantitative PCR. As expected, non-draining LNs 
from control and ADAM10B−/− mice had similar CXCL13, CCL19, and CCL21 expression 
(Figure 9A). In sharp contrast, draining LNs isolated from ADAM10B−/− mice exhibited 
increased CCL21 expression, whereas CXCL13 levels were comparable. CCL19 levels 
trended higher, but the increase was not statistically significant (Figure 9B). Analysis of 
CCL21 expression by immunohistochemistry revealed diffuse staining in the 
ADAM10B−/− LNs consistent with the localization of T cells within draining LNs (Figure 
9B). These results demonstrate that B cell-expressed ADAM10 is important for 
maintenance of lymphoid architecture by regulating chemokine expression during active 
immune responses.   
Defect in humoral in ADAM10B-/- mice is Notch2 and CD23-independent 
Recent studies have suggested that Notch signaling might be involved in antibody 
production and ASC differentiation50,57. ADAM10 is critical for Notch signaling. 
ADAM10B−/− mice that have constitutively active Notch2 signaling in B cells 
(ADAM10B−/−N2ICD-TgB+) were immunized, and antibody production, GC formation, and 
LN architecture were examined to determine whether the antibody production defects 
were due to impaired Notch signaling. As expected, expression of N2ICD recovered MZ 
B development in these mice, demonstrating that the transgene was indeed active 
(Figure 10A). Littermate controls, ADAM10B−/−, and ADAM10B−/− N2ICD-TgB+ mice were 
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immunized. Consistent with previous experiments, ADAM10B−/− mice had significantly 
reduced levels of NP-specific antibodies. Importantly, introduction of N2ICD transgene 
failed to rescue the defect in antibody production and GC formation, and did not prevent 
changes in LN architecture (Figure 10B,C). These results demonstrate that increased 
Notch signaling cannot rescue the defects in humoral responses observed in 
ADAM10B−/− mice.  
Our lab reported that ADAM10 is responsible for the cleavage of the low-affinity 
IgE receptor, CD23119, and consequently, ADAM10B−/− B cells have increased CD23 
expression56,127. Studies have revealed that CD23 overexpression leads to decreased 
IgG1 and IgE production112,128. However, when CD23Tg mice were immunized with NP-
KLH, analysis of NP-specific IgG indicated that CD23Tg mice had a normal antibody 
response to NP-KLH (Figure 11). Furthermore, it has been previously reported that 
CD23Tg mice form GCs post-immunization with T-dependent antigens.  It should be 
noted that the GCs observed in CD23Tg mice had a more globular appearance than 
WT129.  These results suggest that the humoral defect observed in ADAM10B−/− mice is 
not secondary to CD23 overexpression, however, this should be more carefully 
addressed. 
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Figure 9. Chemokine expression in draining LNs 
Mice were immunized in the footpad with 10μg NP-KLH. Fourteen days post-
immunization, draining and non-draining LNs were isolated and chemokine expression 
was analyzed by quantitative PCR for CCL19, CCL21, and CXCL13. Non-draining (A) 
and draining (B) LNs are shown. (C) Draining LNs were stained for CCL21 and CD3.  
Pictures are representative of three mice per group *p < 0.05. Bars represent the mean 
± SE of eight mice per group. Data are representative of two independent experiments. 
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Figure 10.  Defects in humoral responses in ADAM10B-/- mice seem to be Notch2-
independent 
(A) Splenocytes isolated from ADAM10B-/-, ADAM10B-/-N2ICD-TgB+ and WT mice were 
stained with B220, CD23, CD21/35 and IgM.  MZ B cells were defined as B220+CD23-
/loCD21/35hiIgM+. (B) ADAM10B-/-, ADAM10B-/-N2ICD-TgB+, and WT mice were immunized 
i.p. with NP-KLH emulsified in alum. At the indicated times, serum samples were 
collected and total NP-specific IgG was determined by ELISA.  Bars represent the mean 
± SE of 5 mice per group.  (C) Mice were immunized in the footpad with NP-KLH, 14 
days later draining LNs were isolated and stained for GL7 and IgD (top) and Thy1.2 and 
B220 (bottom).  Data represents results obtained in two independent experiments. 
(*p<0.05, **p<0.01, ***p<0.001, One-way ANOVA with Tukey post-test).  Significance 
refers to ADAM10B-/- compared to WT and ADAM10B-/-N2ICD-TgB+ compared to WT.  
ADAM10B-/- and ADAM10B-/-N2ICD-TgB+ were not different from each other at any time 
point. 
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Figure 11.  CD23Tg mice have a normal IgG response to NP-KLH 
CD23Tg and WT mice were immunized with NP-KLH emulsified in alum.  At the 
indicated times, serum samples were collected and total NP-specific IgG was 
determined by ELISA.  Bars represent the mean ± SE of 8 mice per group. Data 
represent results obtained in two independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
49 
 
 
 
 
 
 
 
 
 
 
 
 
   
50 
 
1.3.3 Discussion 
Members of the ADAM family regulate a wide range of functions, including cell 
migration, proliferation, and adhesion130. ADAM10, in particular, has been recently 
shown to be critical for lymphocyte development through initiation of the canonical 
Notch signaling pathway47,56. We report that ADAM10 is essential for the maintenance 
of splenic and LN architecture during responses to T-dependent Ags. A decrease in Ag-
specific IgG production is seen both with respect to serum levels and IgG ASCs, 
indicating that PC differentiation is influenced. Cells producing high-affinity antibodies 
were particularly affected, consistent with a defect in GC reactions and markedly 
repressed FDC-reticula. Moreover, ADAM10-deficient B cells are able to class switch 
normally when stimulated in vitro. Therefore, the defective humoral response in 
ADAM10B−/− mice results from impaired B cell activation in vivo.  
Impaired Notch signaling and increased CD23 expression, are not likely to contribute to 
the phenotype observed in ADAM10B-/- mice 
To determine the mechanism for the observed severely impaired humoral 
functions and lymphoid architecture disruption, we investigated the two clear substrates 
for ADAM10 in B cells: Notch and CD2347,56,119. The role of notch signaling in mature B 
cell function is controversial. Although some studies have clearly shown a role for Notch 
in antibody production, others fail to identify such a role57,131. To assess the role of 
Notch signaling in antibody production, we overexpressed N2ICD in a B cell-specific 
manner. In this study, we show that restoration of Notch2 signaling in ADAM10B−/− mice 
is not sufficient to rescue antibody production or GC formation. Studies have shown that 
N2ICD and N1ICD have redundant functions. Our results, therefore, suggest that the 
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phenotype observed in ADAM10B−/− mice is not dependent on Notch1 or Notch2 
signaling132. However, the role of Notch1 in B cell biology should be more thoroughly 
studied. In vitro studies have demonstrated that Notch signaling enhances B cell 
activation133 and support GC B cell survival134. Although Notch signaling enhances 
humoral responses in vitro, decreased Notch signaling does not explain the phenotype 
observed in ADAM10B−/− mice. Because Notch signaling also enhances CD21 
expression, this finding also suggests that CD21 is not involved in the ADAM10B−/− 
phenotype. In addition, unlike CD21/CD35−/− mice, ADAM10B−/− mice had impaired 
affinity maturation and failed to mount an antibody response comparable with controls 
even after immunization with large Ag dosages (i.e., 1 mg)135.  
CD23 is also known as the low affinity IgE receptor and is another B cell-expressed 
ADAM10 substrate is CD23119. We have recently demonstrated that CD23 surface 
expression is significantly enhanced after deletion of ADAM10 in B cells56. Defects 
observed in ADAM10B−/− could result from CD23 overexpression. Previous studies with 
CD23Tg mice, however, demonstrated that elevated CD23 levels resulted in inhibition 
of IgE and IgG1 production, whereas other classes were not significantly affected. 
Furthermore, the defect was evident only after boosting112,129. In contrast, in 
ADAM10B−/− mice, all classes of IgG were influenced, and this defect was observed 
after one injection. Moreover, when immunized with NP-KLH, CD23Tg mice had Ig 
levels comparable with that of WT. In contrast, ADAM10B−/− mice showed diminished 
levels of both low- and high-affinity anti-NP antibodies. These results indicate that 
elevated CD23 levels do not explain the phenotype of ADAM10B−/− mice. It is likely that 
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B cells express another ADAM10 substrate that is responsible for the observed 
phenotype in ADAM10B-/- mice.  
ADAM10 is important for B cell follicle formation and maintenance of lymphoid 
architecture 
In lymphoid organs, the correct positioning of cells, such as B and T cells, is 
dictated by the local production of chemokines by stromal cells, as well as the 
coordinated expression of chemokine receptors by migrating cells125. The positioning of 
these cells and the migration during an immune response are critical for adequate 
interaction between them134. Our results demonstrate that although B cell-expressed 
ADAM10 is dispensable for proper cellular positioning during LN and spleen 
development, ADAM10 is critical for the maintenance of the correct position of cells 
after immune stimulation.  
CCL21, CCL19, and CXCL13 have been shown to play a key role in inducing 
and maintaining normal cellular compartments1. Draining LNs from ADAM10B−/− mice 
showed increased CCL21 expression. This increase in CCL21 was also confirmed at 
the protein level by immunohistochemistry. Interestingly, ADAM10B−/− mice had a larger 
area of CCL21 staining. The larger area of production is consistent with the aberrant T 
cell localization seen in draining LNs.  
FDCs are important for GC development, CSR, SHR, and affinity maturation, as 
well as induction of recall responses136–139. FDCs also secrete CXCL13 and are thus 
important for recruitment of CXCR5-expressing B cells and T cells into the follicle140, 
and are important for the maintenance B and T cell zones134. The loss of B and T cell 
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segregation and the lack of GCs in the draining secondary lymphoid tissues of 
ADAM10B−/− mice is thus consistent with fewer activated FDC networks. TNFα is 
another ADAM10 substrate, and it has been implicated in the formation of primary B cell 
follicles and GCs. TNFα global knockout mice have severe defects in T-dependent 
immune response as well as have defective FDC networks, GC formation and B cell 
follicle maintenance141.  Additionally studies done with mice expressing non-cleavable 
TNFα on B cells have defective secondary lymphoid tissue formation142.  The primary 
sheddase for TNFα is ADAM17, the ADAM most closely related in structure to 
ADAM1012,143.  Recent work done by Folgosa et al. has shown that ADAM10 deletion 
results in up regulation of ADAM17 in a compensatory mechanism29,144.  This up 
regulation of ADAM17 increases the cleavage of membrane bound TNFα, converting its 
active soluble form144.  Additionally, these studies show that the compensatory increase 
in ADAM17 and thus increased cleavage of TNFα induces a feedback loop to further 
increase TNFα production29.  Folgosa et al. shows that ADAM10B-/- mice express 
increased levels of ADAM17, decreased levels of ADAM10 and increased TNFα on B 
cells29.  This increase in TNFα is also seen within the immunized LNs of ADAM10B-/- 
mice.  This work implicates that increased TNFα in ADAM10B-/- mice results in the 
observed defects see in secondary lymphoid architecture29.   
Conclusions 
In conclusion, examination of humoral responses in B cell-specific ADAM10-
deficient mice has demonstrated that ADAM10 is critical for the maintenance of splenic 
and LN architecture during active immune responses. ADAM10B−/− mice have impaired 
GC formation, affinity maturation, and CSR. Therefore, B cell-expressed ADAM10 is 
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required for proper humoral responses. Thus, B cell-expressed ADAM10 is essential for 
the maintenance of lymphoid structure after Ag challenge. 
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Chapter 4:  B cell ADAM10 expression and activity is increased during active 
allergy 
1.4.1 Introduction to CD23 
 The low affinity IgE receptor, (FcεRII) is also known as CD23.  Through an 
unknown mechanism, when IgE is bound, signaling though this receptor shuts down IgE 
synthesis, creating a negative feedback loop145,146.  CD23 is a 45kDa (in humans), type 
II transmembrane protein and is a member of the calcium-dependent (C-type) lectin 
family.  CD23, in its membrane bound form is a trimer145,146.  It has two isoforms, CD23a 
and CD23b, in mice the first being found on B cells and FDCs and the latter found 
mainly on gut epithelial cells and FDCs139,147,148.  In humans CD23a is found on B 
lymphocytes and CD23b is found on a variety of hematopoietic cells and others cell 
types including epithelial cells149. 
 Murine models of CD23 expression have given insight into the in vivo effects of 
CD23 on IgE synthesis.  CD23 deficient mice show increased antigen specific IgE when 
immunized with T-dependent antigens150.  They also show increased specific-IgE and 
airway hyper-responsiveness to murine asthma models151.  CD23Tg mice created using 
the MHC class I promoter and IgH enhancer have decreased basal serum IgE levels as 
well as IgG1.  These mice also have decreased IgE and IgG1 in response to ova/alum 
immunization and helminth infections112.  Both strains of mice show evidence, that 
CD23 is an important negative regulator of IgE synthesis.  CD23 can be cleaved into a 
soluble form. Soluble CD23 (sCD23) can still bind IgE, but with much lower affinity than 
it’s membrane bound form146,152. Soluble CD23 has also been shown to bind CD11b-
CD18 on monocytes, leading to activation, differentiation into macrophages and release 
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of inflammatory mediators153,154.  Soluble CD23 has been shown to be increased in sera 
of allergic patients in active allergy season, correlative with increased IgE levels155.  
Increased cleavage of CD23 leaves less membrane bound CD23 to negatively regulate 
IgE response as well as increased sCD23 to interact with other ligands to increase 
inflammation.  This makes blocking cleavage of CD23 an important target in regulating 
IgE synthesis and allergic response.  This has been demonstrated using an antibody 
against CD23 in a mouse model of human rheumatoid arthritis resulting in reduction of 
clinical symptoms that was dose dependent156. 
 ADAM10 has been shown as the principal protein responsible for cleaving 
CD23119.  ADAM10 is ubiquitously expressed on all cells types.  ADAM10 has many 
other important substrates (previously described, see section 1.1.1).  ADAM10B-/- mice 
have decreased sCD23 and increased membrane bound CD23, but similar CD23 
message levels56. This supports the model of CD23 cleavage where CD23 is 
internalized by the B cell and moved into Multi-vesicular bodies (MVBs) where it then 
interacts with ADAM10 with increased binding152.  ADAM10, being a major regulator of 
CD23 has potential to be an important therapeutic target in regulating IgE synthesis in 
allergic disease.  ADAM10’s importance in cleavage of many other essential proteins 
makes regulating it difficult, but local drug delivery systems could potentially allow local 
benefits without global negative side effects. 
1.4.2 ADAM10 in allergic asthma models 
In a previous study in our lab, Mathews et al. showed that when surface levels of 
CD23 are increased, the features of IgE-dependent experimental asthma are reduced. 
This was shown using CD23Tg mice and ADAM10B-/- mice, which both have high levels 
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of surface CD23 as well as with WT mice treated intranasally with ADAM10 inhibitor152. 
It was also shown that when ADAM10 was blocked either genetically or with an inhibitor, 
there was a decrease in antigen-specific IgE, Th2 cytokines in the lung, lung AHR, lung 
inflammation, and infiltration of eosinophils152. Additionally, with the ADAM10 inhibitor, 
Th2 transcription factor, GATA3 expression was decreased, but Th1 transcription factor, 
Tbet, was not152. Overall, these results demonstrate that ADAM10 is important to the 
Th2 driven allergic response beyond control over IgE synthesis by CD23 cleavage.  
1.4.2 ADAM10 in allergic patients 
Previous studies have shown that increased serum IgE in allergic patients with 
seasonal allergic rhinitis correlate with increased sCD23155.  This argues that ADAM10 
levels are responsible for this increase in sCD23 in active allergic patients.   Moreover, 
given the data showing that B cell ADAM10 plays an important role in regulating Th2 
immune responses in mouse models of asthma, we wanted to characterize the ADAM 
levels on patients in active allergic disease.  Here, we show that symptomatic allergic 
patients have increased total ADAM10 expression on B cells, but not on T cells or 
monocytes.  We additionally show that allergic patients have increased ADAM10 activity 
on B cells as measured by sCD23 output. 
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Chapter 5:  Materials and Methods 
1.5.1 Human studies 
Allergic rhinitis (allergic) patients and non-allergic, control patients were recruited to the 
study by Dr. Anne-Marie Irani in pediatric allergy clinic at Virginia Commonwealth 
University.  Patients were consented and completed an IRB approved survey before 
enrollment into the study was permitted.  Twenty mLs of peripheral blood was obtained 
from either allergic or non-allergic controls.  Peripheral blood mononuclear cells (PBMC) 
were separated using Ficoll-Paque Plus (GE Healthcare), then stained for flow 
cytometry or set up for in vitro cultures. 
1.5.2 Flow cytometry 
Staining protocol 
Human PBMC were washed with PBS and 100,000 cells were resuspended in 50µL 
FACs Buffer (see section 1.2.6 for recipe).  Samples were blocked on ice for 15 minutes 
with Human Fc Block (Milltinyi Biotec).  Anti-human antibodies were then added at 
concentrations according to manufacturer’s protocol.  For intracellular total staining, 
cells were fixed with 500µL x for 15 mins on ice (add fixative name here).  Samples 
were then washed with PBS and permeabilized with 1X Perm Wash (company) for 10 
minutes on ice.  Samples were washed in PBS and resuspended in 50µL PBS.  
Samples were then Fc blocked and stained as described above.  Samples were run on 
the Canto (BD) with Diva software and data was analyzed with Flowjo v7.6.5 software 
(Tree Star). 
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Antibodies 
All antibodies used for Allergic patient flow cytometry are listed in Table 3. 
1.5.3 In vitro cultures 
Allergic patient or control PBMC was counted and plated in cRPMI 1640 containing 10% 
FBS, 2mM L-glutamine, 50µM 2-mercaptoethanol,100 U/mL penicillin, 100g/mL 
streptomycin, 1mM HEPES (Quality Biological), and 1mM sodium pyruvate (Cellgro).  
PBMC was cultured at set cell concentrations with 200ng/mL human IL-21 (American 
Type Culture Collection (ATCC)), anti-CD40 (Clone G28-5, ATCC), and 10ng/mL rhIL-4 
(R&D).  10µM ADAM10 inhibitor or DMSO vehicle control were added where described.  
Cell-free Supernatants were harvested on Day 5 for sCD23 ELISA. 
1.5.4 Enzyme Linked Immunosorbent Assay 
sCD23 ELISA 
 Plates were coated with mouse anti-human CD23 (the Binding Site) at 2µg/mL in 
BBS (see previous section 1.2.5 for recipe) and incubated at 37°C for 1 hour.  Plates 
were then washed three times with ELISA wash (section 1.2.5).  Plates were blocked in 
PBS with 10%FBS for 1 hour at 37°C and were washed as above.  Samples were 
added at various concentrations, diluted in media.  EcCD23LZ (in house) standards 
started at 1µg/mL and were serially diluted in media.  Plates were incubated and 
washed as previous.  Sheep anti-human CD23 (the Binding Site) was added at 1:200 
dilution in block.  Plates were incubated as previous.  Plates were then washed five 
times with ELISA wash and the detection antibody, Rabbit anti-Sheep IgG conjugated to 
horseradish peroxidase HRP (Southern Biotech) was added at 1:1000 diluted in block. 
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Plates were again incubated as previous and were then washed seven times with 
ELISA wash.  TMB substrate was added at a 1:1 mixture and incubated for 15 minutes 
at room temperature in the dark.  When plates were fully developed, STOP solution 
(0.18M H2SO4) was added to stop the reaction by denaturing the HRP enzyme. Plates 
were read at 450nm.  
1.5.5 Reagents 
The ADAM10 hydroxamate inhibitors, INC008765157, were synthesized by the Incyte 
Corporation. These inhibitors are very selective for ADAM10 as shown by both cell free 
as well as cell-based assays requiring at least 5 fold higher concentrations to inhibit 
MMP12 and at least 20 fold to inhibit any other enzymes including ADAM17157. 
1.5.6 Statistical analyses 
Data was analyzed as in section 1.2.8 except that when noted, error bars represent a 
95% confidence interval. 
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Table 3.  Antibodies for flow cytometry 
Specificity Clone Conjugate Company 
Human-ADAM10 163003 FITC R&D 
Human-CD19 HIB19 PE Biolegend 
Human-CD3 HIT3A PE Biolegend 
Human-CD14 HCD14 APC Biolegend 
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Chapter 6:  Characterizing ADAM10 in allergic patients PBMC 
1.6.1  Allergic Patients B cells have increased ADAM10 levels and activity. 
Allergic patients have increased total B cell ADAM10 
Previous studies have shown that increased serum IgE in allergic patients with 
seasonal allergic rhinitis correlate with increased sCD23155.  This argues that ADAM10 
levels are responsible for this increase in sCD23 in active allergic patients.  Therefore, 
we examined total ADAM10 levels in allergic patients versus control.  Allergic patients 
were identified by Dr. Anne-Marie Irani.  Patients were consented and asked to fill out 
an IRB approved questionnaire.  Twenty milliliters of blood was collected with 
venipuncture from each patient enrolled in our study, allergic or control.   
Clinical diagnosis, Nasal cytology, symptom score and sensitization information 
such as skin-prick testing or RAS test are all standard of care at the clinic where our 
patients are recruited.  The study clinicians, Dr. Anne-Marie Irani, MD and Dr. Neil 
Roberts, MD, have access to this information to better classify the patients, without 
patients having to undergo any additional procedures.  Our patient questionnaire asks if 
the patient has had a positive skin test result and what they are allergic to.  It confirms 
that the patients are having allergic symptoms at the time of blood draw and provides a 
checklist of symptoms for easy description.  Symptoms listed are sneezing, itchy nose 
or eyes, runny nose, redness in the eyes, wheezing or coughing.  It also asks what 
medications that the patients are currently taking.  It specifically asks if the patient is on 
anti-histamines or steroids.  This information helped us classify each patient as being in 
active allergy as well as to exclude medicated patients for this study.  We recruited 
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patients with asthma and allergic rhinitis, both conditions known to have elevated serum 
IgE levels158–160.   
Total ADAM10 levels were measured on B cells and T cells.  Membrane bound 
ADAM10 was traditionally thought to be involved in the cleavage of CD23.  Though 
some plasma membrane bound ADAM10 may be cleaving CD23, we consider this to be 
a minimal contribution.  Recent data has shown that the majority of cleavage takes 
place inside the cell35.  This makes it necessary to stain intracellular for ADAM10 as well 
as staining for membrane bound ADAM10.  In Figure 12A and B, we show that total 
ADAM10 is significantly elevated in patients with allergic disease over control, whereas 
membrane ADAM10 levels alone are comparable. 
ADAM10 is not elevated on T cells or monocytes of allergic patients 
ADAM10 levels on T cells and monocytes were used as controls to show that this 
is a B cell specific phenomenon and that ADAM10 is not constitutively elevated in all 
peripheral leukocyte varieties in active allergy.  Total ADAM10 levels were not different 
on CD3+ T cells or CD14+ monocytes from allergic vs. control PBMC (Figure 13A,B) 
sCD23 is increased in culture supernatant of stimulated allergic patient PBMC over 
control in an ADAM10 dependent manner 
 ADAM10 was identified as the primary ‘sheddase’ for CD23119.  This makes the 
soluble product of ADAM10 cleavage of CD23 or sCD23, a good indicator of ADAM10 
activity.  PBMC from allergic patients or controls was plated with conditions to stimulate 
B cell proliferation.  After five days of culture, sCD23 was analyzed from the 
supernatants.  Allergic patient cultures were found to have higher levels of sCD23 
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(Figure 14A).  To confirm this was from ADAM10, an ADAM10 inhibitor was added to 
the culture.  Compared to vehicle, ADAM10 inhibition reduced both allergic and control 
sCD23 (Figure 14B).  This shows that CD23 cleavage is due to ADAM10 activity. 
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Figure 12. Allergic patients have increased total B cell ADAM10 
(A) Peripheral blood CD19+ B cells from 16 control (square) and 16 allergic (circle) 
patients were fixed, permeabilized, and analyzed for total ADAM10 (A) Error bars 
indicate 95% confidence interval. (B) Peripheral blood CD19+ B cells from control 
(circle) and allergic (square) patients were analyzed for surface ADAM10 expression. 
***p <0.0005. 
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Figure 13.  ADAM10 is not elevated on T cells or monocytes of allergic patients 
Peripheral blood CD3+ T cells (A) and CD14+ monocytes (B) were fixed, permeabilized, 
and analyzed for total ADAM10 expression by flow cytometry. Gated off of live cells 
based on FSC and SSC. In A, Allergic are represented by (square) and control (circle). 
In B, Allergic are represented by (red circle) and control (black square).  There is no 
significant difference between columns (A,B).  Error bars represent ± SEM. 
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Figure 14. sCD23 is increased in culture supernatant of stimulated allergic patient 
PBMC over control in an ADAM10 dependent manner 
Cell-free culture supernatants were measured for sCD23 levels by ELISA. A. After five 
days of stimulation with IL-21, IL-4 and anti-CD40 sCD23 was measured of control 
(triangle) or allergic (circle) culture supernatants.  B. 10µg ADAM10 inhibitor INC008765 
was added to cultures of allergic (closed bar) or control (open bar) PBMC. ADAM10 
inhibitor was dissolved in DMSO.  Statistical analyses compare DMSO vehicle and 
inhibitor.  Error bars represent ± SEM.  *p<0.05, ***p<0.0005. 
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Section 2 
Chapter 1: ADAM10 in MDSC development and function 
2.1.1 ADAM10 and myeloid cell development 
In the classical model of hematopoiesis, hematopoietic stem cells (HSCs) 
differentiate to yield common myeloid progenitors (CMP) and CLP161. CMPs undergo 
further differentiation into mature myeloid cells, including myeloid-derived suppressor 
cells (MDSC). Due to the negative role of these suppressor cells in anti-tumor 
responses, myeloid differentiation has been the subject of many recent 
investigations162. As discussed further below, numerous hematopoietic pathways, 
including Notch signaling, have been implicated but remain controversial. Several 
investigators have reported that alterations in Notch signaling have minimal effects on 
the myeloid compartment48,163,164.Yet, Kawamata et al. reported that constitutive Notch 
signaling promotes myeloid differentiation in a non-cell autonomous manner52.This is 
supported by a report of abrogated B cell and myeloid cell development in mice 
deficient in downstream targets of Notch165. However, other studies have indicated that 
Notch signaling inhibits myeloid differentiation166,167. Qyang et al. demonstrated that 
blockade of Notch signaling at the γ-secretase cleavage site induces myeloid 
accumulation167.  
 Many of these alterations were observed in mice with altered lymphocyte 
development. This suggests that ADAM10 directed Notch signaling may modulate the 
differentiation pathway of CLPs and CMPs from a common upstream progenitor. Two 
groups have recently described common myelo-lymphoid progenitors (CMLPs) that are 
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indistinguishable from HSC161,168. Although these multipotent cells often commit to the B 
or T cell lineage, they retain the potential for myeloid development. Therefore, 
alterations in Notch signaling during lymphocyte development could also affect 
myelopoiesis. Collectively, these findings indicate that myeloid differentiation may be 
regulated by the signal strength and temporal stage of Notch signaling. Therefore, 
examination of other Notch regulators, including ADAM10, could clarify the role of Notch 
signaling in myeloid differentiation. 
2.1.2 Development of myeloid derived suppressor cells (MDSCs) 
The hierarchal differentiation of multipotent progenitors into mature blood cells of 
various lineages is known as hematopoiesis. The microenvironment of the BM provides 
a complex network of cytokines, transcription factors, and intercellular signaling 
pathways that regulate this process169. HSCs are characterized as lacking lineage 
markers.  They express the receptor tyrosine kinase (RTK) c-kit and the surface protein 
Sca-1, together termed Lin- Sca-1+c-kit+ (LSK)170. The expression of Flt3 RTK and 
CD34 further subdivide the LSK compartment into self-renewing long and short-term 
HSC populations as well as a multipotent progenitor (MPP) population. This hierarchy 
descends deeper into lymphoid and myeloid compartments where the progenitors are 
again subdivided into three distinct populations based upon CD34 and low affinity IgG 
Fc receptors (FcγRII/RIII). These include CD34+FcgRII/IIIlo common myeloid progenitors 
(CMP), CD34+FcgRII/IIIhi granulocyte-macrophage progenitors (GMP), and CD34-
FcgRII/IIIlo megakaryocyte-erythroid progenitors (MEP)171.  MPPs then give rise to either 
lineage restricted common myelo-erythroid progenitors (CMEP) or CLPs172. This 
process is dependent upon the expression of three proteins: c-kit, the IL-7 receptor and 
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recombination activation gene 1 (RAG1)173. The relative expression of these act as a 
‘switch’ that determines the ultimate hematopoietic destination. While RAG1 and IL-7R 
expressing CLPs become T and B cells, c-kit+ CMEPs generate myeloid and erythroid 
cells174,175.  
This classical model has been recently challenged by the idea that lineage 
restriction is not necessarily permanent. Several independent observations indicate that 
early thymocyte and B cell progenitors retain myeloid potential, leading to an alternative, 
‘myeloid-based’ mechanism of hematopoiesis161,168. In this model, CMLPs are observed 
give rise to either B cells, T cells, or myeloid cells. The myeloid-based mechanism 
excludes the existence of CLPs, stating that differentiation occurs from these CMLP and 
CMEP progenitors176. This suggests that, although committed toward T or B lineage, 
progenitor cells retain the potential towards myeloid lineage. The existence of progenitor 
myeloid, B and T (p-MBT) cells which are committed B or T cells, yet retain the ability to 
revert back to myeloid cells further support this possibility177. Additionally, the 
observation of several leukemic disease states containing cells of both myeloid and 
lymphoid origin indicate that a close relationship exists between p-MTB progenitors161. 
This process is heavily influenced by the microvasculature in terms of cytokines and 
signaling pathways it can provide to a developing HSC. Therefore, the cytokine profiles 
in any given pathologic state can also heavily impact hematopoiesis and thus the 
subsequent immune response.  
 During acute inflammatory reactions, the host enters a state of ‘emergency’ 
hematopoiesis characterized by increased recruitment of myeloid lineage cells such as 
neutrophils and macrophages178. Unresolved inflammation increases myelopoiesis, 
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shifting the distribution of myeloid subpopulations179. This results in the premature 
release from the BM, a heterogeneous population of mononuclear (CD11b+Gr-1intLy6G- 
Ly6C+) and polymorphonuclear (CD11b+Gr-1highLy6G+ Ly6C-) MDSCs162. These cells 
accumulate in a spectrum of disease states including cancer, the natural aging process, 
solid organ transplantation, parasitic infections, sepsis, autoimmune disease, trauma, 
and burns180–183. The phenotypic and functional characteristics of MDSCs strongly 
underscore their myeloid origin. Common cytokines involved in myeloid development 
have been implicated in the induction of MDSCs. These factors include macrophage-
colony stimulating factor (M-CSF), granulocyte-macrophage colony stimulating factor 
(GM-CSF), IL-6, vascular endothelia growth factor (VEGF), and granulocyte-colony 
stimulating factor (G-CSF). Several transcription factors involved in myelopoiesis are 
interferon-regulatory factor 8 (IRF-8), CAAT/enhancer binding protein-beta (C/EBP-β), 
and PU.1.  These have also been demonstrated to regulate MDSC development184. In 
addition to myeloid differentiation antigen Gr-1 and CD11b, MDSCs also express 
various other markers that are traditionally used to define myeloid cells such as 
CX3CR1, CCR2, CXCL10, CD206, and IL-1β. Recent investigations demonstrate that, 
at the tumor site, MDSCs bear several classically activated (M1) and alternatively 
activated (M2) macrophage phenotypic and functional characteristics185. MDSCs 
express IL-1β, TNFα, CXCL10, and inducible nitric oxide synthase (iNOS) that is 
characteristic to M1 macrophages as well as CD206, and arginase I (Arg I), which are 
M2 specific. Since MDSC development and proliferation occur in an asynchronous 
manner along the differentiation of CMPs and GMPs toward mature myeloid cells, it is 
not surprising that they retain a wide spectrum of myeloid cell characteristics.  
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2.1.3 Development of the ADAM10Tg mouse 
ADAM10Tg mice that overexpress murine ADAM10 cDNA under control of the H-
2Kb promoter and the IgH enhancer region were generated by our lab to study the role 
of ADAM10 in lymphocyte development.  The H-2Kb vector allows expression in early 
lymphocyte progenitors112,186,187.  Inclusion of the IgH enhancer results in preferential 
expression on B lineage cells.  This overexpression of ADAM10 was observed on BM 
cells and markedly reduced the numbers of pro, pre, and immature B cells in the BM 
and an almost complete loss of peripheral B2 B cells56.  The only B cell population 
unaltered by ADAM10 overexpression were peritoneal lavage fluid resident B1a 
(B220intCD11b+CD5+) and B1b cells (B220intCD11b+CD5-)56.  ADAM10 overexpression 
did not alter peripheral T cell levels56. 
 ADAM10Tg animals also exhibited significant myeloid accumulation. In the BM of 
these mice, CD11b+Gr-1+ cells constitute over 90% of the BM cells.  These cells leave 
the BM and migrate to all secondary lymphoid organs.  Spleens of ADAM10Tg mice are 
increased at least 300% in size, filled with these cells. CD11b+Gr-1+ cells outside the 
BM are classified as MDSCs, consisting of monocytic (CD11b+Ly6C+Ly6G-) and 
granulocytic (CD11b+Ly6CintLy6G+) subsets188.  This heterogeneous population was 
observed within the MDSCs in the ADAM10Tg56.   
This expansion of myeloid cells and blockade of B2 cell development in 
ADAM10Tg mice indicates that ADAM10 regulates the commitment of BM progenitors 
to myeloid or lymphoid lineages. Investigations by Gibb et al. showed that 
hematopoietic alterations in ADAM10Tg mice occur prior to the commitment of CLPs to 
the B cells169. Additionally, LSKs are unaffected in the ADAM10Tg but myeloid 
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progenitors are drastically altered.  The profile of myeloid progenitors in ADAM10Tg 
mice shows an almost complete reduction in GMPs and MEPs, with a dramatic increase 
in CMPs, accounting for the overexpression of CD11b+Gr-1+ myeloid cells169.  This was 
confirmed to be a cell intrinsic result of overexpression of ADAM10 and not to be 
alterations in the stromal compartment of the BM56.  
 As previously described, ADAM10 disruption and thus defunct Notch signaling 
dramatically effects embryonic, thymocyte, and MZB development22,47,56.  Studies done 
by Gibb et al. suggest that ADAM10 overexpression may cause myeloid development 
by dysregulating Notch signaling in the absence of sufficient ligand engagement. This is 
caused by generating excessive S2 product that is not processed in the absence of 
ligand-induced γ-secretase activity169. They additionally found evidence that ADAM10 
activity blocks B cell development169.   
Although MDSC accumulation is a byproduct of ADAM10 overexpression in early 
hematopoietic progenitors, ADAM10 expression is not altered in these cells. Here, we 
examined whether ADAM10Tg mice could be exploited to study MDSC-mediated 
immune regulation in an environment devoid of confounding tumor-derived factors. 
2.1.4 Introduction to MDSC Function 
 Despite the ambiguity surrounding their origin, MDSCs are most prominently 
recognized for their role in the anti-tumor immune response.  MDSCs are a 
heterogeneous population divided into two main subpopulations: monocytic and 
granulocytic.  In mice, CD11b+Ly6G-Ly6C+ and CD11b+Ly6G+Ly6Clo surface markers 
define these cells, respectively162,169,189.  Although human markers differ, both subsets 
   
77 
 
are represented.  The heterogeneity of these cells allows for a broad range of cellular 
functions within the total population.  MDSCs have been extensively studied in the 
context of cancer and exert their pro-neoplastic effects through the release of small 
soluble oxidizers, the impairment of T cell/antigen recognition, and the depletion of 
essential amino acids from the local extracellular environment resulting in T cell 
suppression190.  Both subpopulations of MDSCs have been shown to play integral roles 
in this suppression190.  The cumulative effect is increased tumor progression and 
diminished therapy results191.  MDSCs additionally accumulate in and contribute to 
other disease states, such as parasitic infection where MDSCs have been shown to 
play an immunosupportive role183,192,193. 
MDSCs collectively represent a heterogeneous cell population with different 
patterns of surface protein expression.   In the murine system are unified by expression 
of Gr-1 and CD11b. The Gr-1 epitope comprises of Ly6C and Ly6G molecules that are 
members of the Ly-6 family of low molecular weight phosphatidylinositol-anchored cell 
surface glycoproteins194–196.  Expression of the two distinct epitopes of Gr-1, allow the 
differentiation between the two major subpopulations of MDSCs. Ly6G+Ly6Clo MDSCs 
are considered granulocytic and morphologically resemble polymorphonuclear (PMN) 
granulocytes while Ly6C+ MDSCs are considered monocytic and resemble 
mononuclear monocytes. In humans, MDSCs are defined as Lin-HLA-DR-CD34-CD33+ 
and further categorized into monocytic and granulocytic MDSCs by CD14+ and CD15+ 
expression, respectively190. In mice, studies indicate that engagement of the Gr-1 
epitope through Ly6G or Ly6C can differentially regulate myeloid cell activity and the 
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subsequent immune response194,197,198. For example, ligation through Ly6G can induce 
cell death while Ly6C can lead to cellular expansion and differentiation194,198. 
Many groups have reported the utilization of other protein makers to further 
delineate monocytic MDSCs and granulocytic MDSCs. In humans, granulocytic MDSCs 
are defined as CD11b+CD33+CD14loCD15hi and can be further characterized by 
expression of CD66b, a member of the carcinoembryonic antigen family that is 
commonly expressed on human neutrophils. Additionally, human granulocytic MDSCs 
have also been indicated to express VEGFR1 and low levels of CD62L199–201. Although 
these surface proteins are often associated with neutrophils, the main differentiating 
factor between granulocytic MDSCs and neutrophils in humans is that in contrast to 
conventional neutrophils, granulocytic MDSCs are purified from the mononuclear cell 
fraction in density gradients of peripheral blood202.  Another marker, CD124 or IL-4Rα, 
can be used to mark granulocytic MDSCs in patients with non-small cell lung cancer, 
but in melanoma and colorectal cancers it is found on both subpopulations203–205.  
Granulocytic MDSCs, as demonstrated by Trellakis et al., exhibit higher levels of the 
S100 protein, S100A8/A9 complex as compared to S100A9 on monocytic MDSCs in 
patients with head and neck squamous cell cancer (HNSCC)206. Human granulocytic 
MDSCs express IL-13R under suppressive conditions and lower levels of CD33 as 
compared to monocytic MDSCs190,202,206,207.  Work by Duffy et al. on sorting and storage 
of MDSC subsets from gastrointestinal (GI) tumors identifies that CD33 expression may 
not be a beneficial marker for MDSC isolation from human patients.  They show that 
CD33+ and CD33- CD15+ MDSCs have equivalent CD8+ T cell suppression208.   
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Human monocytic MDSCs are mainly defined as CD11b+CD33+CD14hiCD15lo.  
The preferential markers to delineate human monocytic MDSCs from granulocytic 
MDSCs favor granulocytic MDSCs.  But work done by Mandruzzato et al. shows that IL-
4Rα found on both subpopulation of human MDSCs, is important as a suppressive 
marker only in the monocytic MDSC population205.  A third subpopulation of MDSCs is 
often described.  These MDSCs are considered immature MDSCs and are defined by 
Lin-HLA-DRlo/-CD33+CD14-CD15-204.  These MDSCs are thought by many groups to be 
the lineage precursors in humans to granulocytic and monocytic MDSCs188,205,209–214. 
Murine MDSCs have been studied extensively, thus markers identifying the two 
subpopulations are many. Granulocytic MDSCs in mice are defined as 
CD11b+Ly6CloLy6G+.  Researchers have also been known to separate these cells out 
by Gr-1 expression, as granulocytic MDSCs are Gr-1high.  Other groups also indicate 
that granulocytic MDSCs express SLAMF4 (CD244) and/ or CSF-R (CD115) in tumor 
bearing mice203.  Furthermore, Youn and colleagues reported the expression of M-
CSFR on granulocytic MDSCs and utilization of CD244 as a marker of granulocytic 
MDSC identification and T cell suppressing nature. The authors indicate that CD244+ 
granulocytic MDSCs are capable of inhibiting antigen specific T cell responses while 
CD244- granulocytic MDSCs are unable to do so215.  Additionally, Toh et al, reports that 
granulocytic MDSCs express CXCR2 (IL-8Rβ), which binds CXCL1, CXCL2, and 
CXCL5. Granulocytic MDSCs also express CXCL1 and CXCL2 while tumors express 
CXCL5. The ligation of these particular molecules leads to the accumulation of 
granulocytic MDSCs and not monocytic MDSCs in the murine tumor microenvironment. 
In fact, inhibition of CXCR2 inhibited granulocytic MDSC trafficking to primary 
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melanoma tumor216. This is supported by another finding in a murine model of traumatic 
spinal cord injury, indicating the expression of CXCR1 and CXCR2 on granulocytic 
MDSCs217.  
Murine monocytic MDSCs are defined by markers CD11b+Ly6G- Ly6C+.  
Monocytic MDSCs are additionally Gr-1 intermediate and can be differentiated from 
high Gr-1 expressing granulocytic MDSCs without the use of the Ly6G or Ly6C 
epitopes.  In addition, monocytic MDSCs are also characterized by expression of CCR2, 
which is expressed mainly by monocytic MDSCs and not granulocytic MDSCs218. In 
tumor conditions, CCR2 induces monocyte trafficking from the BM, limits entry of tumor 
specific T cells into the tumor microenvironment, and leads to T cell inhibition by 
MDSCs in contact-dependent manner. Murine monocytic MDSCs are further define by 
CD49d, CCR7, and CX3CR1 expression217,219,220. Another group reported the presence 
of F4/80 and CD93 on monocytic MDSCs in Experimental Autoimmune 
Encephalomyelitis (EAE)221.  
In addition to Gr-1 and CD11b in the murine system, both populations are also 
identified by functional markers such as Dectin-1, a non-toll like pattern recognition 
receptor, death receptor FAS, and ADAM1747,198,200.  Both populations of MDSCs also 
express TNFR1 and TNFR2222. 
2.1.5 Survival and Proliferation  
Like neutrophils, granulocytic MDSCs have a reduced life-span, similar to the 3.8 
days reported for neutrophils and are more sensitive to cryopreservation as compared 
to monocytic MDSCs196,208,215. However, granulocytic MDSCs are quickly repopulated 
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from the BM and exhibit up to 80% survival when exposed to tumor explant supernatant 
and GM-CSF177,196,201,223. This has been attributed to delayed apoptosis by increased 
CXCL8224. Despite the prolonged life-span, these conditions did not induce granulocytic 
MDSC proliferation, just survival. This has led to the current notion that monocytic 
MDSCs are the only subset capable of proliferation. In fact, in the same study, Youn et 
al. demonstrates that splenic monocytic MDSCs incorporated more than two-fold BrdU 
as compared to granulocytic MDSCs in tumor bearing mice207.  
2.1.6 Polarization and differentiation 
In addition to a shorter life span, granulocytic MDSCs are also incapable of 
differentiation while monocytic MDSCs can give rise to mature myeloid cells207. In fact, 
CD11b+Gr-1+CCR2+CX3CR1low monocytic MDSCs are capable of differentiating into 
DCs and macrophages under appropriate stimuli219. A recent study indicates that 
monocytic MDSCs can also differentiate into granulocytic MDSCs via epigenetic 
silencing of the retinoblastoma gene. Interestingly, the same study also suggests that 
granulocytic MDSCs can lose their immunosuppressive characteristics and become 
phagocytic upon ex vivo exposure to tumor explant supernatants and GM-CSF225.  
In addition to differentiating into mature cells, MDSCs can be polarized towards 
immunostimulatory type1 or immunoinhibitory type2 cells. Paired immunoglobulin-like 
receptors A and B (PIR-A and PIR-B) along with human PIR homologues belong to the 
immunoglobulin super family. These molecules have recently been demonstrated to 
differentially regulate MDSC polarization. PIR-A and PIR-B were first identified as 
homologues to the human Fc receptor for immunoglobulin A (IgA). It has recently been 
reported that PIR signaling can alter polarization of monocytic MDSCs between the 
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classically activated proinflammatory phenotype (M1) to an alternatively activated anti-
inflammatory (M2) phenotype and vice versa. PIR-A delivers activation signals in 
complex with a homodimeric Fc common γ chain, which harbors an immunoreceptor 
tyrosine-based activation motif (ITAM), resulting in cytokine production in myeloid 
cells226–228.In contrast, PIR-B engagement results in negative signal transduction upon 
phosphorylation of immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and 
recruitment of SH2-homology–containing protein-tyrosine phosphatase-1 (SHP-1) and 
SHP-2. Yan et al. reports that PIR-A ligation induces immunostimulatory M1 like 
monocytic MDSCs while PIR-B inhibits this interaction, in favor of M2-like M-MDSCs. In 
fact, SHP1 inhibition can shift M2 monocytic MDSCs to M1-MDSCs. Furthermore, 
Fridlender et al. also demonstrate that granulocytic MDSCs can also be polarized 
between G1 and G2 phenotypes but this is dependent upon TGF-β signaling. MDSCs 
and tumor cells secrete large amounts of TGF-β that induces pro-tumor G2 granulocytic 
MDSCs. However, blockade of TGF-β signaling via TGF-βR antagonization 
reprogrammed G2 granulocytic MDSCs to tumoricidal G1 granulocytic MDSCs229. 
2.1.7 Oxidative Metabolism of MDSCs 
While both subpopulations of MDSCs express Arg1. Granulocytic MDSCs and 
Monocytic MDSCs specifically generate reactive oxygen species (ROS) and inducible 
nitric oxide (iNOS), respectively162.  Arg1 is widely expressed in murine myeloid lineage 
cells, yet is limited to neutrophil lineage in humans215. The expression of Arg1 allows 
granulocytic MDSCs to contribute to cancer progression via T cell suppression. Arg1 
acts by consuming the essential amino acid L-arginine (L-Arg) and metabolizes it to L-
ornithine and urea, both essential components of cellular proliferation and 
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detoxification230. This in vitro L-Arg depletion by MDSCs, inhibited antigen-specific T cell 
proliferation in OT-1 and OT-2 transgenic mice231,232. Furthermore, in the absence of L-
Arg, T cells exhibit decreased CD3ζ expression, Jak-3, NFκB-p65 translocation and 
IFN-γ production232. CD3ζ is an essential component of the TCR, as it is imperative for 
the intracellular signaling cascade and subsequent T cell activation233. Loss of L-Arg 
decreases cyclin D mRNA transcriptional rates as well as translation, thus arresting T 
cells in G0-G1 phase234. However the depletion of L-Arg does not result in apoptosis 
and both CD3ζ expression and proliferative potential can be restored upon L-Arg 
administration235. Nonetheless, Kusmartsev et al. report that under limited L-Arg 
concentration, NOS produces peroxynitrites (ONOO2), which are strong oxidizing 
agents that nitrate proteins and cause T cell apoptosis236. Arg1 production can be 
induced through IL-13/IL-4Rα signaling and in a murine model of graft versus host 
disease (GVHD) limits disease through T cell suppression182.  
In addition to Arg1, granulocytic MDSCs induce T cell suppression via the 
production of ROS. Although ROS can be produced by several mechanisms, NADPH 
oxidase (NOX2) is primarily responsible for ROS production in leukocytes237. The main 
consequence of MDSC-mediated ROS production is inhibition of T cells in an antigen-
specific manner by inducing MHC class-I restricted T cell tolerance238. Nagaraj et al. 
report that ROS nitrates tyrosine residues on CD8 and the TCR to alter peptide 
recognition but does not induce T cell deletion239. Finally, Granulocytic MDSCs limit 
natural kill cell (NK) responses via H2O2 production240. However, additional experiments 
are required to further elucidate the mechanism of this interaction215. 
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Monocytic MDSCs are more potent suppressors of the immune response188. 
Perhaps one of the main contributions of monocytic MDSC in pathologic conditions is 
the up regulation of iNOS, which generates nitric oxide (NO). Mazzoni et al. report that 
NO production by MDSCs blocks peptide-specific T cell proliferation. Further analysis 
revealed this is due to the prevention of T cells from entering the cell cycle. 
Interestingly, this was reversible.  When T cells were stimulated with Con A in the 
presence of MDSCs, they only regained their proliferative potential once the MDSCs 
were removed. Thus, it is plausible that although monocytic MDSCs prevent T cell 
proliferation, they do not induce apoptosis but transiently induce T cell suppression241. 
The contribution of NO is further elucidated by the observation that MDSCs generated 
from iNOS deficient mice are not suppressive242. Another consequence of iNOS is the 
consumption of L-arginine as discussed above. 
2.1.8 Cytokine production 
Although the cytokine expression profile of each subset is dependent on disease 
state, each subset has been identified with certain cytokines. For example, granulocytic 
MDSCs secrete TNFα upon exposure to LPS, IFNγ, and TGF-β. Monocytic MDSCs 
have been shown to secrete IL-6, IL-10, IL-23, TGF-β, and VEGF-α219,220. The 
concomitant secretion of IL-10 and TGF-β also allows monocytic MDSCs to be potent 
inducers of CD4+CD25+Foxp3+ T-regulatory cells219,220.  
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2.1.9 Cell Signaling 
STAT signaling 
Both monocytic MDSCs and granulocytic MDSCs signal through Janus Kinase 
(Jak) / signal transducer and activator of transcription (STAT) pathways243. STAT 
proteins are latent cytoplasmic transcription factors activated by a variety of 
hematopoietic and immune-mediated cytokine receptors. Monocytic MDSCs utilize 
STAT1 to induce downstream T cell suppression188. Of the STAT signaling pathways, 
STAT3 has been strongly linked with MDSC proliferation and survival162,183. STAT3 
additionally promotes the activity of MDSCs, particularly Arg1 in CD14+ monocytic 
MDSCs244. Using the receptor tyrosine kinase inhibitor, sunitinib, Ko and colleagues 
demonstrate differential STAT3 and STAT5 signaling in murine monocytic MDSCs and 
granulocytic MDSCs. The authors indicate that sunitinib down regulates STAT3, 
subsequently abrogating monocytic MDSC proliferation and impairing granulocytic 
MDSC survival. However, the addition of GM-CSF provides protection via STAT5 
signaling245. Tumor derived factor induction of STAT3 and STAT5 signaling has also 
been implicated in MDSC accumulation through down-regulation of IRF-8 in tumor 
bearing mice as well as late stage breast cancer patients.  Mice overexpressing IRF-8 
have decreased MDSC accumulation and attenuated tumor progression246.   
Notch signaling 
Altered Notch signaling is implicated in MDSC accumulation in the ADAM10Tg 
mice247.  Notch signaling was found to be severely decreased in granulocytic MDSCs 
from breast cancer patients and from tumor bearing mice248. Serine/Threonine casein 
kinase 2 (CK2) is ubiquitously expressed and implicated in Notch signaling248.  Recent 
   
86 
 
work by Cheng et al. showed that in tumor bearing mice CK2 catalytic activity is 
increased in granulocytic MDSCs, but not monocytic MDSCs248.  This enhanced 
catalytic activity of CK2 disrupts the interaction between Notch and transcriptional 
repression CSL, which is needed for normal Notch signaling and DC formation.  
Inhibition of CK2 decreased tumor conditioned media-induced proliferation of murine 
tumor generated granulocytic MDSCs, but had no effect on monocytic MDSCs248.  This 
work implicates tumor derived factors as driving CK2 activity and thus altered Notch 
signaling and the accumulation of MDSCs in cancer. 
2.1.10 Cytokine induced MDSC expansion 
Granulocyte-macrophage colony stimulating factor (GM-CSF) and granulocyte-
colony stimulating factor (G-CSF) are two cytokines predominately associated with in 
vivo MDSC accumulation and in vitro MDSC generation in humans and mice162,169,220. 
GM-CSF is recognized as a critical hematopoietic cytokine, mediating the differentiation 
of myeloid progenitors into granulocytes, eosinophils, monocytes, megakaryocytes, and 
erythrocytes. G-CSF and its receptor are critical regulators of steady state and 
emergency granulopoiesis. G-CSF promotes the survival, mobilization, and proliferation 
of myeloid progenitor cells alongside neutrophil differentiation. Several studies indicate 
that each cytokine preferentially induces granulocytic or monocytic MDSCs. Exposure of 
GM-CSF alone induces immunosuppressive monocytic MDSCs while G-CSF induces 
granulocytic MDSCs249,250. In fact, in human glioblastoma patients, they exhibit high 
levels of G-CSF concomitant with granulocytic MDSC accumulation251. Under steady 
state conditions, G-CSF acts in concert with CXCR2 ligands, CXCL1 and CXCL8 to 
induce mobilization and recruitment of neutrophils, respectively. Therefore, it has been 
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proposed that G-CSF may induce expansion of granulocytic MDSCs via CXCL1 and 
mobilization via CXCL8196. In terms of GM-CSF, Dolcetti et al. demonstrates that 4T1 
mammary cancer cell line, deficient in GM-CSF but not G-CSF, is less 
immunosuppressive due to the differential expansion of G-MDSCs over M-MDSCs250. 
The reduced tumor growth is accompanied by an increase in antigen specific T cells 
lymphocytes in LNs of mice challenged with GM-CSF deficient 4T1. These mice also 
exhibited an accumulation of G-MDSCs that did not affect the generation of tumor 
specific T cells197. Moreover, Greten et al. indicate that human CD14+ monocytes 
purified from healthy donors can be differentiated into suppressive M-MDSCs upon co-
culture with IL-4 and GM-CSF220. Interestingly, the combination of GM-CSF and G-CSF 
induces monocytic MDSCs from BM cells after 4-days of co-culture. Additionally, IL-1β 
has been indicated to inhibit NK cell differentiation in favor of granulocytic MDSCs in 
4T1 mammary carcinoma208,216,252. Recently, murine hepatic stellate cells were found to 
mediate MDSC induction via the complement factor C3 upon adoptive transfer253.  In 
humans, activated hepatic stellate cells induced monocytic MDSCs in a contact 
dependent and CD44 dependent manner204. Lastly, Simpson and colleagues 
demonstrated that the inflammatory cytokine, macrophage inhibitory factor (MIF), 
induces monocytic MDSC differentiation rather than granulocytic MDSCs254. 
2.1.11 Subset accumulation in pathological conditions 
Neoplasia. 
The expansion of MDSC phenotypes is dependent upon the immunoregulatory 
factors altered by a given tumor or tumor model in mice. In humans, monocytic MDSCs 
are mostly associated with melanoma, prostate, lung, gastrointestinal, and 
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hepatocellular carcinoma while G-MDSCs are associated with breast, colon, pancreatic, 
bladder, and HNSC carcinoma220. Granulocytic MDSCs are found to be the most 
abundant population in solid tumors while monocytic MDSCs are more frequent in 
leukemia255. A detailed list is summarized elsewhere, but the overall trend is the 
dominant accumulation of granulocytic MDSCs in human cancer196,225. However, in 
patients with hepatocellular carcinoma, CD14+ monocytic MDSCs continue to be the 
most frequent population in the peripheral blood and tumor220. In humans with renal cell 
carcinoma (RCC) and HNSCC, granulocytic MDSC accumulation is associated with an 
increase in tumor and serum expression of CXCL8 (IL-8), a potent inducer of neutrophil 
motility to site of inflammation224. 
 In naïve mice, MDSCs comprise 2-4% of total nucleated splenocytes with a 3:1 
ratio of granulocytic MDSC to monocytic MDSC220. However, MDSCs can increase up 
to 50% with a 5:1 granulocytic MDSC to monocytic MDSC ratio in tumor bearing 
mice225. The population of granulocytic MDSCs becomes consistently increased in all 
tumor models, whereas the frequency of monocytic MDSCs is only significantly 
increased in a few models such as EL-4 lymphoma and ANV mammary carcinoma. 
Only in Lewis Lung Carcinoma (LLC), granulocytic MDSCs and monocytic MDSCs are 
equally elevated212. Moreover, in a given host, granulocytic MDSCs tend to localize at 
the primary tumor site (24.5% vs 4.2%) while monocytic MDSCs are found in cutaneous 
tumors (3.9% vs. 2.8%)218. In a mouse model of multiple myeloma (MM), monocytic 
MDSCs begin to accumulate within one week of tumor induction while granulocytic 
MDSCs accumulate weeks later. Despite the delay in kinetics, granulocytic MDSCs 
continue to be the dominant population both in the BM and peripheral blood256. In tumor 
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bearing mice, granulocytic MDSCs are recruited out of the BM in response to stromal 
cell derived factor 1α (SDF-1α), the ligand for CXCR4. This was also supported by a 
separate observation indicating the importance of CXCR2 ligand in the recruitment of 
granulocytic MDSCs to primary tumor site. In fact, granulocytic MDSCs were 5 times 
more abundant as monocytic MDSCs and CXCR2 inhibition significantly abrogated this 
observation256. 
 While most attention has been given to the pathogenic mechanism of monocytic 
MDSCs, granulocytic MDSCs are now beginning to be appreciated for their contribution 
to tumor progression. Using a model of spontaneous melanoma, Toh and colleagues 
indicate that granulocytic MDSCs are needed for the early stages of cancer 
dissemination, as late depletion did not alter metastasis to skin, LNs, or lung. 
Additionally, upon co-culture with granulocytic MDSCs, NBT-II bladder carcinoma cells 
acquired a mesenchymal morphology, consisting of actin microfilament redistribution 
and down regulation of E-Cadherin. This was attributed to the production of Hepatocyte 
Growth Factor (HGF) and TGF-β, known inducers of epithelial-mesenchymal transition 
(EMT). Moreover, the same study reported that granulocytic MDSCs promoted tumor 
cell proliferation in a contact-independent manner218. 
Infection 
MDSCs, predominantly granulocytic MDSCs, have been shown to accumulate in 
infections with microorganisms. In this context, they can play a beneficial role in limiting 
unwanted inflammation as mice unable to expand MDSCs exhibit markedly higher 
mortalities to sepsis-associated inflammation183,256,257. As mentioned earlier, bacterial 
infections can skew MDSCs towards antitumor properties. The administration of 
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attenuated Salmonella enterica serovar Typhimurium vaccine (RASV) results in an 
accumulation of MDSCs, particularly the granulocytic subset. These MDSCs were very 
sensitive to LPS stimulation, released large amounts of TNFα, and exhibited anti-tumor 
properties. RASV treatment reduced Her-2/neu expressing tumor growth, shifted MDSC 
differentiation towards granulocytic MDSCs, and enhanced CTL anti-tumor response. It 
is for this reason that Salmonella-based cancer immunotherapies has been pursued 
with promising preclinical results192,258. Furthermore, by limiting immune activation 
MDSCs play a protective role in sepsis. Delano et al. demonstrated that polymicrobial 
sepsis induced significant MDSC accumulation. More reports are surfacing, indicating a 
protective role of MDSCs in microbial infections, especially Pseudomonas aeruginosa 
colonization in burn victims and Staphlococcus aureus biofilm formation post orthopedic 
joint surgery183,195. More recently, it was reported that MDSCs express dectin -1, a non-
Toll-like pattern recognition receptor for β-Glucans, which are the main components of 
numerous bacteria, fungi, and yeast cell wall199. The authors report that whole β-
Glucans particle (WPG) administration preferentially enhances the survival of 
granulocytic MDSCs but does not induce their differentiation. In contrast, WPG 
treatment reduced monocytic MDSC survival but promoted differentiation towards 
CD11c+F4/80+ non-immunosuppressive cells. Monocytic MDSCs were no longer able to 
suppress T cell proliferation in the presence of WPG199. This could be contributed to the 
fact that WPG reduced NO and Arg1 expression in monocytic MDSCs while it did not 
alter ROS expression of granulocytic MDSCs.  
The protozoan parasite, Trypanosoma cruzi is the causative agent of myocarditis 
that manifests into Chagas disease. MDSCs comprise the majority of the inflammatory 
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cell infiltrates in the heart. The most abundant subset in this case is monocytic MDSCs 
(70%) as compared to granulocytic MDSCs (20%)259. Authors of this finding indicate 
that this is mainly mediated via CCL2 chemokine. Interestingly, these infiltrating 
monocytic MDSCs in the heart are not migrating from the BM but rather being 
replenished from the spleen. Like those isolated from the tumor microenvironment, the 
infiltrating monocytic MDSCs also express high levels of Arg1 and iNOS, and inhibit T 
cell proliferation. Given another report indicating the accumulation of granulocytic 
MDSCs in the peripheral organs of T. cruzi infected mice, it is possible that granulocytic 
MDSCs and monocytic MDSCs preferentially migrate to specific anatomical sites in a 
given disease state259,260. 
While the accumulation of MDSCs in parasitic infection has been reported, the 
immunomodulatory potential of these cells remained unknown261. However, here we 
report the beneficial role of MDSCs in this context in the Th2 helminth Nippostrongylus 
brasiliensis. We additionally investigate the mediators and other cell types that are 
involved. 
2.1.12 Interaction with cells other than T cells 
Macrophages 
Macrophages are capable of fighting both intracellular and extracellular 
pathogens and are thus classified into two distinct subsets based upon the cytokines 
required for their activation and the pathogens they target262. Classically activated M1 
macrophages are normally activated by IFN-γ or in response to lipopolysaccharides 
(LPS) to release NO in targeting intracellular pathogens as well as IL-12 and IL-23263. 
   
92 
 
Type I macrophages are characterized as capable of antigen presentation and 
promoting T cell proliferation and activity. In contrast, type 2 macrophages are 
considered to have poor antigen presentation capability as well as inhibit T cell 
proliferation and activity. Upon stimulation by IL-4 or IL-13, alternatively activated (M2) 
macrophages secrete IL-10, TGF-β and Arg-1 in response to extracellular pathogens264. 
MDSCs have not only been shown to resemble M2-like macrophages but also interact 
with macrophages. MDSCs decrease IL-12 production by macrophages and skew their 
differentiation towards an M2 phenotype.  Macrophages in turn promote MDSC IL-10 
production265. Although the authors of this study did not differentiate the subset of 
MDSCs, it can be deduced based on morphology and cytokine production that this 
interaction is mainly within the monocytic MDSC fraction.  In Staphylococcal aureus 
biofilm infections of orthopedic joints, M1 macrophages are essential for clearance of 
the bacteria. Recruitment of MDSCs into the joint causes the skewing of macrophages 
to the M2 phenotype.  This MDSC induced M2 macrophage skewing severely limits the 
ability of the immune system to clear the infection, thus inducing a persistent, chronic 
infection266. 
Dendritic Cells 
 Another cell known to interact with MDSCs is DCs. DCs are professional APCs 
that identify, process, and present antigens to naïve, resting T cells267. This is critical for 
the generation of an appropriate immune response. MDSCs secrete IL-10 that inhibits 
toll like receptor (TLR) ligation and subsequent IL-12 production by DCs. This in turn 
reduces DC mediated T cell activation268. While MDSCs as a group have been shown to 
limit DC maturation, a recent group indicates CD14+ human monocytic MDSCs impair 
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the quality of a DC vaccine. The authors indicate that monocytic MDSCs not only 
prevent DC maturation but also antigen presentation and migration269. Interestingly, 
MDSCs can be converted to DCs. Two studies have been done to this effect, one 
indicating the requirement of NKT Cells and a-galactosylceramide; and another 
suggesting interaction of iNKT with CD1d on MDSCs252,270.  
Mast Cells 
Recent findings are beginning to suggest that mast cells (MCs) contribute to the 
recruitment and activity of MDSCs193,271,272. While MCs have well been documented to 
mediate allergic inflammation, their demonstrated involvement with neoplastic disease 
is more recent.  Here, we investigate the novel interaction between the MDSC and the 
MC. 
2.1.13 Introduction to the Mast Cell 
MCs are large, granular, long-lived cells that typically reside in sites that interface 
with the environment such as the skin and mucosa of the respiratory and GI tracts273,274.  
MCs originate from the BM and terminally differentiate in the tissues274.  MCs serve as 
important sentinel cells and accumulate in the tissues in response to inflammation275.   
MCs are induced by cytokines IL-3, SCF, IL-4 and IL-9275.  MCs are critical regulators of 
innate and adaptive immunity.  Mast cells express FcεRI, the high affinity receptor for 
IgE. Antigen-specific IgE binds to FcεRI and upon encounter with the antigen; IgE 
cross-links the receptor inducing MC activation and degranulation.  This degranulation 
is responsible for a wide variety of allergic reaction such as life-threatening 
anaphylaxis275.  They are key regulators of the anti-parasitic immune response276–278 
through the production of cytokines, and effector cell recruitment, including MDSCs261.  
   
94 
 
It has been long known that increased MC numbers at the tumor site correlates with 
negative prognosis278,279.  This was presumably thought due to their secretion of various 
pro-inflammatory cytokines, MCs have also been shown to secrete mediators such as 
5-LO and IL-17 to recruit MDSCs to the tumor site272,279. 
Mast Cell secreted histamine on MDSC function 
Activated MCs secrete histamine, proteases, and lipid-derived mediators. The 
biogenic amine, histamine, is considered a major mediator released by MCs. Histamine 
acts on a spectrum of cell types through GPCRs, known as HR1–4. The expression 
profile of the HRs determines the net effect on cell growth, motility, phenotypic 
alterations, and signaling mechanisms280–282. Through effects on target cells, histamine 
induces vasodilation, vasopermeability, smooth muscle contraction, and mucus 
production283. Numerous studies have linked excessive histamine production to allergic 
reactions, infections, and tumor growth284,285. Myeloid cells have been reported to 
express HRs and HDC, the enzyme required for histamine synthesis286. Histamine, in 
turn, protects myeloid cells against apoptosis and promotes cytokine production. In fact, 
co-culture of monocytes with histamine has been shown to increase IL-10 and inhibit IL-
12, thus skewing toward Th2 immunity287. Thus, histamine can alter the cytokine milieu, 
transcription factors, and signaling pathways important for MDSC accumulation288. 
Mast Cell secreted IL-13 on MDSC function 
IL-13 is a cytokine made by many cell types including MCs289,290.  IL-4 and IL-13 
are both Th2-polarizing cytokines with overlapping roles291,292.  IL-4 binds IL-4 receptor 
subunit alpha (IL-4Rα) complexed to both the common gamma chain as well as IL-13 
receptor subunit alpha (IL-13Rα).  IL-13 is only able to bind to IL-4Rα with IL-13Rα.  
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However the downstream signaling appears to be divergent dependent on which ligand 
is bound291,292. IL-13 is primarily responsible for the “weep and sweep” associated with 
intestinal parasitic clearance289,290.  This includes enteric nerve stimulation and goblet 
cell hyperplasia289,290.  The role of IL-13 in the context of neoplasia has been a 
controversial one.  Initial studies found beneficial roles for both IL-13 and IL-4 in tumor 
rejection292–295.  These effects were noticed mainly in tumor lines that were genetically 
engineered to overexpress the cytokine292,293.  Currently, the evidence demonstrating 
IL-13 as tumor promoting is becoming more and more abundant296–298. Phase I/II clinical 
trials are even underway for use of IL-13-PE (Cintredekin besudotox) in patients with 
metastatic and locally advanced adrenocortical carcinoma (ACC) and other advanced 
solid tumors with high expression of IL13Rα2299. Human studies of pancreatic, 
esophageal, and gastric tumors show that increased IL-13 in plasma is directly 
correlated with MDSC levels and increased mortality296.  IL4Rα is expressed on MDSCs 
and is related to the suppressive nature of the cells300.  IL-13 signaling through IL-4Rα 
on MDSCs induces increased production of Arg1, thus, increasing T cell suppression300.  
Mice deficient in IL-4Rα have decreased Arg1 expression in the tumor 
microenvironment and decreased tumor growth in a mouse model of glioma301.  
Additionally, with blockade of IL-4Rα and subsequent loss of IL-13 signaling, 4T1 tumor 
progression is delayed.  MDSC apoptosis is increased as well as CD8+ T cell infiltration 
to the tumor site298.  The source of IL-13 has been debated, until recently when MC-
derived IL-13 was shown to play an important role in tumor-genesis of pancreatic ductal 
adenocarcinoma297.  The function of IL-13 in tumor development seems to be closely 
related to the source, timing of expression, dosage, as well as the molecular and 
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cellular environments301.  Other than induction of Arg1, thus increasing suppressive 
capabilities of MDSCs, the role of IL-13 in MDSC function is largely unknown182. 
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Chapter 2: Methods and Materials 
2.2.1 Mice 
Mice were kept at Virginia Commonwealth University (VCU) in accordance with the 
humane treatment of laboratory animals set forth by the National Institutes of Health 
and the American Association for the Accreditation of Laboratory Animal Care. C57BL/6 
ADAM10Tgs were generated by the VCU Transgenic Mouse Core, as previously 
described247. C57BL/6 WT mice, Pmel-1 and KitWsh/Wsh mice were purchased from The 
Jackson Laboratory (Bar Harbor, ME, USA). Cpa3cre; Mcl-1fl/fl mice302 (C57BL/6 
background) were generously provided by Dr. Stephen Galli (Stanford University, 
Stanford, CA, USA).  All mouse protocols were approved by the VCU Institutional 
Animal Care and Use Committee. 
2.2.2 Cell Lines 
Mouse bone marrow-derived MCs (BMMCs) were derived from femurs of WT mice and 
cultured in cRPMI 1640 containing 10% FBS, 2mM L-glutamine, 100 U/mL penicillin, 
100µg/mL streptomycin, 1mM HEPES (Quality Biological, Gaithersburg, MD,USA), and 
1mM sodium pyruvate (Cellgro, Herndon, VA, USA). Cultures were supplemented with 
IL-3-containing supernatant from WEHI-3 cells (1ng/mL) and stem cell factor containing 
supernatant from BHK-MKL cells (10ng/mL).  Mature BMMCs were used after 28 days 
of culture. The LLC cell line was obtained from the American Type Culture Collection.  
The B16-melanoma cell line was maintained in DMEM with 10% FBS, 1% penicillin,1% 
streptomycin, and 1% L-glutamine. B16 melanoma and GM-CSF–B16 cells were 
provided by Harry D. Bear, MD, PhD and maintained as previously described303. 
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2.2.3 Isolation of MDSCs and AT, T cell depletion, and dye labeling. 
Spleens were harvested from ADAM10Tg or LLC-bearing WT mice, depending upon 
the experimental protocol. They were then dispersed into single-cell suspensions and 
filtered through 70-μm nylon mesh strainers (Invitrogen). Erythrocytes were lysed using 
an ammonium chloride potassium lysing buffer (Quality Biological). T cells were 
depleted using CD90.2 magnetic depletion (Miltenyi Biotec, Auburn, CA, USA), 
according to the manufacturer’s protocol. Gr-1+, Ly6G+, or Ly6C+ cells were purified 
from ADAM10Tg spleens using the EasySep PE-Selection kit (Stemcell 
Technologies,Vancouver, BC,Canada), according to the manufacturer’s protocol. For 
AT studies, 10 × 106 ADAM10Tg MDSCs were injected into the tail vein of each 
experimental group every 3 days.   For T cell depletion, mice were injected i.p. with 200 
μg anti-CD4 (GK1.5) and anti-CD8 (2.43) antibodies on days −3, −2, −1, 0, 5, and 10. 
For AT of dye-labeled MDSCs, cells were stained with the PKH26GL dye-linker kit 
(Sigma-Aldrich, St. Louis, MO, USA), according to the manufacturer’s protocol. 
2.2.4 Arginase1 and iNOS detection 
MDSC cytoplasmic extracts were prepared from isolated ADAM10Tg- and LLC-bearing 
hosts and tested for urea production (DARG-200; BioAssay Systems). NO was 
measured using Greiss Reagent (G7921; Molecular Probes). 
2.2.5 T cell suppression assays 
For polyclonal T cell activation, CD90.2+ T cells were sorted from spleen and activated 
with immobilized anti-CD3 (10μg/mL) and soluble anti-CD28 (1μg/mL) in 96-well plates. 
Sorted MDSCs (Ly6G+, Gr-1+, and Ly6G−) from ADAM10Tg or LLC tumor-bearing mice 
were then added at increasing T cell/MDSC ratios. For Ag-specific T cell suppression 
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assays, soluble gp100 (1μg/mL) was added to defined ratios of pmel-1 transgenic 
splenocytes and ADAM10Tg MDSCs. After 54 hours of culture, 1 mCi [3H] thymidine 
was added to each well for an additional 18 hours, and thymidine incorporation was 
measured. 
2.2.6 BMMC co-culture with ADAM10Tg MDSCs 
BMMCs were derived from femurs of WT naive mice cultured in complete RPMI 1640 
containing 20% WEHI-3–conditioned medium over a 4-wk period. They were 
resuspended at 0.5 × 106 cells/mL, loaded with 0.5μg/ml mouse IgE, and cultured with 
MDSCs at a 1:1 ratio in 10ng/mL IL-3 and 10 ng/mL GM-CSF overnight. MCs were 
activated by DNP-human serum albumin (20–100 ng/mL), and supernatants were 
collected 6 or 18 hours after cross-linking for ELISA. 
2.2.7 Migration Assays 
B16 (2x105), BMMC, or media alone were loaded into the lower well of 8µm transwell 
plates (Corning, Herndon, VA, USA). MDSCs (2x105) were loaded into the upper well.  
Plates were incubated for 4 h at 37°C, and the lower well was harvested for flow 
cytometry. 
2.2.8 Survival curve and proliferation assays 
MDSCs were cultured in cRPMI with 1, 5, 10, or 100µM histamine (Calbiochem, San 
Diego, CA, USA). For survival curves, counts were made with trypan blue dead cell 
exclusion, and cell concentration was 1 x 106/mL in 5mL. For proliferation, MDSCs were 
pre-cultured for 15 min with 10µM CT, CIM, or alone, before histamine addition. Cell 
concentrations were 50,000 cells/well in a 96-well plate. After 48 h, a 24-hour pulse of 
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[H3]-thymidine, 1 mCi/mL (Perkin Elmer, Waltham, MA, USA), was used. Plates were 
harvested using a Filtermate cell harvester onto GF/C plates and read using a 
TopCount plate counter (Perkin Elmer). 
2.2.9 Adoptive immunotherapy of B16 melanoma 
T cells were prepared for adoptive immunotherapy (AIT), as previously described303. 
Recipient mice were injected i.v. with 0.25 × 106 B16 cells. One day prior to AIT, mice 
were treated i.p. with 2 mg cyclophosphamide (CYP) and 1.2 mg gemcitabine (GEM) 
and were treated every 5 days with GEM only.  
2.2.10 PCR and quantitative PCR 
PCR 
Genotyping and PCR were run as described in section 1.2.2.  Primers are listed in 
Table 4. 
qPCR 
MDSCs were isolated, as described previously, and cultured with 100 µM histamine for 
24 hours. Total RNA was extracted using TRIzol reagent (Invitrogen Life Technologies, 
Grand Island, NY, USA). RNA (400 ng/l) was reverse-transcribed using the iScript 
cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). Primers for running an iQ SYBR 
Green Supermix (Bio-Rad) qPCR assay were purchased from Integrated DNA 
Technologies (Coralville, IA, USA). Probes were purchased from Applied Biosystems 
(Life Technologies, Grand Island, NY, USA) Primers and Probes are as listed in Table 
4.  Results were analyzed with Bio-Rad iQ5 Real-Time PCR software (version 2.0). Fold 
variation was determined using ΔΔCt method of analysis. 
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2.2.11 Flow cytometry 
Sample preparation 
Cell isolation and labeling were conducted as described previously in section 1.2.4 and 
1.2.6.  
Immunohistochemistry 
Sample preparation and staining as in section 1.2.6 
Antibodies 
Antibodies are listed in Table 5. 
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Table 4. List of primers for PCR and qPCR 
PCR 
ADAM10Tg Forward 5’-CCA ACA GTG TTA ATT CTG CTC C-3’ 
ADAM10Tg Reverse 5’-TTC TTT CAG CCA GAG TTG TGC G-3’ 
Cpa3-cre Forward 5’-CGA TGC AAC GAG TGA TGA GG-3’ 
Cpa3-cre Reverse 5’-GCA TTG CTG TCA CTT GGT CGT-3’ 
oIMR5147 5’-GCA GTA CAG GTT CAA GCC GAT G-3’ 
oIMR5148 5’-CTG AGA GTT GTA CCG GAC AA-3’ 
qPCR 
Arg1 Forward 5’-GAC CAC AGT CTG GCA GTT GG-3’ 
Arg1 Reverse 5’-TGG TTG TCA GGG GAG TGT TG-3’ 
iNOS Forward 5’-CAC CCC AAG TTC GAC TGG TT-3’ 
iNOS Reverse 5’-CTA AAG GGA CAG GCG CTG AA-3’ 
IL-13 Mm00434206 
IL-4 Mm00445259 
GAPDH Mm99999915 
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Table 5. List of antibodies used for flow cytometry 
Specificity Clone Label Source 
Mouse-Arg1 9819S unlabeled Cell Signaling 
Mouse-HRH2 M-19 unlabeled Santa Cruz 
Mouse-HRH3 C-20 unlabeled Santa Cruz 
Mouse-HRH4 M-12 unlabeled Santa Cruz 
Mouse-Gr1 RB6-8C5 FITC, PE Biolegend 
Mouse-Ly6C HK1.4 APC Biolegend 
Human-CD15 W6D3 PerCP/Cy5.5 Biolegend 
Mouse-CD11b M170 Pe/Cy7 Biolegend 
Human-CD33 WM-53 Pe/Cy7 Biolegend 
Mouse-HRH1 Polyclonal Pe/Cy5 Bioss 
Human-CD11b ICRF44 APC eBioscience 
Human-CD14 61D3 PE eBioscience 
Mouse-Ly6G 1A8 FITC BD Biosciences 
Goat-IgG Polyclonal FITC Santa Cruz 
Rabbit-IgG Poly 4064 Dylight 649 Biolegend 
Human-CD34 561 FITC Biolegend 
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2.2.12 N. brasiliensis infection, GEM treatment, CET treatment, CIM treatment, B16 
melanoma or LLC injection, and AT of MDSCs 
Eggs per gram of feces enumeration 
N. brasiliensis larvae were generously provided by Joe Urban (Agriculture Research 
Station, Beltsville, MD) and were maintained as previously described304. Each 
experimental group of mice was infected with ∼650 stage 3 larvae (L3) N. brasiliensis. 
Fecal egg burdens were enumerated on days 5–13. Fecal pellets were collected from 
mice and weighed.  Fecal weight determined calculated amount of flotation solution 
(saturated sodium chloride solution in diH2O) to be added. Feces were dissolved in 
500µL diH2O for approximately 30mins. Flotation solution was then added. [(Fecal 
weight (grams) x 60mLs)/1gram]-.5mLdiH2O= x mL flotation solution.  Feces solution 
was then agitated by vortex for 5 seconds and 1mL was immediately removed and 
loaded in the chamber of a McMaster counting slide.  Eggs within counting grid were 
enumerated three times per feces solution sample.  Eggs per gram of feces (EPG) were 
calculated by averaging individual counts and multiplying by 400193,305.   
L4 and L5 enumeration 
Groups of animals were euthanized on day 2 post-infection and lungs were removed.  
Lungs were cut with scissors into approximately 5mm pieces and immersed in 0.5% 
PBS agarose spread over cheesecloth and allowed to solidify.  Cheesecloth bundles 
were hung in the top of 50mL conical tubes filled with 37°C PBS.  Tubes were placed in 
a 37°C incubator for 4 hours.  Lung worms were removed with a transfer pipette and 
enumerated from the bottom fraction of the PBS with a dissecting microscope. 
Additional animals were euthanized on day 7 post-infection, and the proximal halves of 
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the small intestines were harvested. Intestinal pieces were cut into 1 cm sections, sliced 
longitudinally and opened to expose the inter lumen.  Sections were placed lumen side 
down on cheese cloth.  Cheese cloth bundles were suspended from tops of 50mL 
conical tubes filled with pre-warmed PBS.  After incubation for four hours at 37°C, adult 
worms were removed from the bottom fraction of PBS and enumerated using a 
dissecting microscope.  
Serum collection, drug administration, and AT of MDSCs 
Serum was collected by tail vein nick, days 7 or 14 post-infection. Serum was collected 
by cardiac puncture at the termination of the experiment. For mice injected with GEM, 
1.2 mg was injected i.p. starting on day 0 and repeated every 5 d throughout the 
experiment. For AT studies, WT mice were injected with 5–10 × 106 naive ADAM10Tg 
MDSCs via tail vein injection starting at day -1 of infection and repeated every 3 days 
thereafter. For mice treated with CT, 0.5 mg/kg was injected i.p., starting on Day -1 and 
repeated daily. For mice injected with CIM, 20 mg/kg was injected i.p., starting on Day -
1 and repeated every 2 days. 
B16 melanoma or LLC injection 
For B16 melanoma or LLC, mice were injected i.v. with 250,000 cells, monitored daily, 
and killed after 3 weeks; lungs were harvested and weighed to determine degree of 
colonization. Or lung nodules were counted, as previously described303,306; if too many 
to count, they were assigned a count of 250.  For LLC, at the termination of the 
experiment, lungs were filled by tracheal perfusion with 5% India ink solution and then 
removed and fixed in Feketes buffer. 
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2.2.13 Human MDSCs 
Human studies were conducted under appropriate Institutional Review Board-approved 
protocols. All patients gave informed consent for this research. Blood (20 mL) was 
collected in ETDA-coated vacuum tubes from allergic patients, identified as 
symptomatic or non-allergic controls, and PBMC were isolated using Ficoll-Paque 
separation medium (GE Healthcare, Buckinghamshire, UK). 
2.2.14 Statistical analysis 
P values were calculated using unpaired two-tailed Student’s t-tests or unpaired Mann-
Whitney analysis in GraphPad Prism v5. Error bars represent the SEM or SD between 
samples as noted in figure legends. P < 0.05 is considered statistically significant. 
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Chapter 3:  Results 
2.3.1 Mast Cells critically augment MDSC activity 
MDSCs from ADAM10Tg mice are phenotypically and functionally analogous to tumor-
induced MDSCs 
Although MDSC accumulation is a byproduct of ADAM10 overexpression in early 
hematopoietic progenitors, ADAM10 expression is not altered in these cells247. To 
ascertain whether ADAM10Tg-derived MDSCs are functional, ex vivo T cell suppression 
assays were performed. ADAM10Tg MDSCs inhibited T cell proliferation of both 
ADAM10Tg and WT purified T cells under polyclonal (Figure 15A,B) and Ag-specific 
(Figure 15C) conditions in a manner parallel to tumor-derived MDSCs (Figure 15D). 
Tumor-derived MDSCs can be divided into granulocytic (CD11b+Ly6Ghigh) and more 
immunosuppressive monocytic (CD11b+Ly6Chigh) subsets307. Accordingly, monocytic 
MDSCs possessed more suppressive potential. Furthermore, similar to T cells from 
tumor-bearing hosts, ADAM10Tg T cells exhibited reduced levels of L-selectin (CD-
62L), a receptor required for homing of naive T cells to the LNs (Figure 15E, F)198. 
MDSCs impair the T cell response through the activity of arginase 1 and inducible NO 
synthase. Accordingly, ADAM10Tg MDSCs had levels of these enzymes that were 
comparable to tumor-derived MDSCs (Figure 15G,H)191. These ex vivo observations 
indicate that MDSCs present in tumor-free ADAM10Tg animals behave similarly to 
tumor-derived MDSCs. 
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Monocytic MDSCs promote B16 metastasis 
We used the B16 melanoma model to examine in vivo activities of MDSCs from 
ADAM10Tg mice. B16 was injected i.v.; although not a true metastasis, this allows 
comparison of tumor colonization into the lung with and without MDSCs and is 
commonly used to assess AIT303. When challenged with B16, ADAM10Tg animals were 
more susceptible to metastasis than were WT controls (Figure 16A). The ADAM10Tg 
animals had tumor nodules that were too numerous to count and were consequently 
assigned a count of 250. Parallel to the ex vivo assay, the suppressive activity of 
MDSCs was attributed to the monocytic population. When WT mice were challenged 
with B16 and AT of either monocytic or granulocytic MDSCs, melanoma metastasized 
more aggressively in mice given the monocytic subset, and granulocytic MDSCs had no 
effect (Figure 17A). AIT exerted a minimal effect on ADAM10Tg mice, suggesting that 
the presence of MDSCs diminished the activity of adoptively transferred T cells. 
Although AIT treatment did not completely abolish metastasis in WT lungs, it induced a 
significant decrease in metastatic lesions. Given that lympho-depleting chemotherapy is 
known to enhance AIT308, the protocol was modified to incorporate CYP and GEM. CYP 
lympho-depletes recipient mice, permitting homeostatic proliferation of transferred T 
cells; GEM preferentially decreases MDSC levels in tumor-bearing mice309,310. CYP and 
GEM alone and in combination in WT mice did not significantly alter metastasis, 
indicating that they have minimal effects on tumor cells (Figure 17C). However, GEM 
selectively diminished the MDSC population in ADAM10Tg mice without affecting 
lymphocyte levels (Figure 17B). ADAM10Tg mice treated with GEM alone exhibited an 
antitumor response comparable to WT counterparts, demonstrating that T cell function 
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is restored upon MDSC depletion (Figure 16B,C). Additionally, the combination of 
GEM, CYP, and AIT (tri-therapy) resulted in complete regression of metastasis in both 
WT and ADAM10Tgs (Fig. 16B, C). Figure 16D illustrates the significant abrogation of 
metastasis arising from tri-therapy. Ideal AIT would use tumor-specific T cells and 
chemotherapy. Thus, the AIT protocol was adjusted to incorporate pmel-1 mice that are 
TCR transgenic for gp100 melanoma peptide303. Similar results were observed, in that 
successful AIT required MDSC depletion (Figure 17C). Thus, MDSCs in ADAM10Tg 
mice are functionally analogous to tumor-derived MDSCs, promote tumor metastasis, 
and compromise the efficacy of tumor immunotherapy. 
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Figure 15. MDSCs from ADAM10Tg mice are phenotypically and functionally 
analogous to tumor-derived MDSCs.  
(A) Proliferation of WT and ADAM10Tg (B) T cells or (C) pmel-1 TCR transgenic 
splenocytes in the presence of increasing amounts of CD11b+ MDSCs (Ly6G+ (dotted 
line),Ly6G-(dashed line), or Gr-1+(solid line)); WT and ADAM10Tg T cells were 
stimulated with immobilized anti-CD3 and soluble anti-CD28. (D) Tumor-derived 
MDSCs were purified from LLC bearing mice and used in suppression assays with 
Pmel1 splenocytes at increasing ratios (T cells or splenocytes: MDSCs, *p<0.05). All 
Pmel-1 splenocytes were stimulated with soluble gp100. (E) Cell surface expression of 
L-selectin (CD62L) by CD4+ and CD8+ (Isotype control (grey filled), WT (solid line) and 
ADAM10Tg (dashed line) (F) gated T cells from peripheral LNs. Lysates of MDSCs 
derived from LLC bearing WT hosts and ADAM10Tg MDSCs were analyzed for the 
activity of (G) Arginase by urea production and (H) Nitric oxide by Greiss Reagent. The 
data is representative of at least three independent experiments with splenocytes from 
three or more mice. 
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Figure 16. MDSC depletion restores the antitumor response and prevents 
metastatic progression of B16 melanoma in ADAM10Tg mice 
(A) Number of lung metastases in WT and ADAM10Tg animals challenged with B16 
melanoma with (filled bars) or without (open bars) AIT (A), as described in Materials and 
Methods. Number of lung metastases of WT (B) or ADAM10Tg (C) mice challenged 
with B16 and treated as in (A), with the addition of CYP (C) and GEM (G). (D) 
Representative lungs of WT and ADAM10Tg mice with AIT, with and without CYP and 
GEM. Data represent five mice/group. *p < 0.05 versus respective untreated controls. 
ND, None detected. 
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Figure 17. Gemcitabine selectively depletes MDSCs, which allows for effective 
AIT with tumor specific T cells  
(A) Quantification of B16 lung metastasis in WTC57 with AT of either granulocytic 
(CD11b+Ly6G+) or monocytic (CD11b+Ly6C+) MDSCS. (B) Cytometric analysis of 
peripheral blood leukocyte levels in ADAM10Tg mice following i.p. injections with 
gemcitabine (upward arrow) every five days for three weeks, *p<0.05. (C) Number of 
B16 lung metastases in mice treated with AIT comprised of pmel-1 transgenic T cells 
and chemotherapeutics as described in Methods. More than five mice were used per 
group in three independent experiments. *p<0.05 in comparison to respective untreated 
controls and #p<0.05 in comparison to respective AIT+ CYP treatment. 
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MDSCs enhance the immune response against N. brasiliensis  
Next, we examined the effect of MDSCs on the immune response in anti-parasite 
immunity. Although MDSC accumulation following N. brasiliensis infection has been 
reported261, the direct immunomodulatory role of MDSCs in anti-N. brasiliensis 
responses has not been examined. In N. brasiliensis infection, a WT response is 
characterized by production of Th2-associated cytokines that ultimately mediate adult 
worm clearance 10–12 d post-inoculation311. Following N. brasiliensis challenge, 
ADAM10Tg animals had significantly reduced fecal egg counts compared with WT 
controls (Figure 18A). This is highly correlated with 50% reduction in L5 adult worm 
burden in ADAM10Tgs (Figure18B) and a 25% reduction in L4 stage worms in the lung 
(Figure 18C). This indicated that MDSCs may facilitate parasite clearance. To 
determine whether the increased worm clearance correlated with an increase in Th2 
cytokines, we examined a panel of Th2 cytokines. Analysis of peak infection (day 7) 
serum levels of IL-4, IL-5, and IL-13 demonstrated significantly enhanced levels in N. 
brasiliensis-infected ADAM10Tg animals compared with infected littermates (Figure 
19). Additionally, IL-17 and IL-33, which were reported to recruit MDSCs, were also 
elevated in serum of ADAM10Tg mice271,312.  On Day 14, mesenteric lymph nodes 
(MLN) were taken from N. brasiliensis infected ADAM10Tg mice and LM controls.  
These nodes were stained for Gr-1 to elucidate location of MDSCs (Figure 20). 
To determine whether enhanced N. brasiliensis clearance is dependent on 
MDSC activity, MDSCs were depleted from ADAM10Tg mice. GEM treatment resulted 
in elevated egg counts in ADAM10Tg mice similar to WT levels (Figure 21A). 
Additionally, N. brasiliensis infection resulted in a modest 4–5-fold increase in MDSCs in 
   
117 
 
WT spleens from days 0 to 14. This level of WT MDSCs is sufficient to promote N. 
brasiliensis clearance and prevent a chronic infection (Figure 21B). However, GEM-
mediated MDSC depletion in WT mice significantly exacerbated the peak level of N. 
brasiliensis infection (Figure 21C). We additionally examined the intestines of mice 
treated with GEM to confirm that off-target effects were not responsible for results seen.  
MCs are an important mediator of N. brasiliensis clearance and MCs per villus/crypt unit 
were not adversely affected with GEM treatment (Figure 21D).  Taken together, the 
data indicate that the enhanced immune response in ADAM10Tgs is a consequence of 
elevated MDSC levels.  
Next, to eliminate off-target effects of GEM, ADAM10Tg MDSCs were purified 
and adoptively transferred to WT mice over the course of N. brasiliensis infection. Like 
the MDSCs that were observed accumulating following N. brasiliensis infection, the 
transferred MDSCs also contained both Ly-6G+ and Ly6C+ populations. AT of MDSCs 
resulted in significantly reduced egg counts, comparable to ADAM10Tgs (Figure 22A). 
Additionally L5 adult worms were reduced, but L4 lung worms were not (Figure 22B,C).  
This indicates that AT MDSCs do not reach the level needed to decrease lung worms 
by Day2.  To confirm our findings with MDSCs were not only a result of ADAM10Tg 
MDSCs, MDSCs were harvested from spleens and tumors of LLC-bearing mice and 
injected i.v. into WT mice during N. brasiliensis infection.  Tumor derived MDSCs were 
able to additionally mediate N. brasiliensis clearance confirming that ADAM10Tg 
MDSCs are analogous to tumor-derived MDSCs (Figure 22D). 
Granulocytic MDCSs mediate N. brasiliensis clearance in a T cell-independent fashion 
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To determine which MDSC subset was responsible for this observation, MDSCs 
were purified based upon Ly6G and Ly6C expression and adoptively transferred into 
WT N. brasiliensis-infected mice. The Ly6Ghigh population had the same effect as did 
total Gr-1+–purified MDSCs, whereas the adoptively transferred Ly6Chigh population had 
no effect. This indicates that the granulocytic population of MDSCs mediates the anti-N. 
brasiliensis immunity (Figure 23A). The direct role of MDSCs was further supported in 
WT mice that were T cell depleted. Flow cytometry confirmed T cell depletion (Figure 
24). These mice exhibited the same rapid rate of clearance as WT adoptively 
transferred with MDSCs (Figure 23B). As expected, N. brasiliensis clearance was 
significantly slower in T cell-depleted WT mice without AT of MDSCs (Figure 23B) and 
chronic, unresolved infection was evident by L5 adult worms on Day 14 (Figure 23C). 
Mast Cells are essential for MDSC-mediated parasitic clearance 
 Mucosal MC hyperplasia is a hallmark of gastrointestinal helminth infection that 
enhances the immune response, leading to parasite clearance277,313. Mice deficient in 
MCs exhibit delayed clearance kinetics314. Given that MCs mainly produce Th2-
polarizing and proinflammatory cytokines and that MCs chemoattract MDSCs, we 
examined whether the interaction between the two cell types could be contributing to 
the enhanced N. brasiliensis expulsion. Surprisingly, AT of MDSCs into MC-deficient 
mice did not enhance N. brasiliensis expulsion, indicating that an MDSC/MC interaction 
is critical for MDSC-mediated anti-N.  brasiliensis responses (Figure 26A-C). To 
confirm that this was not unique to KitWsh/Wsh mice, which have other hematopoietic 
issues, two studies were done.  KitWsh/Wsh mice, which were reconstituted with WT 
BMMCs, responded to AT of MDSC with enhanced parasite clearance (Figure 26C).  In 
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addition, another strain of MC-deficient mice, Cpa3cre; Mcl-1fl/fl (C57BL/6 background) 
was tested. These mice express Cre recombinase under the control of the Cpa3 
promoter. C57BL/6-Cpa3cre; Mcl-1fl/fl mice are severely deficient in MCs and basophils 
with no other apparent hematologic changes302. Similar to KitWsh/Wsh mice, AT of MDSCs 
also failed to clear N. brasiliensis in the Cpa3cre; Mcl-1fl/fl mice. These studies further 
confirm that MCs are required for MDSC-mediated parasite clearance (Figure 26D).  To 
assess this interaction ex vivo, MCs were co-cultured with MDSCs. This resulted in a 
synergistic increase in IL-6, IL-13, TNFα, and MIP-1α (Figure 27). 
MCs also contribute to MDSC-mediated immune suppression in B16 melanoma  
Given that MDSCs require MCs to enhance anti-N. brasiliensis immunity, the B16 
metastasis study was re-evaluated in MC-deficient mice. Several groups demonstrated 
that MCs recruit MDSCs, which accumulate in the tumor microenvironment and 
correlate with poor prognosis. In addition, MC-deficient mice have decreased rates of 
tumor growth that increases to WT levels subsequent to MC reconstitution315. 
Therefore, we anticipated that B16 melanoma cells would metastasize more slowly in 
KitWsh/Wsh mice compared with WT controls, but it would be enhanced with MDSC AT. 
KitWsh/Wsh and WT mice were injected with B16, with and without AT of MDSCs. WT 
mice were more susceptible to B16 metastasis compared with KitWsh/Wsh mice. Upon 
MDSC AT, WT mice exhibited similar levels of tumor nodules as did B16 ADAM10Tgs, 
indicating the direct contribution of MDSCs to the immune response. However, much to 
our surprise, AT of MDSCs into KitWsh/Wsh mice failed to increase B16 metastasis 
(Figure 28). Thus, these results demonstrate that MDSCs promote B16 melanoma 
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metastasis in an MC-dependent manner and indicate that MDSC/MC interactions 
significantly enhance the MDSC-mediated suppression of antitumor immunity. 
MCs promote MDSC trafficking and parasite clearance 
Given the literature highlighting MCs as attractants of MDSCs and the 
importance of MDSC recruitment in an immune response, the trafficking behavior of 
MDSCs was analyzed after AT in the presence or absence of MCs. MDSCs were 
labeled with the PKH26GL lipid dye and AT by i.v. injection into naïve mice. As shown in 
Figure 29A and B, 18 h post-AT, MDSCs preferentially trafficked to the liver; this 
agrees with other published results316. To determine whether MDSCs exhibit similar 
trafficking patterns during the course of N. brasiliensis infection, MDSCs were labeled 
and infused concomitant with N. brasiliensis challenge in WT and MC-deficient KitWsh/Wsh 
mice. As with naive mice, MDSCs trafficked to liver in infected WT mice. However, the 
accumulation of MDSCs in the liver was reduced significantly in KitWsh/Wsh mice, 
indicating the role of MCs in MDSC recruitment (Figure 29C–E). The PKH26GL dye 
used for labeling does not affect MDSC functionality, as labeled cells were fully capable 
of reducing parasite egg burden in the feces (Figure 30). Livers of KitWsh/Wsh mice on 
Day7 post N. brasiliensis infection were sectioned and stained for Gr-1 expressing 
MDSCs.  The immunohistochemistry reinforces finding of reduced migration MDSCs to 
the liver (Figure 31). These results were supported by in vitro migration assays, in 
which MDSCs exhibited a high degree of migration toward MCs (Figure 32). This is 
consistent with published literature, indicating that MDSCs traffic to the liver in tumor 
models and that MCs secrete mediators from the liver through the bile317. 
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We next wanted to see if MDSC accumulation and migration to the liver are MC-
dependent during tumor development. A model of B16 melanoma metastasis was used. 
In B16 melanoma, WT lung colonization is exacerbated with the AT of MDSCs. While in 
Cpa3cre; Mcl-1fl/fl MC-deficient mice, AT of MDSCs did not cause increased lung 
colonization, confirming previous data published with the KitWsh/Wsh mice (Figure 
33A)193. Additionally, MDSCs are reduced in liver but not in spleen over WT mice, with 
or without AT of MDSCs (Figure 33B). 
MDSC interaction with MCs maintains the granulocytic population in vitro. 
 Since MCs are required for MDSC effects in vivo, we wanted to look at 
MC/MDSC co-cultures in vitro.  We cultured MDSCs for five days in culture with and 
without MCs in media supplemented for MC growth, then looked at the subpopulations 
of MDSCs.  Without MCs, the granulocytic MDSC population does not survive in vitro.  
However, in the presence of MCs, the granulocytic MDSC population is maintained in 
vitro (Figure 34). 
 
 
 
 
 
 
 
   
122 
 
Figure 18. ADAM10Tg mice are resistant to N. brasiliensis infection 
(A) Eggs per gram of feces (EPG) were determined at the indicated times in WT and 
ADAM10Tg mice upon infection with 650 N. brasiliensis L3 worms. (B) WT and 
ADAM10Tg mice were examined on day seven for adult worm recovery and (C) on day 
two for L4 lung larval stage as described in Materials and Methods. . *p<0.05; 
**p<0.005. Error bars are ± SEM. Data represents five mice per group. 
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Figure 19. ADAM10Tg MDSCs have increased cytokine expression over WT 
during N. brasiliensis infection. 
Day 7 serum from ADAM10Tg or WT mice infected with N. brasiliensis.  Cytokine 
analysis on serum was performed using a Milliplex Mouse Cytokine Kit. *p<0.05. Error 
bars are ± SEM. Data represents five mice per group. 
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Figure 20. MDSCs accumulate in mesenteric lymph nodes in N. brasiliensis 
infection 
MLNs were harvested from WT or ADAM10Tg mice on Day 14 post N. brasiliensis 
infection. MLNs were sectioned and stained with anti-Gr1 (blue) and anti-CD3 (red).  
Pictures are representative of 5 mice per group. 
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Figure 21. Gemcitabine depletion of MDSCs restores WT response to N. 
brasiliensis infection to ADAM10Tg mice. 
(A) ADAM10Tg mice were treated with GEM during N. brasiliensis infection.  EPG were 
enumerated. Data represents at least five mice per group and two independent 
experiments. (B) Spleens of mice were harvested at day 14 post N. brasiliensis infection 
and percent Gr-1+CD11b+ MDSCs were gated off of total live cells.  Plots are 
representative of five mice per group.  (C) WT mice were treated with GEM during N. 
brasiliensis infection.  EPG were enumerated. (D)  Day 15 post infection, N. brasiliensis 
infected ADAM10Tg mice with or without GEM.  Proximal half of the small intestines 
were stained with toluidine blue to enumerate mast cells.  Mast cells from ten villus/crypt 
units (VCU) were counted per mouse.  Data represents at least five mice per group. 
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Figure 22.  Adoptive transfer of MDSCs from ADAM10Tg mice or LLC-tumor 
bearing mice induce increased parasitic clearance of N. brasiliensis. 
(A) EPG were determined at the indicated times in WT and WT mice with AT of 
ADAM10Tg MDSCs upon infection with 650 N. brasiliensis L3 worms.  (B) WT and WT 
mice with AT of ADAM10Tg MDSCs examined on day seven for L5 adult worm recovery 
or (C) L4 lung worm recovery. (D) EPG were determined at the indicated times in WT 
and WT mice with AT MDSCs from LLC-tumor bearing mice.  *p<0.05, **p<0.005.  Error 
bars are representative of ± SEM.  Data represents at least five mice per group and at 
least two independent experiments. 
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Figure 23.  Granulocytic MDSCs are responsible for MDSC enhanced parasitic 
clearance in a T cell independent manner 
(A) Enumerated EPG of infected WT mice with AT of either the CD11b+Ly6GhighLy6Clow 
or CD11b+Ly6GlowLy6Chigh population of MDSCs.  (B) EPG of WT mice, with or without 
MDSC AT, and with or without depletion of CD4 and CD8 T cells, as described in 
Materials and Methods. (C) In T cell depleted mice, L5 adult worms were enumerated 
on Day 14 to confirm clearance or chronic infection.  .  *p<0.05, **p<0.005.  Error bars 
are representative of ± SEM.  Data represents at least five mice per group. 
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Figure 24. T cell depleting antibodies completely deplete T cells. 
Peripheral blood of WT and T cell depleted mice after injection with CD4 and CD8 
depleting antibodies prior to N. brasiliensis infection for experiment in Figure 23.  (A) 
Percent positive for B220. (B) Percent positive for CD4. (C) Percent positive for CD8.  
Flow cytometry plots are representative of at least five mice per group. 
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Figure 25.  Monocytic MDSCs promote B16 melanoma colonization to the lungs. 
Quantification of B16 lung metastasis in WT/C57 with AT of either granulocytic MDSCs 
(CD11b+Ly6G+) or monocytic MDSCs (CD11b+Ly6C+), as described in Methods. More 
than five mice were used per group in three independent experiments. *p<0.05 in 
comparison to respective granulocytic MDSC group. 
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Figure 26. MCs are required for MDSC-mediated N. brasiliensis clearance 
(A) Enumerated EPG on days noted of MC-deficient KitWsh/Wsh mice, with or without 
MDSCs and infected with 650 N. brasiliensis L3 worms. (B) Adult worms enumerated on 
day 7. (C) KitWsh/Wsh mice were reconstituted with BMMC as described in Methods and 
Materials.  Reconstituted mice were AT with or without MDSCs and infected with N. 
brasiliensis.  Significance refers to reconstituted KitWsh/Wsh mice with AT of  MDSCs as 
compared to KitWsh/Wsh mice with AT of  MDSCs.  (D) MC-deficient Cpa3cre, Mcl-1flox/flox 
mice were infected with N. brasiliensis, with or without AT of MDSCs, and EPG were 
enumerated on noted days.  The data represent at least five mice per group. *p< 0.05, 
**p< 0.005, ***p<0.005. 
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Figure 27. MC/MDSC interaction augments cytokine production.  
BMMCs were co-cultured with ADAM10Tg MDSCs, as described in Materials and 
Methods. Supernatants were collected and analyzed for the production of IL-6 (A), IL-13 
(B), MIP-1α (C), and TNFα (D). The data represent pooled spleens of at least three 
mice/group. *p < 0.05 versus MCs alone. Figure courtesy of Johanna K. Morales and 
John J. Ryan, Virginia Commonwealth University, Richmond, VA, USA. 
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Figure 28. MC/MDSC interaction is required for MDSC-mediated immune 
suppression. 
 Photographic representation (A) and quantification (B) of B16 lung metastasis in control 
C57 and KitWsh/Wsh mice, with and without AT of MDSCs. The data are representative of 
at least five mice/group. *p < 0.05 versus WT alone or KitWsh/Wsh with MDSCs. 
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Figure 29. MDSCs preferentially migrate to the liver in a MC-dependent manner 
(A) WT mice given labeled MDSCs, analyzed 18 hours later. MDSC in liver, peripheral 
blood (PB), spleen, and bone marrow (BM). Data compiled in B. (C) Wsh or WT was 
given labeled MDSCs, infected with N. brasiliensis, and examined for MDSC staining on 
Day 7. Cell percentage of PKH26GL+ cells out of total Gr1+CD11b+ cells (D) and 
number (E) from C. (F). MDSCs were given on Days -1, 2, and 5.  *P<0.05; 
***P<0.0005. Mean ± SD; n=5/group. 
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Figure 30. PKH26GL+ MDSCs are functional 
WT mice with or without AT of labeled MDSCs on Days -1, 2 and 5.  Mice infected with 
N. brasiliensis and examined for EPG on Day 7. *P<0.05.  Mean ± SD; n=5 mice/group. 
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Figure 31. MDSCs do not traffic to livers of MC-deficient mice during N. 
brasiliensis infection 
WT or Wsh mice with AT of MDSCs on Days -1, 2, and 5 were infected with N. 
brasiliensis on Day 0.  Livers were sectioned and stained with Gr-1+ (green) MDSCs. 
Pictures are representative of five mice per group. 
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Figure 32. MDSCs migrate preferentially to mast cells 
MDSCs placed in top well of 8µm transwell plate.  B16 melanoma, MCs or media alone 
were placed in the bottom well.  Four-hour MDSC migration was assessed by flow 
cytometry. *P<0.05. Mean ± SD; n=5/group. 
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Figure 33.  MCs are required for MDSC-mediated tumor progression 
(A) Cpa3creMcl-1fl/fl (MC-/-) or WT Mice were challenged with B16 melanoma 
concomitant with or without MDSCs.  Mice were sacrificed and lung tumor colonies 
were enumerated. (B) Liver and spleen were examined for MDSC accumulation. 
*P<0.05, n= at least four mice per group. 
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Figure 34. Mast cells help maintain the granulocytic population of MDSCs in vitro 
MDSCs were cultured with and without MCs, in media containing IL-3 and SCF to 
maintain MC survival.  Culture was maintained for 5 days and then harvested for flow 
cytometric analysis.  Live cells were assessed for CD11b staining. CD11b+ cells were 
gated to look at the Ly6G+ or Ly6C+ distribution. 
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2.3.2 Mast cell histamine promotes immunoregulatory activity of MDSCs 
MDSCs express HR1 and HR2 
Given the contribution of histamine to MDSC activity, cell proliferation, and Th2-
skewed immune responses280,286, we examined whether histamine could serve as a 
potential mediator in the MC/MDSC cross-communication. Liver MDSCs were 
examined, as they were the population most affected in MC-deficient mice. They 
express HR1–3 but not 4 (Figure 35A). Splenic MDSCs express high levels of HR1, as 
shown in Figure 35B. Additionally, purified MDSCs express detectable HR2 and 3 but 
not 4 (Figure 35C). 
Histamine induces MDSC proliferation and differential gene expression in monocytic 
versus granulocytic MDSCs 
As shown in Figure 36A and B, in vitro exposure to histamine promoted survival 
and proliferation of MDSCs in a dose-dependent manner. The contribution of histamine 
was confirmed using CT, CIM, HR1, and HR2 antagonists, respectively. As shown in 
Figure 36C, CT and CIM inhibited histamine-stimulated cell proliferation. Both subtypes 
of MDSCs are responsive to histamine; however, the monocytic subset is significantly 
more sensitive to the proliferative effects of histamine than are granulocytic MDSCs 
(Figure 36D). 
Given the ability of histamine to induce MDSC proliferation in vitro, a logical step 
was to examine its role in modulating markers of MDSC activity. Accordingly, monocytic 
or granulocytic MDSCs were cultured with 100 µM histamine, as in Figure 36A, and 
analyzed for expression of Arg1 and iNOS via qPCR. It has been documented that 
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MDSC immunosuppression largely results from impairment of T cell activity modulated 
by these enzymes162,318. In the presence of histamine, we observed a fivefold increase 
(ΔΔCt method)319 in the expression of Arg1 and a twofold increase in the expression of 
iNOS in monocytic MDSCs over granulocytic MDSCs. However, the granulocytic 
MDSCs exhibit a fivefold decrease in the expression of Arg1 and a threefold decrease 
in the expression of iNOS, exhibiting striking differential gene expression between the 
two populations (Figure 37A,B).These data are reinforced by intracellular flow 
cytometry, showing increased protein expression of Arg1 by monocytic MDSCs when 
exposed to histamine in vitro but unchanged expression by the granulocytic MDSC 
(Figure 38A, B). 
Arg1 and iNOS are essential for classical MDSC-mediated T cell suppression, 
whereas IL-13 and IL-4 are important Th2 cytokines involved in N. brasiliensis 
clearance. With addition of histamine, granulocytic MDSCs—the population important 
for augmented parasitic clearance—increased IL-4 expression fourfold and IL-13 
expression over 200-fold compared with monocytic MDSCs (Figure 37C). 
Histamine antagonist prevents MDSC-mediated N. brasiliensis expulsion and tumor 
progression 
To confirm the effects of histamine on MDSC activity in vivo, mice were infected 
with 650 L3 N. brasiliensis, a Th2 helminth. MDSCs were AT i.v. in conjunction with CT, 
CIM, HR1, or HR2 antagonists, respectively. Administration of CT or CIM significantly 
abrogated the ability of MDSCs to increase the clearance of N. brasiliensis (Fig. 39A, 
B). This was correlated with reduced-infiltrating MDSCs in the liver (Figure 39C) and 
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diminished phenotypic conversion toward granulocytic MDSCs (Figure 39D), which is 
the important phenotype for N. brasiliensis clearance193.  
As histamine induces increased iNOS and Arg1 message (Figure 37A, B), both 
important for MDSC-induced T cell suppression, we analyzed whether histamine 
blockade affected MDSC-induced tumor progression. A mouse model of melanoma was 
used (B16). This model does not naturally accumulate large numbers of MDSCs, so AT 
of MDSCs was used to increase MDSC numbers. Mice receiving AT with MDSCs and 
treated with CIM had significantly reduced colonization to the lungs with B16 melanoma 
compared with mice that received MDSCs but no CIM, as determined by lung weight 
(Figure 40). CIM alone had no significant effect on tumor burden in the absence of AT 
of MDSCs. This is consistent with data showing similar results using a model of murine 
Lewis lung carcinoma, a model with natural accumulation of MDSCs, where CIM 
treatment resulted in reduced tumor size320. 
MDSCs are increased in allergic patients 
Allergy is a MC-mediated, Th2-dependent immune response. Allergic patients 
experiencing symptoms have increased levels of circulating MC-derived histamine321. 
Additionally, Deshane et al.322 describe MDSCs as being involved in Th2-driven airway 
hyper-responsiveness. To elucidate the translational relevance of our findings, we 
isolated PBMC from patients currently experiencing allergy symptoms and non-allergic 
controls, as determined by a patient questionnaire. Patients that reported taking 
antihistamines were excluded from the study. PBMC was examined by flow cytometry; 
human MDSCs are defined as CD34- CD33+CD11b+ cells220. Monocytic MDSCs are 
defined as CD34-CD11b+CD14+ and granulocytic MDSCs as CD34- 
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CD11b+CD15+220(Figure 42). Allergic patients were found to exhibit 40% more 
circulating MDSCs than controls (Figure 41A, B). Interestingly the monocytic subset of 
MDSCs appeared to be the dominant subpopulation in the controls, but was not 
elevated significantly in allergic patients (Figure 41C). However, the granulocytic 
MDSCs, which are the population implicated to be more important in Th2 responses, 
such as helminth immunity, were increased significantly with 20% more in the allergic 
patients compared with controls (Figure 41D).  MDSCs are elevated in the peripheral 
blood of patients with cancer. To elucidate the response of human MDSCs to histamine, 
MDSCs were sorted from the blood of cancer patients and stimulated with or without 
histamine. Histamine promotes increased survival of human MDSCs at 48 hours over 
media alone (Figure 43).  
IL-13-/- mice have reduced MDSC accumulation in the periphery  
 Given the striking trafficking data and the emerging role of MC-IL-13 in tumor, 
mice deficient in IL-13 (IL-13-/-) were injected s.c. with LLC. In this model, MDSCs were 
generated by the BM, but they were unable to escape out of the blood and traffic to the 
liver as indicated by a higher percentage of MDSCs in the peripheral blood (PB) and 
fewer in the liver compared to tumor-bearing WT mice (Figure 44A,B).  Interestingly, 
despite increased PB MDSCs, the IL-13-/- mice had smaller tumor volume compared to 
WT.  These findings introduce a novel hypothesis that MC-secreted IL-13 recruits 
MDSCs out of the circulation and into MC resident tissues, where they further increase 
their suppressive properties through IL-4Rα signaling and enhance development of 
tumor metastasis.  This hypothesis is reinforced by preliminary data using a LLC 
colonization model in which IL-13-/- mice had dramatically fewer tumor colonies in the 
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lungs over WT (Figure 44C), and fewer MDSCs in the liver (Figure 44D).  Interestingly, 
these IL-13-/- mice had significantly increased PB MDSCs over WT (Figure 44D). 
 Backcrossing the IL-13-/- mice to the ADAM10Tg has allowed us to generate IL-
13-/- MDSCs as well as observe the effects IL-13 has on MDSC development.  
ADAM10TgIL-13-/- mice have reduced MDSCs levels in the liver and spleen, as 
compared to ADAM10Tgs (Figures 45 and 46).  Yet, BM precursors to CMPs are 
unaffected (Figure 47).  This shows that MDSC development is unaffected and points 
to alterations in MDSC trafficking or survival. 
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Figure 35. MDSCs express HRs  
A.  HR expression on liver MDSCs as compared to secondary alone (shaded).  B. H1 
receptor expression on splenic ADAM10Tg MDSCs was determined by comparing HR1 
staining on (line) MDSCs and comparing it to HR1 staining on GR1+CD11b- cells 
(shaded). HR2 (C), HR3 (D) and HR4 (E) presence was determined by flow cytometry 
of isolated MDSCs after 12 hours of culture in cRPMI. (Shaded area represents 
secondary antibody alone)  Three independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
   
162 
 
 
 
 
 
 
 
   
163 
 
Figure 36. Histamine increases MDSC survival and proliferation 
(A) Survival assessed by trypan blue exclusion over time course of MDSCs alone 
(circle) or with histamine (triangle). (B and C) Proliferation assays of MDSCs cultured 
alone, with histamine (H), or in combination with indicated agents, as measured by 
counts per minute (CPM). (D) MDSCs were cultured with histamine or media. *P<0.05; 
**P<0.005; ***P<0.0005. Mean ± SD; n=10/group and at least two independent 
experiments. 
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Figure 37. Histamine influences MDSC gene expression 
Ly6C+ or Ly6G+ MDSCs were cultured ± histamine and analyzed (48 h) for Arg1 (A) or 
iNOS (B) message. Fold change of histamine-treated/media alone (A and B). Fold 
change of IL-13 and IL-4 message from histamine treated Ly6G+/Ly6C+ cells (C). After 
normalization to GAPDH, data were analyzed using the ΔΔCt method.***P<0.0005. 
Mean ± SD; n=5 from two experiments. 
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Figure 38. Ly6C+ MDSCs express increased Arg1 protein with Histamine    
MDSCs were isolated from ADAM10Tg spleen and treated with histamine for 12 hours.  
Arg1 expression was determined by utilizing intracellular flow cytometry. Ly6C+CD11b+ 
(A.) or Ly6G+CD11b+ (B.) MDSCs with histamine treatment (dashed line) or without 
(solid line), as compared to secondary alone (shaded). 
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Figure 39. HR1 and HR2 antagonists blocks MDSC mediated N. brasiliensis 
clearance 
 A, B. Eggs/gm feces in N. brasiliensis infected, ±MDSCs (M) on indicated days and 
±daily CT treatment (A) or every other day CIM treatment (B).  C. Day 14 analysis of 
total MDSCs. D.  Flow cytometric determination of liver monocytic or granulocytic 
populations.  *P<0.05, ***P<0.0005. Mean ± SD, n≥5 with two independent 
experiments.  
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Figure 40. HR antagonization inhibits MDSC mediated tumor progression  
Mice were challenged with B16 concomitant with MDSCs in the presence or absence of 
cimetidine (CIM), an HR2 antagonist. Mice were subsequently sacrificed and their lungs 
weighed for B16 colonization. Error bars represent Mean ± SD. *P<0.05. n=at least five 
mice per group. 
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Figure 41. Allergic patients have increased circulating MDSCs. Symptomatic 
allergic patients were compared with non-allergic controls.  
Cells were isolated from peripheral blood gating strategy (Figure 41). Percent total 
MDSCs (B) and subpopulations, CD14+ (C) or CD15+ (D), were determined by flow 
cytometry. (A) Representative allergic patient versus control and (B–D) compiled.*P < 
0.05. Mean ± SD. Allergic patients, n=6; controls, n=6. 
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Figure 42. MDSC gating strategy for allergic patient study.    
CD34- cells were gated off of the live cell population and CD33+CD11b+ dual positive 
MDSCs were analyzed (as shown in Figure 40A,B). For subpopulations, this was 
further extrapolated by looking at the CD11b+ CD15+ or CD11b+CD14+ populations and 
analyzed (as shown in Figure 40A,C,D) 
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Figure 43.  Human MDSCs have increased survival in the presence of histamine. 
MDSCs sorted as HLA-DRlo/-CD11b+CD33+ from peripheral blood of a stage 1 breast 
cancer patient.  Cells were stained for flow cytometry prior to culture and after 48 hours 
of culture with 100µM histamine or in media alone. Patient data is representative of two 
independent experiments.  Data is courtesy of Kyle K. Payne and Masoud Manjilli, 
Ph.D. at Virginia Commonwealth University, Richmond, VA, USA. 
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Figure 44. IL13 is important for MDSC-driven suppression of tumor immunity  
A. IL13-/- or WT Mice were challenged with LLC s.c. tumors. Tumor volume (A) and 
percent Gr1+CD11b+ cells in spleen/liver (B) were assessed. C. Mice were challenged 
with LLC i.v. and lungs were infused with India ink to visualize tumor, representative 
lungs. D. Percent Gr1+CD11b+ cells in spleen/lungs were analyzed by flow cytometry. 
Error bars represent Mean ± SD. *P<0.05. n>5 mice/group. 
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Figure 45. IL13 deficiency decreases MDSC accumulation in the liver 
A,B. IL13-/- or WT naïve mice liver by flow cytometry and C,D. IL-13-/-ADAM10Tg  or 
ADAM10Tg.  Livers stained for Gr-1+CD11b+ of total live cells (A) and Ly6C+Ly6G+ of 
total CD11b+ cells (B). Representative flow cytometry plots. 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
182 
 
 
   
183 
 
Figure 46. IL13 deficiency decreases MDSC accumulation in the spleen 
A,B. IL13-/- or WT naïve mice spleen by flow cytometry and C,D. IL-13-/-ADAM10Tg  or 
ADAM10Tg.  Spleens stained for Gr-1+CD11b+ of total live cells (A) and Ly6C+Ly6G+ of 
total CD11b+ cells (B). Representative flow cytometry plots. 
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Figure 47.  IL13 deficiency does not affect committed progenitor cells of the bone 
marrow 
A. IL13-/- or WT naïve mice BM by flow cytometry and B. IL-13-/-ADAM10Tg or 
ADAM10Tg.  BM from Lineage- of total live cells and divided into c-kit and sca-1 
staining.  Representative flow cytometry plots. 
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2.3.3 Discussion 
The ADAM10Tg mouse affords a unique tool to characterize the immune-
modulatory potential of MDSCs in an environment free of established tumor. Because 
the ADAM10Tgs suffer no confounding pathology, this was an ideal system in which to 
elucidate the immunomodulatory roles of MDSCs. We used this system to investigate 
roles for MDSCs in both neoplasia and helminth infection. In B16 metastasis, monocytic 
MDSCs strongly suppressed the immune response, whereas granulocytic MDSCs failed 
to promote metastasis (Figure 25). However, in N. brasiliensis infection, the 
granulocytic MDSCs enhanced the anti-parasitic immune response, and the monocytic 
MDSCs had no effect (Figure 23). AT studies demonstrated that this differential 
immune regulation by MDSCs occurs in an MC-dependent manner. The ex vivo co-
culture studies indicate that MDSC/MC interactions may modulate immune responses 
by increasing cytokine production. MDSCs traffic to MCs, affording a synergistic Th2-
skewed immune response. Although undesirable in the context of neoplasia, the 
observed response is ideal in helminth infections. Overall, this data is indicative that 
inhibition of MC function may serve as a novel target to inhibit MDSC activity. 
The use of AT of labeled MDSCs allowed examination of their trafficking pattern 
and migration during parasitic infection.  Previous literature indicates that during tumor 
progression, MDSCs traffic and accumulate in the liver in addition to the tumor site, 
where they inhibit Kupffer cells and T cells to dampen anti-tumor immune 
responses316,323,324. Similarly, in our N. brasiliensis infection model, MDSCs 
preferentially migrated to the liver (Figure 29A, B). Previous work has shown that liver-
accumulated MDSCs produce an array of proinflammatory and regulatory cytokines and 
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chemokines in response to tumor challenge316. This would argue that the liver is a 
critical site for MDSC function. In models of MC deficiency, where MDSCs do not traffic 
to the liver, MDSCs do not function as efficiently193.  MCs are seen in normal liver 
surrounding the vessels and the bile ducts in the portal tracts as well as to a lesser 
extent in the hepatic parenchyma325.  It has been reported that hepatic MCs release 
histamine and other mediators through the portal bile ducts and into the bile317. 
Therefore, we hypothesized that MDSCs may interact with hepatic MCs in the liver and 
become further activated. The attraction between these two cells may explain that in the 
absence of MCs, MDSC migration to the liver and parasite expulsion are reduced 
significantly (Figure 29).   
MCs and histamine have been shown to play an important role in parasitic 
clearance. Increased numbers of MCs and concentrations of histamine are positively 
correlated with natural helminth resistance324. The role of histamine in parasitic infection 
has been ascribed to smooth muscle contraction to enhance the “sweep” portion of the 
“weep and sweep” method of parasitic clearance, acting in conjunction with IL-13/IL-
4326,327. Taken in conjunction with the positive correlation of histamine levels and 
parasitic resistance, this could imply that natural immunity in these animals may not only 
be a result of the effect of histamine on smooth muscle cells but also effects via MDSC 
activation and proliferation. Whereas potentially, this could be tested using mice 
deficient in HDC, the secondary increase in goblet cells seen in these mice would be a 
complicating issue328. To our knowledge, the response to helminth infection has not 
been reported in these mice.  
   
189 
 
The addition of histamine to MDSCs protected against cell death and increased 
cellular proliferation in vitro (Figure 36A, B). Furthermore, histamine enhanced 
expression of T cell suppression markers Arg1 and iNOS in monocytic MDSCs and 
decreased expression of these markers in granulocytic MDSCs (Figure 37A, B). As a 
result of these findings, T cell suppression by monocytic MDSCs should be increased 
after exposure to histamine or culture with MCs. These studies are currently underway. 
The granulocytic MDSCs increase IL-13 and IL-4 expression over monocytic MDSCs 
when exposed to histamine. IL-13 is essential in N, brasiliensis infection for worm 
expulsion responsible for increased mucus production and enteric nerve 
stimulation291,292. This expression reinforces the differential roles that both subsets of 
MDSCs play193,329. These studies are supported by a recent publication, in which 
histamine blockade with CIM increased MDSC apoptosis, reduced Arg1 and iNOS 
enzyme expression, and decreased MDSC accumulation in a mouse model of LLC320. 
These results indicate that MCs enhance site-specific migration and as a result of 
histamine secretion, induce increased MDSC proliferation and differential gene 
expression. We hypothesize that in liver, as well as other sites of immune response, 
resident MCs attract MDSCs and activate them via histamine release. This affords the 
production of soluble mediators that can act locally and distally by secretion into the bile 
in our parasitic model. Given our findings and other published studies on MDSCs, the 
following model is suggested (Figure 48). MDSCs secrete Th2 cytokines, notably IL-4 
and IL-13, which promote Th2 differentiation, along with IL-6 and TGF-β that 
chemoattract additional MCs. The T cells not only contribute to the pool of IL-4 and IL-
13 but also increase IgE synthesis. IgE, in turn, further activates MCs. These events 
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afford a self-sustaining and synergistic cycle of MC/MDSC activation, resulting in 
increased survival and proliferation/activation of MDSCs, in addition to a Th2-skewed 
immune response. This Th2-skewed immune response is detrimental in the setting of 
allergic disease or neoplasia but beneficial for parasite clearance. 
The importance of the histamine/MDSC interaction was demonstrated 
dramatically in that histamine blockade, with HR1 and HR2 antagonists, reversed in 
vitro the proliferative effects of histamine (Figure 36C) and reversed in vivo MDSC-
mediated clearance of parasites, similar to the deficit in MDSC functions found in MC-
deficient mouse models (Figure 39A, D). Impressively, HR2 blockade also decreased 
lung tumor burden in a B16 melanoma model (Figure 40) and other tumor models320. In 
addition to having the same effect on parasite clearance, HR1 and HR2 blockade 
decreased liver MDSC accumulation significantly (Figure 39B). This suggests that HR1 
and HR2 have overlapping roles in the MDSC/MC interaction and when blocked, result 
in reduced total MDSC function. The HR1 antagonist, CT, has been shown previously to 
affect migration of other cells of myeloid lineage, such as monocytes, in vitro and could 
be responsible for the reduced trafficking when the drug is used330,331. HR2 antagonists 
have been shown to affect production in T cells of IL-13, IL-4, and IL-5, all cytokines 
important in N. brasiliensis infection291,292. In this manuscript, we show that granulocytic 
MDSCs are producing IL-4 and IL-13 message after histamine addition (Figure 37C), 
and this finding suggests that CIM may work by reducing MDSC IL-4 and IL-13 
production. Whereas the MC/MDSC interaction is multifaceted, we propose that MC-
derived histamine drives distinct MDSC subpopulations to differential gene expression, 
inducing phenotypic activation that further directs the activity of the MDSC. 
   
191 
 
Up-regulation of MDSCs in patient peripheral blood has been detected in many 
cancers332–334 and suggested as a marker of poor prognosis335. The link between 
inflammation and cancer has been studied heavily in the last decade. MC and MDSC 
interactions can potentially serve as a bridge between allergic inflammation and 
tumorigenic host responses279,336,337. This is the first report that patients with allergic 
inflammation have increased circulating MDSCs (Figure 41A, B). Taken together, our 
results have important implications for regulation of MDSC survival, trafficking, and 
activity via antihistamines for disease states, in which the accumulation of MDSCs is 
detrimental to the host. 
IL-13, as mentioned earlier, is a Th2 cytokine that is functionally redundant with 
IL-4338.  Both IL-4 and IL-13 bind IL-4Rα, a subunit that complexes with either common 
γ chain, IL-13Rα1 or IL-13Rα2.  IL-4 can bind IL-4Rα complexed with either common γ 
chain or IL-13Rα1.  But, when complexed with IL-13Rα2, only IL-13 will bind it, thus 
inducing IL-13 specific effects338.  The bulk source of IL-13 in the body is made by Th 
cells, but IL-13 is also secreted by mast cells339,340.  Interestingly, in a model of peanut-
induced allergy in the gut, it was uncovered that IgE mediated MC-degranulation 
through FcεRI induced IL-13 production by the MC and that this IL-13 production was 
essential for the development of the intestinal allergic responses to peanut340.  
Interestingly, IL-13 from the MC drove primarily CCL2 (MCP-1) production.  Most 
importantly, in a model where MC-deficient mice were reconstituted with IL-13-/- MCs, so 
that only MC-IL-13 was absent, mice completely failed to develop allergic diarrhea340.  
In other studies, IL-13 has emerged as a key driver of CCL2 expression339–342.  IL-13 
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drives CCL2 expression in the human endothelium in vitro, as well as the bronchiolar 
and intestinal epithelium in mouse models of allergic disease in vivo341,342.  
The liver is emerging as a protective niche for MDSCs343,344.  MDSC depletion by 
anti-Gr-1 administration fails to eliminate them from the liver in tumor-bearing mice343.  
The accumulation of MDSCs in the livers of these mice seems to be CCL2/CCR2 
dependent343. CCL2 is a chemokine that binds to CCR2. MDSCs have been shown to 
express CCR2345.  Elevated levels of CCL2 in the circulation of breast cancer patients is 
been correlated with poor prognosis345.  CCR2-/- or CCL2-/- mice both have reduced 
tumor burden and reduced trafficking of MDSCs345.   In mouse models of hepatocellular 
carcinoma, CCR2+ MDSCs migrate in vivo in response to the ligand CCL2346,347.  CCR2-
/- mice additionally exhibit deficiencies in MDSC migration to hepatocellular carcinoma 
tumor sites347. Hepatocytes have been shown to make CCL2 and recruit myeloid cells in 
humans with obesity and murine models of this disease.  This recruitment promotes 
hepatic steatosis348.  This CCL2/CCR2 dependent accumulation in the liver is 
additionally seen in mouse models of colitis343. 
Data from Figure 44 shows that IL-13-/- mice have reduced tumor burden in 
primary and metastatic models.  Interestingly, these mice have increased MDSC levels 
in the circulation.  We hypothesize that this reduction in MDSC numbers in the tissues, 
but increase in circulation is a result of a disrupted CCL2 chemokine gradient.  This 
disruption results in excess MDSCs stuck in the circulation, where they eventually 
perish.  Further study is underway to confirm this theory, as well as to determine if MC-
IL-13 is the driving source for the CCL2 dysregulation.  
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Figure 48. Model of MDSC/MC interaction  
MCs are required for MDSC activity. MCs in the liver release IL-13, which induces 
production of CCL2 by hepatocytes.  This creates a chemokine gradient that increases 
migration of CCR2 expressing MDSCs, resulting in accumulation in the liver.  MCs 
release mediators, such as histamine, that induce MDSC activation, proliferation, and 
Th2 cytokine production. This enhanced cytokine production culminates in Th2-skewed 
immune responses that promote allergy and parasitic clearance and diminish antitumor 
responses. 
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Section 3 
Chapter 1: B1 B cell IgE production in helminth infection 
3.1.1 Introduction to B1 cells 
B cells are divided into multiple lineages.  There are four mature B cell lineages 
in the mouse: FO B cells (B2 cells), MZ B cells, B regulatory cells (B reg), and B1 
cells349.  MZ B cells and B1 cells are both termed innate-like B cells. B1 cells are distinct 
from B2 cells in the fact that B1 cells can self-replenish and are long lived. Murine B1 
cells are found mainly in the pleural and peritoneal cavities350,351. They are derived from 
the fetal liver and exist in a self-replenishing B1 cell pool. B1 cells have also been 
shown to transport and present antigen352,353.  They are delineated from B2 cells by 
expression of CD23 and CD11b.  B1 cells are CD23-, CD11b+, B220int, CD19+, IgMhigh 
and IgDlo 354.  CD5 is a marker that subdivides the two distinct B1 populations.  B1a 
cells are CD5+, while B1b cells are CD5-. 
In these cells the BCR repertoire is enriched for highly poly-specific receptors 
with low-affinities to a broad range of antigens355. Antibody generation in these cells 
generally occurs without T-cell help, SHM, or affinity maturation, and class switching 
was thought to be limited349. These cells produce low affinity or ‘natural’ antibody 
important in immediate response to pathogens356–359.  In vitro studies with B1 cells have 
mainly linked them with IgM antibody production, but in vivo studies hint that B1 cells 
can generate other isotypes.  In vivo B1a cells and B1b cells seem to both be linked to 
antibody production, but each cell tends to lean towards promotion of certain classes of 
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antibody.  B1a cells are linked to in vivo production of IgG2a, IgG2b and IgG3, while 
B1b cells were previously linked to in vivo production of IgG1 and IgE360,361. 
B1 cells were first described in 1983362.  Since then, B1 cells have been 
described in resistance to intestinal flora, defense from viral pathogens, generating 
autoimmune responses and responding to parasites363–366. B1 cells are well known 
secretors of IgM and gut IgA, but direct evidence of IgG or IgE production is only hinted 
at in a few papers367. Balb/c Xid mice carry an X-linked mutation that prevents B1 cell 
development.  When these mice are infected with T. cruzi, they display significantly 
lower levels of specific and non-specific antibody368. Additionally, in a mouse model of 
Schistosomiasis, which is a Th2 infection characterized by high IL-4, IL-5, and non-
specific IgE, B1b cells have been shown to stain positive for IgE and thus be capable of 
IgE production369.  Next, Mice injected with Natterins, a protease that induces a strong 
antibody driven-Th2 response similar to DerP1, B1b cells are dramatically increased in 
the peritoneal lavage.  In this model B1b cells stimulate ASCs to make increased IgE370. 
Lastly, ES-62 is a phosphoryl choline (PC)-containing glycoprotein that is secreted by 
filarial nematodes.  ES-62 induces B2 cell hypo-responsiveness. Interestingly, ES-62 
activates B1 cells to proliferate and mice treated with this glycoprotein still have high 
IgE371.  These cases argue that B1 cells may play an important role in producing 
immunoglobulin, but don’t definitively show that B1 immunoglobulin production is 
accounting for the increases seen. 
 B1 cells are described as being activated to produce antibody in a few different 
ways.  Cytokine IL-5 paired with IL-6 induces B1 cells to make in vivo IgA in the 
gut350,370.  IL-5 alone stimulates B1 cell proliferation in both B1a and B1b subsets, in 
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vivo, as they both express IL-5 receptor350.  IL-5 in conjunction with IL-4 or IL-4 in 
conjunction with CD40L stimulation by T cells was shown to induce B1 cells to make 
IgG1 or IgE in vitro372.  Kaneko et al. claimed that anti-CD40 and IL-4 stimulation on B1 
cells has the potential to produce more IgE than B2 cells372.  Unfortunately, B1 cells 
were sorted out the peritoneal cavity based only upon CD5loB220int expression372.  
Hastings et al. in 2006 showed that a population of B2 cells exists in the peritoneal 
cavity that expresses both CD5lo and B220int expression.  They are segregated from B1 
cells by CD11b expression.  These peritoneal B2 cells survive in vitro culture and 
produce antibody373.  This indicates that B2 cells cannot be ruled out of the population 
sorted by Kaneko et al. due to the fact that they did not sort based on CD11b staining.  
Both subsets of B1 cells additionally express IL-9 receptor, and IL-9 transgenic mice 
have been shown to have dramatically increased B1 cells.  These mice additionally 
make increased antibody in response to antigen stimulation.  But, in vitro B1 
proliferation or antibody production was unsuccessful361. Excitingly, a new study was 
just released by Ghosh et al., which showed that during a model of fungal asthma, B1 
cells in the pleural cavity secreted IgE into the BALF.  µMT mice have a disruption in the 
µ heavy chain causing a block in B cell development at the pre-B cell stage374. But 
surprisingly develop a population of CD19+CD9+IgD+CD23- B1 cells375.  Since these 
mice lack evidence of any B2 cells, IgG and IgE production can be contributed to the B1 
cells in vivo375.  In all, in vivo models hint that B1 cells may be able to produce IgG and 
even IgE, but more extensive evidence is needed, as well as successful in vitro culture. 
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3.1.2 Introduction to IgE 
 IgE is the first line of defense against intestinal helminths.  IgE levels are tightly 
regulated, being the Ig with the lowest levels in vivo376.  Interestingly, only very small 
amounts of antigen are detected by IgE, making it a “gatekeeper” of sorts, being the first 
to detect foreign particles in areas of interface with the environment.  When these 
foreign particles are innocuous, such as pollen, cat dander or peanut proteins, IgE 
moves from beneficial to potentially life threatening.  IgE mediates allergic responses 
from mild reactions to severe, such as allergic rhinitis, atopic dermatitis, urticaria, 
asthma, and anaphylactic shock377. 
 IgE controls the immune system in one of three ways described here. First, 
antigen specific IgE is loaded onto MCs or basophils, FcεRI, where it can stay for up to 
21 days waiting to bind to antigen, cross-link the FcεRI and degranulate the cell378.  This 
releases mediators such as histamine, lipid mediators, and other biologically active 
products immediately, while additionally activating the MC or basophil to induce late 
stage cytokine production377.  All of this induces the symptoms of various allergic 
diseases depending upon the location of the reaction.  Second, circulating IgE can bind 
to its antigen creating an IgE-immune complex.  IgE immune complexes are then picked 
up by circulating FO B cells via CD23, the low affinity IgE receptor (FcεRII).  These 
CD23+ B cells then traffic to the splenic follicles, where antigen transfer ensues 
(described further in section 4) and subsequent rapid increases in specific CD4+ T cell 
proliferation and antigen-specific IgG responses occurs379.  Third, circulating IgE can 
bind to CD23 on B cells, inducing a negative regulatory response to shut down and 
control excessive IgE synthesis145. 
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 There are two ways for a B cells to class switch to IgE.  The first and more 
traditional route is through the intermediate γ heavy chain (µ to γ to ε)380.  This route of 
CSR is mediated in the GC and induces high-affinity antibodies380.  The high levels of 
IgE production seen in helminth infections is not always high-affinity.  A considerable 
amount of the IgE is considered to be low-affinity.  This low-affinity IgE is thought to be 
mediated from a direct µ to ε switch380.  We hypothesize that B1 cells generate IgE 
through this mechanism. 
3.1.3 Correlation between allergy and helminth infections 
One in five children in industrialized countries suffers from allergic diseases such 
as asthma, allergic rhinitis and eczema381.  In these industrialized countries, helminth 
infection is greatly reduced and when observed it is commonly associated with a 
reduced parasite burden382.  One billion individuals are heavily infected with helminth 
worldwide and are rarely affected by allergic disease172.  Many epidemiological studies 
have proven this correlation382,383. Allergic diseases share many factors with helminth 
infections, including a similar cytokine milieu and most importantly up-regulation of 
IgE382,383.  These factors induce the symptomology of allergic disease, yet in helminth 
infected individuals, are protective against this symptomology382,383.  This is despite 
helminth being the strongest natural promoter of IgE synthesis384. It is well established 
that parasite-specific IgE is important for anti-helminth immunity, but helminthes are 
also known to elicit large amounts of polyclonal or non-specific IgE in the serum of 
infected individuals.  This has been thought to be a protective response384.  Helminth 
evolution has selected this trait that benefits parasite life and reproduction, assisting the 
helminth in immune evasion384.  
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Utilizing the intestinal helminth N. brasiliensis we show that B1 cells sorted from 
peritoneal lavage of WT infected mice produce high levels of IgE in culture, whereas B1 
cells from uninfected mice do not.  We additionally show that this phenomenon is 
augmented with the addition of myeloid derived suppressor cells (MDSCs).  MDSCs 
have been shown to accumulate in parasitic infection.  Extensive myeloid cell infiltration 
and proliferation has also been associated with B1 cell accumulation in a mouse model 
of Schistosomiasis369.  These cells are most commonly associated with 
immunosuppressive activity.  But, we have shown that these cells play an 
immunosupportive role in the clearance of intestinal helminthes. 
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Chapter 2:  Methods and Materials 
3.2.1 Mice 
Mice were kept at Virginia Commonwealth University (VCU) in accordance with the 
humane treatment of laboratory animals set forth by the National Institutes of Health 
and the American Association for the Accreditation of Laboratory Animal Care. C57BL/6 
ADAM10Tgs were generated by the VCU Transgenic Mouse Core, as previously 
described247. C57BL/6 WT mice were purchased from The Jackson Laboratory (Bar 
Harbor, ME, USA).  All mouse protocols were approved by the VCU Institutional Animal 
Care and Use Committee. 
3.2.2 Isolation of MDSCs and AT, T cell depletion, and dye labeling 
Spleens were harvested from ADAM10Tg. They were then dispersed into single-cell 
suspensions and filtered through 70-μm nylon mesh strainers (Invitrogen). Erythrocytes 
were lysed using an ammonium chloride potassium lysing buffer (Quality Biological). T 
cells were depleted using CD90.2 magnetic depletion (Miltenyi Biotec, Auburn, CA, 
USA), according to the manufacturer’s protocol. Gr-1+ cells were purified from 
ADAM10Tg spleens using the EasySep PE-Selection kit (Stemcell 
Technologies,Vancouver, BC,Canada), according to the manufacturer’s protocol. For 
AT studies, 10 × 106 ADAM10Tg MDSCs were injected into the tail vein of each 
experimental group every 3 days. 
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3.2.3 ELISA 
Total IgE ELISA 
Plates were coated with mouse anti-mouse IgE (B1E3; in house) at 5µg/mL in BBS (see 
previous section 1.2.5 for recipe) and incubated at 37°C for 1 hour.  Plates were then 
washed three times with ELISA wash (section 1.2.5).  Plates were blocked (section 
1.2.5) for 1 hour at 37°C and were washed as above.  Samples were added at various 
concentrations, diluted in block.  Mouse IgE anti-DNP (in house) standards started at 
1µg/mL and were serially diluted in block.  Plates were incubated and washed as 
previous.  Biotinylated rat anti-mouse IgE (R1E4; in house) was added at 1:2000 
dilution in block.  Plates were incubated as previous.  Plates were then washed five 
times with ELISA wash and the detection antibody, streptavidin conjugated to alkaline 
phosphatase (AP) (Southern Biotech) was added at 1:400 diluted in block. Plates were 
again incubated as previous and were then washed five times with ELISA wash.  
Substrate buffer (section 1.2.5) was added at 100µL/well and incubated for 15 minutes 
at room temperature in the dark.  When plates were fully developed, they were read at 
405nm-650nm.  
Total IgG1 ELISA 
Plates were coated with mouse anti-mouse IgG (Southern Biotech) at 5µg/mL in BBS 
(see previous section 1.2.5 for recipe) and incubated at 37°C for 1 hour.  Plates were 
then washed three times with ELISA wash (section 1.2.5).  Plates were blocked (section 
1.2.5) for 1 hour at 37°C and were washed as above.  Samples were added at various 
concentrations, diluted in block.   For standard curve, normal mouse IgG1 (Southern 
Biotech) was used.  Plates were then incubated as previous.  Plates were washed three 
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times with ELISA wash and goat-anti IgG1-AP was diluted in block (1:400 dilution) 
(Southern Biotech).  After 1 hour incubation at 37°C, plates were washed and 
developed with phosphate tablets (Sigma-Aldrich) dissolved in substrate buffer 
(section1.2.5).  Absorbance at 405nm-650nm was measured. 
3.2.4 Flow cytometry, cell sorting and immunohistochemistry 
Flow cytometry 
Cell isolation was conducted as previously described in section1.2.4 and stained as in 
section1.2.6.   
Cell sorting 
Cells were isolated from peritoneal lavage (PL) fluid.  RBC lysis was done as in section 
1.2.4.  PL cells were stained as described in 1.2.6 and sorted on the Aria II (BD 
Biosciences) into FBS coated 15mL conical tubes.   
Immunohistochemistry 
Organs were harvested, prepared and stained as described in section 1.2.6. 
Antibodies 
Antibodies used are listed in Table 6. 
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Table 6. Antibodies used in section 3 
Specificity Clone Conjugate Company 
Flow Cytometry and Cell Sorting 
Mouse-IgE 23G3 FITC Southern Biotech 
Mouse-CD5 53-7.3 PE Biolegend 
Mouse-
B220/CD45R 
RA3-6B2 APC Biolegend 
Mouse-CD11b M170 PE/Cy7 Biolegend 
Mouse IgM R-MM1 PerCP/Cy5.5  
Immunofluorescence 
Mouse-GL7(B and T 
cell activation 
antigen) 
GL7 FITC Biolegend 
Mouse-CD3 1445-2C11 PE Biolegend 
Mouse-
B220/CD45R 
RA3-6B2 PE Biolegend 
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3.2.5 B1 cell culture 
Sorted B1 cells, B1a, B1b or B2 cells were set up in 96 well cell culture plates at 
50,000cells/well.  Cells were incubated in cRPMI 1640 containing 10% FBS, 2mM L-
glutamine, 100 U/mL penicillin, 100µg/mL streptomycin, 1mM HEPES (Quality 
Biological, Gaithersburg, MD,USA), and 1mM sodium pyruvate (Cellgro, Herndon, VA, 
USA)  Cell cultures were supplemented with either CD40L-transfected Chinese hamster 
ovary (CHO) cells as a B cell stimulant (6x104cells/well) or with 2µL/mL of stimulating 
anti-CD40 antibody (Invitrogen) and when noted, IL-4 (10,000U/mL; NIH) for nine days.  
Cell-free supernatants were then harvested and analyzed for IgE production by ELISA.   
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CHAPTER 3:  Th2 helminth infected mice induce a strong B1 cell IgE response 
that is augmented by MDSCs. 
3.3.1 ADAM10Tg mice lack B2 cell development, but elicit a strong IgE response 
during N. brasiliensis infection 
ADAM10Tg mice lack B2 cells but have an intact B1 cell compartment 
 ADAM10Tg mice lack B2 cells due to a defect in hematopoiesis (discussed in 
section 2).  In Figure 49, overexpression of the transgene markedly reduced the levels 
of pro/pre B cells and immature B cells (B220hiIgM+) in BM. This led to a near complete 
loss of peripheral B cells in secondary lymphoid organs (Figure 49). Analysis of B cells 
from peritoneal fluid revealed that levels of B1a (B220intCD11b+CD5+) and B1b cells 
(B220intCD11b+CD5-) in ADAM10Tg mice were not significantly altered compared to 
littermate (LM) controls, whereas B2 cells (B220hiCD11b-CD5-) were nearly absent 
(Figure 50). Thus, the block in B cell development was specific to BM-derived B2 cells. 
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Figure 49. ADAM10 Overexpression blocks B2 B cell development 
(A) Flow cytometric analysis of pro/pre B cells (B220+IgM+) and immature B cells 
(B220hiIgM+) in BM of littermate (LM) and ADAM10Tg progeny. (B)  Flow cytometric 
analysis of CD3+ T cells and B220+ B2 cells in the spleen of ADAM10Tgs or LMs.  Data 
representative of three independent experiments. 
 
 
 
 
 
 
 
 
   
208 
 
 
 
 
 
 
 
   
209 
 
Figure 50. ADAM10 overexpression does not affect B1 cell development 
Flow cytometry on B cell subsets in peritoneal lavage fluid. Panels are gated on B220+ 
cells. B2 cells: B220hiCD11b+ CD5+, B1a cells: B220intCD11b+CD5+, B1b cells: 
B220intCD11b+CD5+.  This is representative of at least three experiments. 
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ADAM10Tg mice have increased B1 IgE production 
 As described in section 2, the ADAM10Tg mouse has an over accumulation of 
MDSCs in vivo.  Mice were infected with N. brasiliensis to ascertain the role of MDSCs 
in Th2 helminth infection (section 2).  A hallmark of N. brasiliensis infection is high IgE 
levels.  Helminth infections are some of the most potent natural inducers of IgE 
synthesis.  Knowing that the ADAM10Tg mouse lacked BM-derived B2 cells, all 
antibody production in the mouse is attributed to B1 cells.  Throughout the infection, IgE 
levels were measured in the serum of ADAM10Tg mice versus WT mice with intact B2 
cell development.  Surprisingly, in the absence of B2 cells, the ADAM10Tg mouse has 
equivalent and at some time points, significantly increased total IgE (Figure 51).  These 
mice additionally had augmented parasitic clearance with decreased worm burdens at 
L4 in the lung, L5 adult worm in the intestine and egg production in the feces (Figure 
18).  This indicates that amplified IgE levels were not due to elevated worm burden.   
ADAM10Tg mice lack GC development 
 To confirm that CSR is occurring outside of GCs to produce IgE, N. brasiliensis 
infected ADAM10Tg mice were euthanized on day 14 post-infection and MLNs were 
harvested.  MLNs are the principle draining LNs during the intestinal helminth infection. 
MLNs were examined for GL7, an activation antigen expressed on GC B and T cells.   
In ADAM10Tg mice, no GC cells were found (Figure 52).  This confirms the hypothesis 
that B1 IgE production is occurring outside of normal GC development.  MLNs were 
additionally examined for B220 and CD3 to look at LN structure (Figure 53).  B220 
staining was evident in small pockets of the ADAM10Tg node, representing fetal liver 
derived B1 B cells colonizing the MLNs (Figure 53).  CD3+ T cells form pocket-like 
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structures behind the B1 cells.  ADAM10Tg MLNs are also filled with Gr-1+ MDSCs as 
evident in Figure 20. 
B1 cells from WT N. brasiliensis infected mice stain positive for IgE 
 To further understand if this B1 IgE production was specific to ADAM10Tg mice, 
we infected C57B/6 WT mice with N. brasiliensis.  On day 7 post-infection, peritoneal 
lavage (PL) fluid and spleens were examined for B cell distribution (Figure 54) and 
each population was further assessed for IgE staining to help delineate the major 
population responsible for IgE production (Figure 55).  Since, SHM, CSR and GC 
response usually take longer we were unable to detect B2 IgE staining.  Interestingly, 
B1a cells stained positive for IgE, confirming that in WT mice, B1 cells are capable of 
IgE production.  This early IgE is majorly attributed to B1a cells, but B1b cells 
additionally stained positive for IgE.  Interestingly, the populations of B1 cells in the 
spleen had a higher percentage of IgE positive staining within the small populations of 
B1 cells (Figure 55). This IgE staining cannot be cytophilic IgE, as B1 cells are CD23 
negative354. 
B1 cells from N. brasiliensis infected mice make IgE in vitro after stimulation with IL-4 
and anti-CD40 
 We next wanted to isolate B1 cells to see if we could induce IgE production in 
vitro.  B1 cells were sorted from PL fluid of N. brasiliensis infected C57B/6 WT mice.  
Both B1 cell populations were sorted, B1a (B220int CD11b+ CD5+) and B1b (B220int 
CD11b+ CD5+).  Cells were plated in vitro with anti-CD40 alone or anti-CD40 and IL-4.  
After nine days, cell-free supernatants were assessed for total IgE production by ELISA.  
Extremely large amounts of IgE were detected in supernatants from B1a cells and B1b 
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cells. Although both B1 populations made IgE, B1a cells, by far, made the highest IgE 
(Figure 56).  Moreover, without addition of IL-4, B1 cells did not make any detectable 
IgE.  To confirm that B1 IgE production is dependent on signals first experienced in 
helminth infection, we sorted B1 cells from naïve C57B/6 WT mice.  B1a and B1b cell 
populations made significantly less IgE from naïve mice than when sorted from N. 
brasiliensis infected mice (Figure 57).  This leads us to believe that possible cytokine 
signals, such as IL-5 or IL-4, induced in parasite infection are required for the B1 switch 
to IgE production. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
214 
 
  
Figure 51. ADAM10Tg mice make increased IgE during N. brasiliensis infection 
Serum was collected from ADAM10Tg (open square) or WT (closed circle) mice on 
days indicated over the course of N. brasiliensis infection and assessed for total IgE by 
ELISA. IgE was assessed on days indicated by ELISA.  *p>0.05; n= at least five mice 
per group. 
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Figure 52. ADAM10Tg mice lack GCs 
MLNs were harvested on day 14 post N. brasiliensis infection.  MLNs were sectioned 
and stained with GL7 (green).  Pictures were taken with a 10x objective and are 
representative of at least three independent experiments. 
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Figure 53. ADAM10Tg mice lack normal secondary lymphoid architecture 
MLNs were harvested on day 14 post N. brasiliensis infection.  MLNs were sectioned 
and stained with B220 (red) or CD3 (green).  Pictures were taken with a 10x objective 
and are representative of at least three independent experiments. 
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Figure 54. Peritoneal lavage and spleens from N. brasiliensis infected mice 
contain B1a, B1b and B2 cells 
 
PL fluid and spleens were harvested from N. brasiliensis infected mice on day 7 post-
infection.  A. Flow cytometry plots of four mice showing PL fluid B1 and B2 cell 
populations from total live cells (top), PL distribution of B2, B1a and B1b cells gated 
from B220+ population (middle) and splenic distribution of B2 and B1 cell populations 
from total live cells (bottom).  B. PL and spleen B1 and B2 cell percentages compiled.  
C.  PL B2, B1a, and B1b cells percentages complied. n= four mice per group. 
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Figure 55. B1a cells from peritoneal lavage and spleens of N. brasiliensis infected 
WT mice stain for IgE 
PL fluid and spleens were harvested from N. brasiliensis infected mice on day 7 post-
infection.  PL (A) or spleen (B) is shown in histograms representing IgE staining.  B2 
cells (black filled) are gated from Figure 54A (top for PL and bottom for spleens).  B1a 
cells (green) and B1b cells (red) were gated as in Figure 54A (middle) for spleens and 
PL.  C. Complied percentages of IgEhigh staining cells, as represented by black bars in 
(A) and (B). *p>0.05, ***p>0.0005; n=four mice per group.  Statistics compare B1a vs 
B1b bars in both PL and spleen. 
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Figure 56. B1 cells sorted from peritoneal lavage fluid of N. brasiliensis infected 
mice make IgE in vitro after stimulation 
PL fluid was sorted on day 7 post infection with N. brasiliensis.  B1a cells were sorted 
as B220intCD11b+CD5+ cells.  B1b cells were sorted as B220intCD11b+CD5- cells.  
Sorting was accomplished with 95% accuracy.  Cells were plated at 50 thousand/well 
and stimulated with anti-CD40 and with IL-4 (red) or without IL-4 (blue) for 9 days as 
described in Methods and Materials.  Total IgE was assessed from cell-free 
supernatants by ELISA.***p>0.0005; n= three replicates per group. nd=none detected. 
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Figure 57. Naïve B1 cells secrete very little IgE without N. brasiliensis infection 
PL fluid was sorted.  B1a cells were sorted as B220intCD11b+CD5+ cells.  B1b cells 
were sorted as B220intCD11b+CD5- cells.  Sorting was accomplished with 95% 
accuracy.  Cells were plated at 50 thousand/well and stimulated with anti-CD40 and 
with or without IL-4 for 9 days as described in Methods and Materials.  Total IgE was 
assessed from cell-free supernatants by ELISA. n= three replicates per group. nd=none 
detected 
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MDSCs enhance B1 IgE production in WT mice 
To investigate whether MDSC accumulation during parasitic infection correlated 
with increased IgE, we administered GEM.  GEM selectively depletes MDSCs without 
affecting lymphocyte levels309,310.  With GEM administration through the course of N. 
brasiliensis infection, IgE levels were significantly decreased (Figure 58).  This lead to 
the hypothesis that B1 cells make IgE during helminth infection and this is augmented 
by the accumulation of MDSCs.   
B1 cells have augmented IgE production that is independent of IgG1 and GCs 
 Next we examined IgG1 levels, as they are usually correlated with the increase in 
IgE.  CSR occurs in the GC from µ to γ and then to ε.  High affinity IgE antibodies are 
made this way380.  CSR outside of the GC results in low affinity, polyclonal antibodies.  It 
can occur with a direct switch from µ to ε380.  It is thought that B1 cells would switch to 
IgE in this manner.  IgG1 levels in the ADAM10Tg mouse infected with N. brasiliensis 
are significantly decreased as compared to WT (Figure 59).  GEM treatment does not 
alter this (Figure 59).  This indicates that B1 cells during helminth infection do not 
undergo CSR through the intermediate γ heavy chain. 
MDSC AT into naïve mice increases IgE production by B1 cells 
 Furthermore, since N. brasiliensis infection induced enhanced myelopoiesis and 
MDSC accumulation in WT mice (Figure 21), we established the hypothesis that 
artificial MDSC accumulation could additionally augment B1 IgE production.  To test 
this, we injected MDSCs i.p. into C57B/6 WT mice 5 days and 1 day prior to sorting of 
B1 B cells from the PL fluid.  In Figure 60, we show that MDSC accumulation indeed 
increases B1 IgE production 
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Figure 58. ADAM10Tg mice make increased IgE during N. brasiliensis infection 
that is reduced upon GEM treatment 
ADAM10Tg mice were treated with GEM (closed square) as described in Methods and 
Materials.  IgE was assessed on days indicated by ELISA.  *p>0.05; n= at least five 
mice per group.  Significance in indicates difference between ADAM10Tg and 
ADAM10Tg treated with GEM at time points indicated. 
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Figure 59. ADAM10Tg mice do not make increased IgG1 and GEM does not affect 
total IgG1 levels in N. brasiliensis infection 
Total IgG1 levels were assessed by ELISA on days indicated.  WT (blue), ADAM10Tg 
(red), and ADAM10Tg mice treated with GEM (purple) as described in Materials and 
Methods.  *p>0.05; n= at least five mice per group.  Significance indicates difference 
between WT and ADAM10Tg at time point indicated. 
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Figure 60. Adoptive transfer of MDSCs into Naïve WT mice induces B1 IgE 
production 
PL fluid was sorted after AT of MDSCs, days -4 and -1 pre-sort.  B1a cells were sorted 
as B220intCD11b+CD5+ cells.  B1b cells were sorted as B220intCD11b+CD5- cells.  
Sorting was accomplished with 95% accuracy.  Cells were plated at 50 thousand/well 
and stimulated with anti-CD40 and with IL-4 for 9 days as described in Methods and 
Materials.  Total IgE was assessed from cell-free supernatants by ELISA. *p>0.05; n= 
three replicates per group. nd =none detected. 
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3.3.2 Discussion 
 The relationship between helminth infection and high IgE is a strong one.  Over 
the years, this has been linked to the absence of allergic disease in countries with 
widespread parasite infection382,383.  Th2 helminthes are strong inducers of IgE384.  IgE 
made in response to these infections are a mix of non-specific, low affinity IgE and high 
affinity, parasite-specific IgE385.  Studies show that this ratio of high affinity to low affinity 
IgE changes depending on how infected the individual is.  Individuals with high parasite 
burdens have mostly low-affinity, non-specific IgE.  Individuals with a low parasite 
burden have increased parasite-specific IgE385.   
N. brasiliensis is a Th2 helminth, similar to the human hookworm.  In WT 
animals, IgE production is not necessary to clear the parasite, as IgE-/- mice clear it 
effectively386.  It is thought that the induction of the IgE response is an evolutionary 
characteristic of the helminth and that induction of large amounts of non-specific and 
low-affinity IgE protects it from high-affinity IgE384.  Studies with the human hookworm 
show the opposite, that a high level of non-specific IgE is associated with decreased 
fecundity and reduced growth of adult worms387.  
The source of this low-affinity IgE was always thought to be FO B cell in origin.  
Until recently, B1 cells have only been hinted at having the ability to class switch to IgE.  
Here, we show that ADAM10Tg mice lacking FO B cells induce high levels of IgE in 
response to infection with N. brasiliensis (Figure 51). This IgE production correlates 
with the increased MDSCs seen in these ADAM10Tg (Figure 51).  Additionally, low-
affinity antibody is thought to be mediated through a direct µ to ε-heavy chain switch380.  
In our mice we show that IgG1 levels remain unchanged, reinforcing that B1 cells direct 
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switch to IgE (Figure 59).  This switch additionally occurs outside of the GC response 
(Figure 52).  We also show that this occurs in WT N. brasiliensis infected mice and can 
reproduce it in vitro (Figures 56,60).   
In vitro B1 production of IgE required that the mouse be infected with the parasite 
before sorting the cells out of the peritoneal cavity.  N. brasiliensis infection up-regulates 
many cytokines associated with Th2 allergy383.  IL-13, IL-4, IL-5, IL-9, IL-33 and IL-25 
are all associated with parasitic infection383.  Many of these have been previously 
associated with B1 cell antibody production or proliferation350,372.   
An unknown signal is first needed to activate the B1 to make IgE that is 
associated with parasitic infection.  MDSCs accumulate naturally in response to 
parasitic infection (Figure 21).  We hypothesize that MDSCs that accumulate in 
helminth infection are the natural source of this signal.  ADAM10Tg mice have an over-
accumulation of MDSCs and have increased B1 IgE production (Figure 51).  In the 
absence of parasitic infection, AT of MDSCs directly into the peritoneal cavity of mice 
increased sorted B1 IgE production in vitro (Figure 60).  This reinforces that MDSCs 
may be providing this activation for the B1 cell.  In our ADAM10Tg mouse we find 
elevated levels of IL-4, IL-5, IL-13, IL-1, and IL-33 (Figure 19).  Post-sort, IL-4 is 
required for B1 IgE production, but it is not enough to induce B1 IgE in naïve mice 
(Figure 56 and 57).  Additionally, anti-CD40 is required (Figure 56).  This alludes to the 
need for CD40 ligand stimulation.  Traditionally, the CD4+ Th cell would have been 
thought to provide this signal, but many other cells express CD40L, including:  mast 
cells, DCs, basophils, macrophages, and eosinophils388.  So, this signal could come 
from many different sources.   
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With flow cytometry and in vitro cultures, we show that B1a cells are producing 
more IgE than B1b cells (Figures 55 and 56).  In previous studies, the B1b cell has 
been eluded to as being capable of IgE production360,361.  We do not dispute this, as we 
additionally see B1b IgE production (Figures 55 and 56).  But, our data indicates that 
B1a cells may be the source for the majority of B1 IgE.  Overall, we definitively show 
that B1 cells can switch to IgE during helminth infection and that these cells may be 
responsible for the high levels of non-specific IgE found in parasitic infection.  We 
additionally reveal a novel role for the MDSC as a potent inducer of B1 IgE synthesis.  
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Section 4 
Chapter 1:  CD23+ B cell-derived exosomes mediate IgE-antigen complex 
mediated immune stimulation 
4.1.1 Introduction 
Antibody, in complex with its antigen, provides the immune system with a 
feedback response against the complexed antigen.  This feedback mechanism results 
in immune stimulation or suppression depending upon the antibody class (reviewed 
in389).  IgE, complexed with antigen, has long been shown to induce a significantly 
increased immune response over antigen alone.  This response results in increased 
antigen specific T cell proliferation and antigen specific IgG in vivo390.  The low affinity 
receptor for IgE (CD23) is traditionally known for its role in the negative regulation of IgE 
synthesis.  But, CD23 has additionally been known to internalize IgE antigen complexes 
and promote antigen presentation.  Extensive studies using CD23-/- animals proved 
CD23 to be essential to the immunostimulatory properties of IgE antigen complexes390.  
Combining antigen presentation properties of CD23 with the observed 
immunostimulation led to the hypothesis that antigen presentation by CD23+ B cells was 
responsible for these activities.  This hypothesis was challenged by the recent finding 
that B cells rapidly transfer the antigen to the spleen391 and were dispensable after 4 
hours post IgE antigen complex injection.  After that period, DCs were required392.  
These intriguing findings suggested that IgE antigen complexes or fragments thereof 
were being carried to the secondary lymphoid system, in this case the spleen, by CD23+ 
B cells and then were being transferred to DCs.  This led to the obvious question, what 
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is the mechanism of this transfer?  Henningson et al392 suggested two possibilities; 
trogocytosis by DCs or exosomal mediated transfer from B cells to DCs.   
Exosomes are defined as tiny membrane bound particles ranging from 30-
150nm.  Although originally discovered in the 1980s and thought to be primarily for 
cellular waste209, exosomal research has undergone a resurgence given the protein and 
micro-RNA cargo that is packed into these particles (reviewed in393).  In a previous 
publication, we demonstrated that CD23 and its protease, ADAM10 were found in B cell 
derived exosomes (bexosomes) from both mouse and human B cells35.   Additionally, 
β2-adrenergic stimulation of B cells further increased both CD23 and ADAM10 levels in 
bexosomes394.  In this study we show that B cells stimulated with anti-CD40 and IL-4, in 
the presence of IgE antigen complexes, release bexosomes that contain both CD23 and 
IgE.  In agreement with earlier studies395, these bexosomes were capable of directly 
stimulating antigen specific T cells in vitro, presumably via the MHC peptide complexes 
found on these bexosomes.  Intriguingly, this stimulation was greatly enhanced if the 
bexosomes were isolated from B cells stimulated in the presence of IgE antigen 
complexes, and this enhanced stimulation was CD23 dependent.  This data supports 
earlier in vitro studies where B cells were shown to directly present IgE antigen 
complexes, taken up via CD23, to T cells396.  Yet, in vivo, direct injection of bexosomes 
did not cause increased T cell proliferation, which agrees with the requirement of 
DCs392.  In contrast, culture of bexosomes with bone marrow derived DCs (BMDC), 
followed by isolation and injection of DCs did directly enhance in vivo antigen specific T 
cell proliferation.  Overall, this supports the hypothesis that bexosomes are responsible 
for antigen transfer from B cells to DCs, thus, providing a mechanism and suggesting a 
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model to explain the importance of DCs in the immunostimulatory activity of IgE 
complexes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
241 
 
Chapter 2: Materials and Methods 
4.2.1 Mice  
Mice were maintained in the Virginia Commonwealth University animal facility in 
accordance to guidelines for the humane treatment of laboratory animals set forth by 
the National Institutes of Health and the American Association for the Accreditation of 
Laboratory Animal Care. C57BL/6 and BALB/C mice were purchased from Jackson 
Labs; DO11.10 and OTII mice were progeny from breeding pairs purchased from 
Jackson Laboratory.  CD23 knockout (BALB/C)397 or B cell specific ADAM10 deficient 
mice (ADAM10B-/-)(BALB/C backcross at least s6 generations)247 were bred in house. 
All mouse protocols were approved by the Virginia Commonwealth University 
Institutional Animal Care and Use Committee. 
4.2.2 Exosomal Cell Cultures  
All fetal bovine serum (FBS) used in exosome cultures was first centrifuged at 
100,000xg for 1 hour to deplete bovine exosomes.  Splenic B cells were isolated using 
B220 positive magnetic bead selection as per manufacturer protocol (Miltenyi Macs 
system) and cultured for 3 days in 6 well plates at 1 x 106 cells/mL in  cRPMI 164029 
containing 1µg/mL anti-CD40 (HM40-3) (Biolegend) and 10,000 U/mL IL-4 (gift from Bill 
Paul NIH).  When indicated, 10 µg/ml of anti-TNP- IgE (IGELb4)398 was present. When 
larger amounts of exosomes were needed, B lymphoma line M12.4.5 (M12)399 was 
used. M12 cells (1 x 106cells/mL – total cell number 3-5 x 108) were cultured for 24 hrs 
in cRPMI 1640/10% FCS containing anti-CD40, IL-4, and anti-TNP (IGELb4) or anti-
DNP IgE (10 µg/mL)398,400.  
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4.2.3 Exosomal Isolation 
Exosomes were isolated as previously described34.   Briefly, apoptotic bodies in cell free 
supernatants were removed by centrifugation at 27,000 x g for 20 minutes.  Finally, 
exosomes were harvested by spinning at 100,000 x g for 1 hour; the exosome pellet 
was resuspended in 5 mL of HBS plus 2mM Ca2+ and pelleted again at 100,000 x g for 
1 hour.  Final exosome pellet were resuspended in HBS plus 2mM Ca2+ and then 
passed through a 0.2μm filter to remove particles larger than 200 nm and to assure 
sterility.  Bradford Assay exosome yields were approximately 1.0-1.62 µg/µL, from B cell 
cultures and about 10-fold higher with M12 cultures depending upon original cell 
number. 
4.2.4 Western Blotting 
Western Blots were performed using 10% Bis-Tris gels and a mini gel system (Life 
Technologies).  Equal amounts of exosome protein (20 µg) were loaded. NuPage MES 
SDS Running Buffer and NuPAGE MES Transfer Buffer were used according to 
manufacturer’s instructions.  After electrophoresis and transfer to nitrocellulose paper, 
blocking was performed using 5% powdered milk solution /0.05% v/v Tween-20 (two 
hours) followed by the primary antibody incubation (1 hour minimum) followed by HRP 
secondary antibody.  Detection was observed by appropriate film exposure. Antibodies 
used were as follows:  Mouse anti-mouse MHCII H2-I/Adβ (5K43) (Santa Cruz); Rabbit 
anti-mouse IgE (Fc specific) (Acris); goat anti-rabbit HRP (Southern Biotech); Rabbit 
anti-mouse CD23 as described401. 
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4.2.5 Specific T cell proliferation:   
In vitro 
DO11.10 T cells were isolated using magnetic bead selection (Miltenyi Macs)B220+, 
CD11b+ and CD11c+ cells were depleted and then CD4 positive T cells were isolated 
using L3T4, non-activating selection.  Bexosomes (15-20 µg /100 µL) were added to 1 x 
105 DO11.10 T cells in a final volume of 200 µL cRPMI/well in 96 well plates; TNP or 
DNP-OVA was added in indicated amounts. After 96 hours, cells were pulsed with 1 
μCi/well of [H3]-thymidine for 24 hours (Perkin Elmer). Plates were then harvested using 
a Filtermate cell harvester onto GFC plates.  Assays were read using a Topcount Plate 
Counter (Perkin Elmer, Waltham, MA).  
In vivo   
(B cell specific ADAM10 deficient) ADAM10B-/-BALB/C or WT BALB/C mice were 
injected with IgE immune complexes (20 µg TNP-OVA + 50 µg anti-TNP-IgE392.  For 
bexosome or BMDC derived dexosome experiments, bexosomes were added to the DC 
cultures for 24 hours.  After washing, LPS was added and cultures were continued for 
72 hours and dexosomes were then isolated by centrifugation. Dexosomes, BMDCs or 
bexosomes or were i.v. injected into BALB/C mice that had been adoptively transferred 
(AT) with DO11.10 total splenocytes 24 hours previous.  After 3 days, DO11.10 cell 
numbers in the spleen were determined either by flow cytometry or 
immunohistochemistry as described392.  
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4.2.6 Flow Cytometry/Immunohistochemistry 
Single cell suspensions were labeled with antibodies for cytometric analysis. Antibodies 
included unlabeled anti-mouse FcγR (2.4G2), FITC-conjugated anti-mouse D011.10 
(KJ1-26) (Biolegend), and PE-conjugated anti-mouse CD4 (145-2C11) (Biolegend). 
Flow cytometric analysis was performed using the Canto (BD Biosciences). Data 
analysis was conducted using FlowJo software v7.6.5 (Tree Star). Sections were 
prepared from frozen tissue and fixed with cold Acetone.  Sections were blocked using 
5% normal horse serum plus 1.5% BSA.  Sections were stained using Biotinylated anti-
DO11.10 (KJ1-26) followed by Streptavidin-APC and anti-B220-PE (RA3-6B2) 
(Biolegend).  Slides were cover slipped utilizing Vectashield Hardset (Vector Labs) and 
imaged on the Leica TCS-SP2 AOBS CLSM Confocal laser-scanning microscope. 
4.2.7 BMDC culture 
Mouse bone marrow-derived dendritic cells (BMDC’s) were derived from femurs of WT 
mice and cultured in complete RPMI (cRPMI) 1640 containing 10% FBS, 2mM L-
glutamine, 100 U/mL penicillin, 100µg/mL streptomycin, 1mM HEPES (Quality 
Biological, Inc.), and 1mM sodium pyruvate (Cellgro). Cultures were supplemented with 
IL-4 1ng/mL (Peprotech) and GM-CSF 50ng/mL (Peprotech).  Mature BMDC were 
harvested after 6 days of culture395.  
4.2.8 Statistical Analysis 
Analyzed as in section 1.2.8. 
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Chapter 3: IgE/Antigen Complexes stimulate OVA specific T cell proliferation 
4.3.1 Results and Discussion 
IgE is associated with bexosomes in a CD23 dependent manner.  
As mentioned, CD23 and ADAM10 are both found associated with bexosomes35.  
In order to determine if IgE is additionally associated, B cells were stimulated with anti-
CD40 േ IL-4 in the presence of IgE/Ag ICs.  After 48 hours of culture, bexosomes were 
isolated by centrifugation.  Equal amounts of protein were analyzed by Western blotting.  
Figure 61A shows that IL-4 stimulated B cells increases bexosomal CD23 levels.  The 
blot indicated equal MHC class II expression.  Interestingly, MHC class II levels were 
not increased by IL-4, in contrast to the well-known cell surface increase induced by this 
cytokine. In an earlier study using LPS as the activator35, we found that ADAM10 was 
needed for bexosomal CD23 expression.  With anti-CD40, CD23 is present even if 
ADAM10-/- B cells are used; although the CD23 expression level is lower (data not 
shown).  This indicates that CD40 activation is more efficient in allowing CD23 
incorporation into bexosomes.   In Figure 61B, the blot is examined using an ε-specific 
anti-IgE antibody, and lane 1 shows a strong 85Kd band indicates the presence of IgE.  
The amount of IgE was additionally increased in the presence of IL-4 (lane 2).  This 
band was not present when B cells lacking CD23 were used (lanes 3 and 4) regardless 
of IL-4 stimulation.  Thus, CD40-mediated CD23+ B cell activation results in release of 
bexosomes that contains CD23 and bound IgE.  To examine if bexosomes additionally 
expressed co-stimulatory molecules in addition to MHCII, Bexosomes were blotted for 
CD80 and CD86 expression (Figure 62).   
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Increased in vivo antigen specific T cell proliferation is seen with bexosomes from anti-
CD40/IL4 activated B cells when IgE/antigen complexes are present in the culture.   
As mentioned above, bexosomes are known to induce antigen specific T cell 
proliferation if isolated from B cells cultured in the presence of the specific antigen395.  
The finding (Figure 61) that CD23 and IgE are present in bexosomes suggests that 
MHC class II peptide loading should be enhanced when IgE complexes are included in 
the culture.  That this is indeed true is shown in Figure 64A where the initial B cells 
were cultured with increasing amounts of antigen (TNP-OVA) alone or the same plus 
anti -TNP-IgE.  With B cells from either BALB/C or C57BL/6 mice and the corresponding 
strains of OVA-specific T cells, DO11.10 (Figure 64A) or OTII (Figure 65), increased 
specific T cell proliferation is seen when antigen specific IgE is present in the cultures. 
This data looks quite similar to the studies that initially demonstrated the enhanced 
antigen-presentation by IgE complexes with CD23+ B cells396 and relates to enhanced 
MHC class II loading due to the increased antigen found in the endosomal 
compartments.  Confirmation that both IgE and CD23 are necessary for the bexosomal 
induced T cell proliferation is shown in Figure 64A where increased T proliferation is 
only seen when both are present.  To determine whether ADAM10 was also needed for 
the enhancement of presentation, we turned to in vivo studies.  WT or B cell-specific 
ADAM10 deficient (ADAM10B-/-) BALB/C mice were i.v. injected on day -1 with 30 million 
DO11.10 total splenocytes.  On day 0, they were i.v. injected with anti-TNP IgE/TNP-
OVA complexes (Methods). Three days later, OVA-specific T-cell proliferation was 
determined by flow cytometry and immunohistochemistry.  WT mice injected with 
IgE/Antigen complexes had increased DO11.10 proliferation, as indicated by the 
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number of antigen specific T cells in the spleen, as compared to WT OVA injected 
(Figure 64B).  This was as expected.  But, the ADAM10B-/- mice had significantly more 
DO11.10 proliferation than did the WT.  This finding was further confirmed by 
immunohistochemistry, where proliferation differences generally look more pronounced. 
The enhanced OVA-specific DO11.10 cell number in the T cell region of the spleen of 
the ADAM10B-/- was clearly evident (Figure 64C).  Thus, B cell ADAM10 is clearly not 
necessary for IgE antigen complex stimulation since this enhancement is seen. As the 
ADAM10B-/- mice have been shown to have enhanced CD23 expression56, we 
hypothesize that the increased CD23 leads to still further IgE-antigen incorporation with 
enhanced MHC class II loading in the endosomal compartment, leading to the results 
shown in Figure 64B and C.  These studies also indicate that MZB are not necessary 
for IgE-antigen complex immunostimulation, since MZB are absent in ADAM10B-/- 
mice56. It also agrees with the observation that IgE complexes were found bound to 
mainly FO B cells and not to MZ B cells392. 
Bexosomes must first go through DCs in order to stimulate T cells in vivo.   
To directly test if bexosomes from B cells activated with anti-CD40 and IL-4 
would stimulate T cells in vivo, bexosomes were isolated from B cells activated as in 
Figure 64A with IgE/OVA complexes. They were injected into BALB/C mice AT with 
OVA-specific DO11.10 cells. This was ineffectual, so to increase the level of bexosomes 
for injection, 3 x 108 M12.4.5 cells were activated instead of primary B cells.  
Bexosomes were isolated and injected into the OVA-specific T cell AT mice.  In neither 
situation did we observe increased levels of OVA-specific T cell proliferation when the 
spleen was examined 3 days post bexosome injection (data not shown).  We 
   
248 
 
considered that the most likely reason for this failure was that the bexosomes were not 
efficiently crossing the HEV to enter the peri-arteriolar lymphoid sheath (PALs) tissue.   
To increase chance for HEV crossing, bexosomes were cultured with LPS activated 
BMDCs, and DC were isolated 3 days post culture with bexosomes.  In contrast to 
directly injected bexosomes, passage of the bexosomes through DCs, with injection of 
the DCs did cause a small but significant increase in OVA-specific proliferation, as 
determined by flow cytometry (Figure 66).  This increase was significantly higher than 
what was seen by control DCs isolated from LPS activated cultured with the same 
amount of TNP-OVA alone or increased amounts.  While the increase in T cell 
proliferation was not as dramatic as seen when directly injecting IgE immune complexes 
(Figure 64B and Figure 66), the results are clearly compatible with exosomes being 
responsible for the transfer of antigen to DCs as described by Henningsson et al392.  
Thus, we propose the following model (Figure 67): IgE immune complexes are picked 
up by CD23+ B cells and this allows efficient transfer into the spleen.  Once there, 
bexosomes are released and picked up by DCs which then activate antigen specific T 
cells and subsequently give the enhanced humoral response that is seen in IgE antigen 
complex injected animals396.  Future studies could examine ways to increase transfer of 
the bexosome incorporated MHC class II cargo to DCs.  If successful, this would allow 
immunization strategies that take advantage of the IgE immune complex stimulation that 
would bypass any difficulties seen by FcεRI interaction with IgE and antigen, and still 
allow efficient sensitization with low amounts of antigen. 
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Figure 61. IgE and CD23 are associated with bexosomes 
(A) Bexosomes were isolated from B cell cultures stimulated with anti-CD40 ± IL-4 or 
IgE as indicated.  Equal bexosome protein was loaded on each lane and the blot was 
probed with polyclonal anti-CD23.  Blot was stripped and probed with anti-MHC class II 
and the result is shown at the bottom of (A).  (B) Exosomes from B cell cultures 
stimulated with anti-CD40 and IgE (All lanes). IL-4 stimulation is as indicated.  Lanes 1 
and 2 are bexosomes from WT mice, Lanes, 3 and 4 are bexosomes from CD23-/- mice. 
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Figure 62. Bexosomes express co-stimulatory molecules CD80 and CD86 
B cells were cultured in exo-free cRPMI under stimulation conditions with anti-CD40 and 
IL-4. Exosomes were isolated after several centrifugation steps.  Western blotting was 
performed on (1) whole B cell lysates or (2) B cell derived exosomes lysates. 
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Figure 63. B cell derived exosomes by electron micrograph 
For the negative staining, exosomes were placed on formvar-coated 150-mesh copper 
grids. The grid, formvar side to the sample, was then placed on top of the drop of 
sample and allowed to rest for 1 minute. Next a drop of the stain was placed on the 
parafilm and the grid was put on top of it for 1 minute.  After 1 minute, the grid was 
picked up, and the excess stain was wicked off.  The grid was then allowed to dry 
completely before scoping. Final developing solutions were tested:  1% Uranyl acetate, 
which gave a grainy image, and 1% Phosphotungstic acid at pH 7.0. 
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Figure 64. Bexosome-induced antigen specific T cell proliferation is enhanced by 
IgE, only when CD23 is present and in vivo IgE immune complex T proliferation is 
enhanced in ADAM10B-/- mice   
(A) B cell cultures stimulated as in Methods.  B cells were incubated with or without IgE 
for 24 hours and then IgE/Ag ICs were added. Bexosomes were isolated.  B cells were 
from either WT or CD23-/-mice.  Bexosomes and purified Ag-specific DO11 T cells were 
cultured for 3 days and proliferation determined using a [3H]-thymidine pulse (Methods).  
(B,C) On day -1 WT or ADAM10B-/- mice were given Ag-specific DO11 T cells and on 
day 0 immunized with IgE/Ag ICs (Methods); on day 3, spleens were removed and 
examined for expanded Ag specific DO11+ CD4+ T cells by flow cytometry (B) or 
immunohistochemistry (C). *p>0.05, ***p>0.0005; n=at least five per group 
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Figure 65. Bexosome-induced antigen specific T cell proliferation is enhanced by 
IgE in C57BL/6 model of OVA-specific T cell proliferation 
B cell cultures stimulated as in Methods.  B cells were incubated with IgE for 24 hours 
and then IgE/Ag ICs were added. Bexosomes were isolated.  B cells were from WT 
C57BL/6 mice.  Bexosomes and purified Ag-specific OTII T cells were cultured for 3 
days and proliferation determined using a [3H]-thymidine pulse (Methods).   
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Figure 66. Increased in vivo T proliferation with i.v. injected DCs incubated with 
bexosomes 
In vitro differentiated LPS activated DCs were incubated with bexosomes stimulated 
with IgE/Ag ICs plus 10µgOVA, 10µgOVA or 300µg OVA for three days.  DCs were 
harvested and equivalent cells were injected into mice AT with DO11 cells.  Spleens 
were assessed by flow cytometry on Day 3.  Percent DO11TgTCR+ cells out of total 
CD4+ T cells were plotted. *p>0.05;  n=5 per group 
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Figure 67. Model for the mechanism of IgE immune complex mediated humoral 
immunity enhancement 
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